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Abstract 
Osteoarthritis (OA) is considered to be one of the leading causes of disability in 
the western countries and it represents an enormous financial burden on healthcare 
systems. OA can arise as the result of cartilage tissue degeneration in response to an 
acute injury or idiopathic degeneration. In both cases degeneration reflects the inherent 
limited self-repair capacity of articular cartilage. Despite significant and broad research 
efforts targeting cartilage defect repair via marrow stimulation, osteochondral graft 
transplantation, in vitro expanded chondrocyte implantation, and/or the use of various 
biomaterials as scaffolds, successful and robust repair remains elusive.  Recent studies 
suggest that cell-based therapies do promote the regeneration of articular cartilage, 
however their modest efficacy suggests that further optimization and even a change in 
approach is needed.  
Previous research from our group demonstrated that the chondrogenic 
differentiation of human bone marrow-derived mesenchymal stem/stromal cells (MSC) 
was enhanced when the cells were assembled into micropellets, rather than traditional 
macroscopic pellets.  Based on this critical finding, I investigated opportunities to 
exploit this phenomenon in cartilage tissue engineering applications.  Through my 
Thesis, I addressed the following three specific questions:  
 
Q1.  Does the micropellet approach also enhance the redifferentiation of 
monolayer expanded chondrocytes? 
Q2.  Can the matrix content and defect filling capacity of engineered cartilage be 
enhanced through the inclusion of donor matrix particles in MSC micropellets?   
Q3. Can chondrogenic and osteogenic micropellets be used as building blocks and 
assembled into macroscopic osteochondral-like tissue? 
 
High-throughput manufacture of micropellets was facilitated via a custom-made 
microwell surface originally generated as a silica wafer and then replicated with soft 
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lithography method. According to this manufacturing process, single cells were seeded 
on a polydimethylsiloxane (PDMS) surface containing the microwell impression. When 
the cells were centrifuged or settled on this microwell surface, they were divided into 
small groups of 100-200 cells, which then formed micropellets within the first hours of 
culture. With this robust micropellet manufacturing technique, three independent but 
closely related studies were conducted, each addressing one of the previously mentioned 
questions. These three studies were reported as separate research articles in this Thesis 
by publication. 
 Chapter 3 addresses the first question and reports on the chondrogenic 
redifferentiation of expanded chondrocytes in macro- or micropellets and under 
normoxic or hypoxic atmospheres. It is a well-known phenomenon that the articular 
chondrocytes dedifferentiate during monolayer expansion. Similar to MSC 
chondrogenesis, pellet culture promotes redifferentiation, however these traditional 
pellets have 1-2 mm diameter, which causes diffusion gradients and mass transport 
issues leading to a heterogenic tissue structure. In order to overcome this problem, I 
tested the chondrocyte redifferentiation in micropellets that were approximately ten 
times smaller than the traditional pellets. According to chondrogenic assays, gene 
expression analyses and histological assessments, the redifferentiation of chondrocytes 
in micropellets was enhanced and yielded homogenous tissue structure. This work also 
demonstrated that micropellets could be assembled in order to engineer macroscopic 
cartilaginous tissue constructs. 
Chapter 4 addresses the second question and reports on the effects of 
incorporation of microscopic cartilage pieces in macro- or micropellets of human bone 
marrow MSC. The fact that larger cartilage defects require a greater number of cells 
limits the applicability of cell-based therapies. As an alternative to articular 
chondrocytes, bone marrow-derived MSC can be harnessed because of their 
proliferation capacity, chondrogenic differentiation potential and ease of harvest. 
Additionally, use of xenogeneic cartilage pieces can increase the volume of engineered 
tissue graft in order to fill the larger defects more effectively. By combining two 
approaches, I tested the incorporation of microscopic bovine cartilage particles, termed 
as “cartilage dust”, into MSC micropellets. Chondrogenic characteristics, gene 
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expression profile and histological structure assessment indicated that incorporation of 
cartilage dust into micropellets had significantly increased the size and cartilaginous 
matrix content, however it did not enhance the chondrogenic differentiation of MSC. It 
is also demonstrated that micropellets with or without cartilage dust can be assembled in 
order to engineer macroscopic cartilaginous tissue constructs.  
Chapter 5 addresses the third question and reports on the assembly of osteogenic 
and chondrogenic micropellets into a biphasic tissue. The main purpose of building an 
osteochondral graft is to exploit more efficient bone-bone integration that takes place at 
the foundation of the defect and stabilizes the cartilaginous graft in place. The method of 
utilizing a scaffold with biphasic characteristics in order to generate an osteochondral 
graft is frequently trialed. In this study, I first tested the chondrogenic and osteogenic 
phenotype change in MSC micropellets, and then constructed the first scaffold-free 
biphasic tissue utilizing micropellets as building blocks.  
In conclusion, this Thesis describes the characteristics of micropellets with 
different cell types (chondrocytes or MSC) and compositions (with or without the 
cartilage dust) under different conditions (hypoxic, normoxic, chondrogenic, 
osteogenic). The results presented in this Thesis introduce a novel intermediate 
component, micropellets, between the single cells and the tissue to be engineered. 
Utilization of micropellets may improve tissue engineering applications and cell-based 
therapies, ultimately leading to development of novel approaches in cartilage defect 
repair. 
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“I do not know what I may appear to the world; but to myself I seem to have been only like a boy playing 
on the seashore, and diverting myself in now and then finding a smoother pebble or a prettier shell than 










Osteoarthritis (OA) is the most common form of joint diseases affecting 250 
million people worldwide [1]. It is even more prevalent in developed countries with 
aging population such as USA, Canada, Europe and Australia [2,3]. In Australia, an 
estimated 1.9 million people were affected by OA in 2012 and it is projected that this 
number will rise to 3 million by 2032 [4]. The financial cost of OA in Australia was 
estimated to be 3.7 billion dollars in 2012, which was equivalent to 6.8% of the total 
health expenditure [4]. In OA, the articular cartilage that is the tissue covering the ends 
of long bones loses its integrity and resilience followed by complications and further 
degeneration until the function of the joint is impaired. Some would even argue that OA 
is similar to an organ failure, if articular cartilage is considered as an organ [5]. OA can 
be classified as primary (idiopathic/unknown cause) or secondary in which the cause of 
disease is another primary disease or a traumatic injury [5]. Hereditary components, sex 
(more prevalent in females) [6], ageing, obesity [7] and injury [8] are the leading risk 
factors of OA. Weight loss and exercise are the highly encouraged lifestyle changes for 
prevention of OA, but the compliance rate is very low [9]. The diagnosis rate peaks 
around the age of 50 and the general symptoms are pain, stiffness, clicking, locking and 
 2 Chapter 1: Introduction 
loss of joint function [10]. At advanced stages, OA causes disability to perform daily life 
activities decreasing the quality of life, therefore causing psychological distress in 
patients. Once diagnosed with OA, patients do not have many options other than joint 
replacement surgery, which is the amputation of damaged cartilage and resurfacing of 
the joint with metal and plastic components (see Chapter 2).  This fact has motivated 
efforts to develop tissue engineering approaches that enable the repair of damaged 
articular cartilage at earlier stages so that the prevalence of OA can be minimized in the 
future.  
2. History of articular cartilage focused medical research  
The unusual characteristics of cartilage were realized around second century. 
Early scientists and physicians were utterly puzzled with the properties of this 
inscrutable tissue. The following historical quotations describing the first scientific 
impressions of cartilage are taken from the paper by Benedek [11], where more of 
similar quotations can be found.  
Galen described the articular cartilage for the first time in 175 as follows: 
“Cartilages are spread on some parts of them [bones], such as the joints, to make them 
smooth, and Nature also uses cartilages occasionally as moderately yielding bodies… 
Cartilage serves as a grease for the joints [12]a”. Galen also noted the function of 
synovial fluid together with the cartilage: “… Nature has again searched out a double 
remedy, first covering each member of the joint with cartilage and then pouring over the 
cartilages themselves a sort of oily substance, a greasy, glutinous fluid, which gives 
every joint an easy movement and protection against wear [12]b”.  
Later in 1536, Niccolo Massa drew attention to the function of the articular 
cartilage: “cartilage is a certain substance like bone, but softer which you will find at the 
extremities of all the bones, large and small according to the need of the member… This 
cartilaginous portion was reserved for many bones at their extremities in order to keep 
two hard surfaces from coming into contact and being broken by movement and to 
maintain something between the final hardness of the bone and the soft flesh…[13]”. 
Interestingly, Massa used the term “reserved” for articular cartilage, however the 
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developmental process, where a thin layer of cartilage is literally reserved, was only 
discovered three centuries later [14]. 
Morgagni described the state of osteoarthritic cartilage and the osteophytes for 
the first time in an autopsy report in 1741: “The head of the right os femoris was not 
rounded into a globular form: and was depress’d, and not cover’d by a smooth and 
white cartilage, but by one of a pale ash-colour: and, indeed, this cartilage was totally 
deficient in the posterior part of the head; so that the bone appear’d naked in that part, 
and form’d into many roundish and protuberant particles [15]”.  
In 1743, Hunter was the first to report the different orientation of the collagen 
fibers, synovial membrane, and lack of self-healing in the case of injury: “… We may 
compare the Texture of a Cartilage to the Pile of Velvet, its Fibres rising up from the 
Bone, as the silky Threads of that rise from the woven Cloth or Basis… Now these 
perpendicular Fibres make the greatest Part of the cartilaginous Substance; but without 
Doubt there are likewise transverse Fibrils which connect them, and make the Whole a 
solid Body, though these last are not easily seen, because being very tender, they are 
destroyed in preparing the Cartilage… Every Joint is invested with a Membrane, which 
forms a complete Bag, and gives a Covering to everything within the Articulation…  The 
Blood-vessels are so small, that they do not admit the red Globules of the Blood; so that 
they remain in a great measure unknown… an ulcerated Cartilage is universally 
allowed to be a very troublesome Disease; that it admits of a Cure with more difficulty 
than a carious Bone; and that, when destroyed, it is never recovered [16]” (Quotations 
are re-used with permission from Elsevier, see App. A).  
In the nineteenth century the biochemistry of the cartilage was revealed and 
individual matrix components were identified [11]. In the twentieth century researchers 
started to develop treatments to heal cartilage injuries (see Chapter 2). With the 
advancements in scientific technology, such as microscopes and analysis instruments, 
today in the twenty-first century we know a lot more about the structure, biomechanical 
function, development and injury of the articular cartilage (see Chapter 2). Currently, it 
is possible to treat injured cartilage in different ways, however none of the existing 
treatment options guarantee full-recovery yet, which perhaps makes the articular 
cartilage the “Achilles’ heel” of the human body.  
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3. Thesis overview 
3.1. Description of research problem 
OA is one of the leading causes of pain and disability worldwide. The biomedical 
research to find the ultimate cure for articular cartilage injuries is still in progress at 
present. Articular cartilage tissue has limited self-healing capacity, therefore there is a 
legitimate need to develop biological therapies to treat cartilage injuries and minimize 
onset of OA and associated financial burden. 
3.2. Overall objectives of the study 
This study aims to improve existing cell-based therapies and introduce novel 
approaches to treat cartilage defects. The most significant contribution of this study to 
the accumulating body of knowledge in cartilage research is the idea of using 
“micropellets” as discrete units to engineer macroscopic cartilage tissue grafts.  An 
analogy of constructing a wall and engineering a tissue can be useful in order to 
understand the significance of the micropellets as an intermediate step between the 
single cells and the whole tissue. One cannot construct a wall directly from sand but 
needs discrete units such as bricks, and then the clay is used to adhere and seal the 
individual bricks. Similarly, this study suggests that adequate building blocks for tissue 
engineering applications is not single cells but micropellets. The tissues with great size 
and high complexity can be generated utilizing multicellular micropellets as the bricks 
and the produced extracellular matrix acts as the clay.  
3.3. Specific aims of the study  
In this Thesis, the following specific aims were addressed in three independent 
research articles: 
- To test the micropellet approach in redifferentiation of monolayer expanded 
human articular chondrocytes 
- To increase matrix content and defect filling properties of human bone 
marrow MSC micropellets with incorporation of donor cartilage particles 
- To assemble osteogenic and chondrogenic micropellets in order to generate a 
scaffold-free osteochondral-like tissue 
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3.4. Linking research papers 
In this project, first an in-house fabricated, custom made microwell platform was 
developed to enable cost effective, high throughput generation of micron size 
micropellets for all studies. After setting up the microwell platform, different ways of 
utilizing micropellets in cartilage tissue engineering were explored. Three specific 
examples of micropellet use, which could potentially be useful in cell-based therapies, 
were reported as three research articles. In the first study, the articular chondrocytes 
were tested in micropellet platform because of their clinical relevance.  Autologous 
chondrocyte is seen as the primary cell source for most of the cell-based therapies. 
However, monolayer expansion of chondrocytes causes loss of chondrogenic phenotype 
and a redifferentiation step is required to restore cell phenotype before implantation. 
Chapter 3 demonstrated how micropellet culture enhances this redifferentiation process 
[17]. The fabrication of microwell platform was also included in Chapter 3. Previously, 
our group demonstrated that bone marrow MSC chondrogenesis was enhanced in 
hypoxic micropellets [18]. In the second study, bone marrow MSC micropellets were 
further examined. Most of the MSC studies conclude that the replication of high matrix 
content found in native cartilage is quite challenging. Chapter 4 explained how the 
cartilaginous matrix content and defect filling properties of MSC micropellets were 
increased with incorporation of donor cartilage particles. Another common challenge in 
cartilage treatment is the inefficient integration of the tissue graft to the defect site. Some 
studies focus on generating osteochondral tissue grafts in order to overcome this 
problem. In the third study, a scaffold-free osteochondral-like tissue was engineered 
using osteogenic and chondrogenic micropellets. Previously, our group reported that 
MSC osteogenesis was also more efficient in micropellets [19]. Chapter 5 demonstrated 
how MSC derived osteogenic and chondrogenic micropellets were assembled to 
generate a scaffold-free osteochondral-like tissue exemplifying the use of micropellets 
as building blocks. In this project, articular chondrocyte micropellets (Chapter 3), donor 
matrix incorporated MSC micropellets (Chapter 4) and a scaffold-free biphasic tissue 
generated with MSC micropellets (Chapter 5) were characterized in vitro.  Testing these 
different micropellets in animal defect models is the next vital step in order to expose the 
potential of micropellet use in clinical applications. 
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3.5. Chapter contents 
In Chapter 1, the greatest clinical motivation for cartilage research, osteoarthritis, 
and its effects are described in order to justify the scientific effort and the financial 
expenses spared for finding alternative ways to treat cartilage injuries. Then some 
historical quotations describing the first scientific and clinical impressions of articular 
cartilage and its injury are provided. Finally, the Thesis overview is listed.  
In Chapter 2, a detailed literature review is compiled. The literature review starts 
with the description of articular cartilage, its components, development and state in 
injury. Then, the existing surgical techniques, including joint replacement, 
microfracture, mosaicplasty and autologous chondrocyte implantation (ACI) are 
explained. Next, cartilage tissue engineering and its components are introduced and 
advancements in the area are discussed. Finally, the significance of using micropellets as 
building blocks in scaffold-free cartilage tissue engineering is explained.  
Chapters 3, 4 and 5 are the result chapters, each exemplifying a specific way of 
using micropellets in ex vivo cartilage tissue generation. Each chapter is in the format of 
a research article therefore includes individual abstract, introduction, materials and 
methods, results, discussion, and conclusion sections. 
In Chapter 3, the redifferentiation of monolayer expanded human articular 
chondrocytes in macro- or micropellets and in normoxic or hypoxic atmosphere is 
reported. Additionally, the amalgamation of the discrete micropellets is investigated 
with the assembly of the micropellets at different time points. The feasibility of 
chondrocyte micropellet use in cartilage tissue engineering is studied. 
In Chapter 4, the incorporation of the microscopic donor cartilage particles, 
termed as “cartilage dust” (CD), into macro- and micropellets of human bone marrow 
derived mesenchymal stem/stromal cells (MSC) is reported. Additionally, the 
amalgamation of the discrete micropellets with and without the CD is investigated with 
the assembly of the micropellets at different time points. The feasibility of CD use in 
order to increase the volume and defect filling capacity of MSC derived chondrogenic 
micropellets is studied.  
In Chapter 5, the differentiation of human bone marrow derived MSC 
micropellets when exposed to chondrogenic and osteogenic media is tested. The 
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chondrogenic and osteogenic characteristics of micropellets is reported in the following 
culture conditions: two weeks of chondrogenic media, one week of chondrogenic 
followed by another week of osteogenic media, one week of osteogenic followed by 
another week of chondrogenic media and two weeks of osteogenic media. Additionally, 
a scaffold-free osteochondral-like tissue is generated with layer by layer assembly of the 
chondrogenic and osteogenic micropellets. The feasibility of engineering a composite 
tissue using different phenotype micropellets as building blocks is studied.  
In Chapter 6, the findings are summarized, discussed and the future perspectives, 
including in vivo experiments, mass production of micropellets and complex tissue 
engineering with micropellets, are outlined.  
 

 Chapter 2: Literature Review 9 
“I am among those who think that science has great beauty. A scientist in his laboratory is not only a 









1. Articular cartilage 
Articular/hyaline cartilage is the tissue covering the ends of the articulating joints 
(Fig. 1). Its function is to provide almost frictionless gliding surfaces in between bones 
and absorb the impact during joint movement. Articular cartilage lacks blood vessels, 
lymphatic vessels and neurons, therefore it relies on diffusion of signal molecules and 
metabolites from the synovial fluid [20]. Whilst the histological assessment of the native 
articular cartilage suggests a relatively simple tissue structure at first glance, decades of 
research have proven that this tissue has a remarkably complex and elegant design. It is 
this complexity that has made replicating and repairing this tissue an unmet challenge.  
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Figure 1. Anatomical structure of the articular cartilage of knee. Image is courtesy of Medical Multimedia 
Group LLC, www.eOrthopod.com , see App.B for permission. 
1.1. Chondrocyte 
 Articular cartilage mostly consists of extracellular matrix (ECM) that is produced 
and maintained by a single cell type, the chondrocyte. Each individual chondrocyte has 
high metabolic activity, however since all chondrocytes only correspond to 1-5% of the 
total volume, the overall metabolic activity of the tissue is very low [21]. The 
chondrocytes are mostly spherical in morphology, sparsely distributed and entrapped by 
matrix in compartments called lacuna (Fig. 2A).  The fluid filling the lacuna (pericellular 
matrix) and the chondrocyte residing in that lacuna are referred as “chondron” [22,23]. It 
is suggested that the pericellular matrix mediates the transduction of biomechanical and 
biochemical signals to the chondrocytes [24] and altered permeability of the chondrons 
in disease might have a role in biomechanical failing of the tissue [25].  
1.2. Extracellular matrix 
The ECM is comprised of different molecules organized in a hierarchical order 
(Fig. 2A).  The collagen is the main component of the ECM, type II dominating other 
types such as type IX, X and XI, which are unique to cartilage [26]. Collagen molecules 
form fibers and cross-linked collagen fibers form a network that entraps the other ECM 
components. The collagen network also provides the tensile strength of the tissue. 
Hyaluronic acid (HA) is a large non-sulfated glycosaminoglycan (GAG) molecule that 
aggregates proteoglycan monomers such as aggrecan in the presence of link protein [27]. 
Aggrecan aggregates keratin sulfate and chondroitin sulfate that are small, negatively 
charged, sulfated GAG (sGAG) molecules (Fig. 2A). The net negative charge of the 
tissue generated by high number of sGAG molecules attracts the positively charged 
cations such as Na+, K+ that causes an influx of water into the tissue in a non-loaded 
state, which is described as Donnan effect [20]. This effect endows articular cartilage its 
compressive strength, and in fact the instant efflux of the water retained in the tissue 
provides the very first shock absorbance. It is this unique and highly organized 
combination of each ECM component in different proportions that makes articular 
cartilage a multi-phasic, non-linearly permeable, viscoelastic tissue [28]. The simple 
histological appearance of this tissue is an illusion.  




 The multi-phasic nature of articular cartilage is highly studied, and it is 
concluded that there are four different zones defined by the alignment of the collagen 
fibers and the chondrocyte morphology (Fig. 2B). The superficial zone is the thin 
uppermost layer with horizontally aligned collagen fibers and flattened chondrocyte 
morphology. This horizontal alignment of the collagen fibers in superficial zone 
provides the greatest tensile strength, which is critical for the integrity of the whole 
tissue. Additionally, the densely packed horizontal collagen fibers act as a barrier from 
synovial fluid, giving the cartilage its immune-privileged status [29]. The middle zone is 
known for the randomly aligned collagen fibers and sparsely distributed spherical 
chondrocytes. The deep zone is distinguished by the perpendicular alignment of collagen 
fibers and the columnar orientation of spherical chondrocytes. The last layer that 
connects the cartilage tissue to underlying bone is the calcified zone, which has 
hypertrophic enlarged chondrocytes that synthesize collagen X. Also the perpendicular 
collagen fibers from deep zone penetrate into calcified zone strengthening the 
connection between the articular cartilage and the underlying bone. A visible line stained 
by basic dyes called ‘tidemark’ separates the deep zone from calcified zone (Fig. 2B). 
Overall, the ultrastructure of articular cartilage provides the greatest tensile strength in 
superficial zone while providing the greatest compressive strength in middle and deep 
zones.  
 















Figure 2. Chondrocyte, ECM and ultrastructure of articular cartilage. Chondrocytes are surrounded 
by lacuna and ECM molecules such as hyaluronic acid (HA), aggrecan, keratin sulfate (KS), chondroitin 
sulfate (CS) are entrapped by the collagen II fibers (A). Chondrocytes and collagen fibers are aligned 
horizontally in superficial zone (SZ), randomly in middle zone (MZ) and vertically in deep zone (DZ); 
tidemark (TM) separates the deep zone and the calcified zone (CZ) (B). Figure is not to scale.  
 
1.4. Mechanical properties 
The thickness of the articular cartilage in the knee changes between 1-5 mm [28]. 
The tensile modulus can decrease from 125 to 40 MPa from the age of 20 to 85 [30] 
while the compressive modulus of the femoral condyles is in the range of 4.3-13 MPa 
[31]. During normal walking the articular cartilage bears ~ 2.5 times the body-weight 
[32], however when climbing stairs or during deep knee bends it could bear up to 3.3 or 
7.8 times the body-weight, respectively [33]. 
1.5. Development  
The development of articular cartilage during embryogenesis is a unique process. 
First, hyaline cartilage templates for the long bones are generated at specific locations, 
sizes and shapes, then converted into bone tissue with a process called endochondral 
ossification (Fig. 3) [34]. Interestingly, the articular cartilage, which has a critical 
function throughout the life, is the “reserved” tissue layer from the primitive cartilage 
skeleton template.  
Limb development is extensively studied, specifically in chick models, in order 
to understand the molecular mechanisms that drive chondrogenesis, which is then 
followed by endochondral ossification (Fig. 3, 4) [35-37]. During limb development, 
first the mesenchymal stem cells from the mesenchyme migrate to the site where the 
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limb is going to be generated. The cells do not interact at that point because of the HA-
rich matrix that facilitates cell movement [38]. Next, HA is degraded [35] enabling the 
formation of cell clusters in which cell-cell interactions are mediated via neural cadherin 
(N-cadherin) and neural cell adhesion molecule (N-CAM) [39]. Next, the gap junctions 
are established to facilitate small molecule exchange in between the cells [40,41]. 
Meanwhile, a chondrogenesis specific isoform of fibronectin is detected around the cell 
clusters [42], which is thought to have a role in translocation of the cells into the clusters 
[43]. This step is referred as “condensation” and shown to be critical for the initiation of 
chondrogenesis and the molecules mediating the process are downregulated or switched 
off as soon as the chondrogenic differentiation initiates (Fig. 4) [44,45].  
The limb growth is a gradual and dynamic process initiated by mesoderm, 
however the ectoderm layer covering the limb mesoderm also has a critical role in 
extension of the limb facilitated by growth factors [46,47]. By the time cells on the more 
proximal area undergo condensation step and chondrogenesis, a group of 
undifferentiated mesenchymal cells on the distal side, under the paracrine effects 
(mostly FGF-2, -4, -8) of the extending ectoderm, continue proliferating and migrating 
towards distal side of the limb [46,48]. Both the epithelial cells of the ectoderm and the 
mesenchymal cells produce BMP-2, -4, -7 that helps maintaining the limb growth [49].  
After mesenchymal condensation, chondrogenic differentiation is initiated. Cells 
liberated from clusters, with the downregulation of the cell attachment molecules [44],  
proliferate and produce cartilage specific matrix molecules such as collagen II, aggrecan 
and link protein until the individual cells are sparsely distributed and entrapped in 
cartilaginous matrix. After maturation and hyaline cartilage formation, the chondrocytes 
undergo a process called hypertrophy, which is then followed by the ossification of the 
cartilage template generating the bone tissue. There are two main regulators of the 
hypertrophy. The first one, parathyroid hormone-related protein/peptide (PTHrP) 
originating from the periarticular region prevents the hypertrophy preserving the mature 
chondrocytes close to the articular surface. The second one, Indian hedgehog (Ihh) 
promotes hypertrophy by initiating the collagen X production, which then leads to the 
vascular invasion and bone formation (Fig. 4) [50]. The opposing effects of these 
molecules were nicely shown in previous studies. PTHrP receptor knockout in a mouse 
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model resulted in early hypertrophy, led to formation of short bones and lack of 
unmineralized cartilage tissue [51], whilst the Ihh misexpression led to the prevention of 
hypertrophy resulting in the cartilaginous skeletal elements failed to be replaced by bone 
[50].  With the initiation and progression of the hypertrophy, blood vessels enter the 
tissue and replace most of the cartilage template with bone leaving the thin layers of 
cartilage at the ends of the bones (Fig. 3), which then act as shock absorbers for a 
comfortable joint movement throughout the life.  
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Figure 3. Embryonic bone formation via endochondral ossification. A hyaline cartilage template is 
formed (a), hypertrophy is initiated in the middle region (b), blood vessel invasion starts in the primary 
ossification center (c), bone formation and blood vessel invasion continues until the heads of the bone (d), 
blood vessels penetrate to the secondary ossification centers (e), maturation of bone tissue and 
vascularization leaving only thin sections of hyaline cartilage on the articulating surfaces (f). Image is 
courtesy of Creative Commons CC-BY, OpenStax College, Bone Formation and Development. OpenStax 
CNX June 28, 2013, see App. C for permission. 
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Figure 4. Molecular cross-talk during endochondral ossification. The critical changes in the expression 
of growth factors, transcription factors and ECM molecules during aggregation, condensation and 
determination, hypertrophy during bone formation. Image is courtesy of Springer, taken from [52], see 
App. D for permission. 
 
1.6. Injury 
The resilience of the cartilage tissue provides painless joint movement for almost 
half a century in normal health conditions. However, the unique properties such as 
avascularity and low cellularity that are critical for its resilience also limit the self-
healing capacity of the tissue. Articular cartilage can only heal microscopic damage to 
the ECM that can be compensated by surrounding chondrocytes, however for 
macroscopic injuries a surgical intervention is required (Fig. 5A) [21]. Once articular 
cartilage is damaged and degenerated, further complications including the synovial fluid 
and the underlying bone are observed. Bone spur (osteophyte) formation at the outer rim 
of the joint surface and the imbalances in pro- and anti- inflammatory cytokines in 
synovial fluid are some of the complications [53]. It is also suggested that the imbalance 
 Chapter 2: Literature Review 17 
in cytokine profile may cause the activation of the proteolytic degradation of cartilage 
matrix [54] initiating a self-destructive phase rather than self-repairing. The size of the 
cartilage injury is generally defined in affected surface area (top view) and the depth of 
the defect (side view). According to depth, the defect is described as chondral (partial-
thickness or full-thickness) and osteochondral (Fig. 6). The partial-thickness defects are 
the superficial injuries on the surface exposing middle or deep layers of articular 
cartilage (Fig. 6A) whereas the full-thickness defects affect all layers of cartilage and 
expose the underlying bone (Fig. 6B). The osteochondral defects affect both the full-
thickness cartilage and underlying bone (Fig. 6C). The size and depth determination of 
the injury is critical in decision making for defect treatment and it is assumed that a 
macroscopic defect bigger than 1 cm2 can lead to further degeneration if left untreated 
[29]. There are a number of surgical treatment options for acute injuries (Fig. 5A) or 





Figure 5. Articular cartilage defect/lesion and osteoarthritic cartilage. A full-thickness cartilage lesion 
that could occur after an acute injury (A). The state of articular cartilage  in an osteoarthritic knee (B). 
Images are courtesy of Medical Multimedia Group LLC, www.eOrthopod.com , see App.B for 
permission. 
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Full-­‐thickness	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Figure 6. Cartilage defect types. According to the affected area cartilage defects could be partial-
thickness (A), full-thickness (B) or osteochondral (C). 
2. Existing surgical treatments 
2.1. Symptomatic approach  
These methods do not repair or stimulate regeneration of the tissue but provide 
temporary (debridement and lavage) or long-term (joint replacement) pain relief in the 
damaged joint [55]. 
2.1.1. Debridement and lavage 
Arthroscopic debridement (removal of damaged tissue) and lavage (irrigation of 
joint) are the first surgical treatments offered in early phases of OA. Since “shaving and 
washing” the defect does not initiate a repair response, it is speculated that the pain relief 
after treatment may be due to a placebo effect [56]. To test this, double-blind trials were 
conducted and no significant difference was found between the control and the treatment 
groups [57,58] confirming the placebo effect. However, these treatments are not 
completely futile, they could be utilized for different purposes. The cell count in the 
synovial fluid obtained by lavage could be informative about the inflammatory state of 
the joint [59]. The debridement could be useful in order to remove loose pieces and flaps 
in the defect area that might compromise the success of a following treatment [60]. 
Debridement also might help revealing or changing the precise geometry of the defect 
when necessary. Therefore, arthroscopic debridement and lavage might serve as a 
preparatory step for following procedures.  
2.1.2. Joint replacement 
Depending on the cartilage damage site hip, knee, shoulder or ankle joints can be 
replaced. Specifically in knee joint, a partial or a total replacement can take place. In a 
total knee replacement procedure, the joint is exposed and the ends of femur and tibia, 
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together with the damaged cartilage are removed. The prosthetic femoral and tibial 
components are cemented to the ends of the bones generating an artificial joint (Fig. 7). 
The joint replacement procedure is still the gold standard and cost-effective clinical 
treatment for advanced OA [61]. It significantly reduces the pain and improves the life 
quality of the patients. However, the prosthetics generally last for a limited time (10-15 
years) and additional replacements may be necessary for younger patients. The number 
of knee replacements performed in Australia, only in 2012 was reported to be 48,502 
[62]. Despite cost-effectiveness of the procedure itself, when combined with indirect 
costs (including hospital bedding etc.) and the high prevalence of the disease, the joint 
replacements are huge financial burdens on national health care systems and patients 
[61,63,64]. Since joint replacements are the last resort with no further future repair 
possibilities, it is necessary to improve early regeneration techniques in order to delay 
and minimize the onset of OA.  
 
 
Figure 7. Artificial joint. In the knee arthroplasty/replacement surgery, the affected cartilage surfaces are 
removed and replaced by metal and plastic components creating an artificial joint. Image is courtesy of 
Medical Multimedia Group LLC, www.eOrthopod.com , see App.B for permission. 
 
2.2. Reparative approach 
2.2.1. Marrow stimulation 
The partial-thickness defects of articular cartilage do not demonstrate any 
spontaneous repair response whereas the full-thickness defects are immediately filled 
with a blood clot originating from the subchondral bone. This “super clot” is thought to 
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recruit stem cells from bone marrow to form a repair tissue [65]. Some techniques are 
developed exploiting this phenomenon.  
First, Magnuson described abrasion arthroplasty where a surgical instrument was 
used to abrade the subchondral bone surface to induce a repair response [66,67]. Later, 
Pridie described a drilling technique to induce repair response from underlying bone 
marrow [68]. Finally, Steadman et al. introduced microfracture where a surgical awl is 
used to create microscopic fractures at the subchondral bone surface (Fig. 8) [69]. 
Microfracture method was found to be more reproducible and less traumatizing when 
compared to Pridie drilling with thermal necrosis or abrasion arthroplasty with extra 
bone removal [70]. 
Despite the rapid blood clot formation, marrow stimulating techniques mostly 
fail to induce the regeneration of hyaline cartilage, which is collagen II abundant, but 
instead yield a fibrocartilage repair tissue, which is collagen I abundant and inferior in 
biomechanical properties [71]. Because the newly formed repair tissue is fragile, 
compliance with the following rehabilitation protocol, which reduces weight-bearing for 
an extended period, is one of the critical factors determining the success of microfracture 
[72]. The temporary nature of the repair tissue was demonstrated with histology images 
in a rabbit model [73] where the efficient integration of the fibrocartilage with native 
tissue was observed at the end of 24 weeks, however the cartilage was further 
degenerated and fissures appeared between the repair tissue and native cartilage after 48 
weeks [74]. Therefore, the repair tissue generated by marrow microfracture is not 
equivalent to the mechanically resilient hyaline cartilage and a repair tissue without 
efficient integration and functionality would eventually fail [75].  From a tissue 
engineering perspective, this technique attracts attention to the potential use of bone 
marrow-derived MSC in cartilage defect treatment.  
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Figure 8. Microfracture procedure. First the defect region is debrided to obtain a smooth and vertical 
edge (A) then the base of the defect is abraded in order to reveal underlying bone (B) then with a surgical 
awl microfractures of 3-4 mm apart are introduced (C) and the bleeding from underlying bone forms a clot 
filling the defect area (D). Image is courtesy of SAGE, taken from [76], see App. E for permission. 
 
2.2.2. Perichondral or periosteal graft transplantation 
The perichondral graft used to treat cartilage lesions of the knee is harvested 
from the cartilaginous part of the lower rib [77]. It was previously shown that 
perichondral graft can regenerate hyaline-like cartilage when tested in a rabbit defect 
model [78]. The results of the first human trial conducted by Homminga et al. were 
optimistic [77]. Similarly, the use of a periosteal flap taken from the tibia to treat 
cartilage lesions was trialed by Niedermann et al. [79]. The rationale for using the 
periosteal flap was the discovery of the chondroprogenitor cells in the cambium layer, 
which is the inner layer of the periosteal flap [80] and the hyaline cartilage formation 
facilitated by the cells originating from the flap when transplanted in rabbit defect model 
[81].  Both techniques had reparative outcomes to some extent, however the limited graft 
size with donor site morbidity, delamination of the grafts, lack of graft harvest 
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reproducibility, the varying graft nature and failure of hyaline cartilage formation due to 
hypertrophy intrinsic to the graft were the limitations of the techniques that led to 
research looking for alternative treatment options.   
2.3. Restorative approach  
2.3.1. Osteochondral tissue transplantation (Mosaicplasty) 
Allogeneic or autologous osteochondral tissue transfer is another way to treat 
large or small cartilage defects, respectively. Allogeneic tissue is generally obtained 
from cadavers, therefore larger size defects could be restored with this approach; 
however, immune response or disease transmission risks and the low chondrocyte 
viability in stored tissue grafts are the challenges which make this method less preferable 
[70,82].  
Autologous osteochondral tissue transfer was first described in 1993 [83] and 
gained wide popularity over the years with the name “mosaicplasty” [84-87]. In this 
procedure, multiple cylindrical osteochondral plugs were taken from the non-load-
bearing site of the same joint and inserted to the primary defect site revealing a mosaic-
like pattern (Fig. 9). Different size plugs could be utilized in order to maximize the 
defect coverage [72]. The method was generally performed as an open surgery because 
of the challenging task of harvesting osteochondral plugs, however keyhole surgery 
versions were also described [88,89]. The procedure had varying clinical success and 
because of the donor site morbidity it was recommended for defects smaller than 4 cm2 
[29]. The vertical integration of the transferred plugs were relatively fast since it 
required bone to bone integration, however the horizontal integration of the plugs with 
each other and the defect site mostly failed due to chondrocyte necrosis around the edges 
of the grafted tissue [90]. Other problems associated with the procedure were the void 
space in between the cylindrical plugs and difficulty of matching the thickness and 
height of the plugs at the defect site. Critically, the need for larger grafts to treat larger 
defects made this method less promising. 
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Figure 9. Mosaicplasty procedure. In mosaicplasty, a number of osteochondral plugs are taken from the 
non-weight bearing site of the cartilage and inserted into the defect site revealing a mosaic like pattern. 
Image is courtesy of BMJ, taken from [91], see App. F for permission. 
 
2.4. Regenerative approach 
Unlike previously described conservative methods, these techniques include 
innovative ex vivo steps in order to facilitate de novo tissue generation or true 
regeneration to replace the damaged cartilage tissue. Some of the innovative steps are 
the enzymatic isolation, monolayer expansion, redifferentiation of human articular 
chondrocytes and the use of biomaterials enabling efficient delivery or distribution of 
the cells in the defect site.  
2.4.1. Autologous chondrocyte implantation 
The very first cell-based therapy for cartilage repair called Autologous 
Chondrocyte Implantation (ACI) was first described by Grande et al. [92] in a rabbit 
model and the first human trial results were reported by Brittberg et al. in 1994 [93]. In 
ACI, a biopsy of articular cartilage (300-500 mg) was taken from the non-load-bearing 
site of the tissue, then the chondrocytes were liberated enzymatically (180,000-455,000 
cells) and expanded in monolayer for 2-3 weeks (up to 2.6-5 million cells), then in an 
open surgery first the defect was covered with a periosteal flap taken from tibia and 
sutured to the rim of the defect, then finally the chondrocyte suspension (50-100 µl) was 
injected beneath the flap (Fig. 10A). After 16-66 months of follow up good-to-excellent 
results were obtained for most of the patients and regeneration of hyaline-like cartilage 
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was reported [93].  It was an innovative breakthrough because for the first time patient’s 
own cells were expanded ex vivo and high number of cells were delivered to the defect 
site effectively. However, the following clinical trials revealed that the method had some 
limitations [94,95]. In addition to donor site morbidities and chondrocyte 
dedifferentiation, the complications associated with periosteal flap use were criticized. A 
second donor site was created with periosteal flap harvest and early delamination of the 
flap was reported in some cases. Additionally, the cells originating from the flap caused 
hypertrophy in the defect site compromising the desired hyaline cartilage regeneration 
by injected chondrocytes [96,97]. Therefore, new generations of ACI [97] were 
described to eliminate some of the complications. The second generation ACI, later 
referred as collagen-covered ACI (CACI) had aimed to replace the periosteal flap with a 
bilayer collagen I/III membrane [98]. CACI had clinical success [99] with reduced 
surgery duration and morbidity, however the collagen membrane still required sutures to 
the defect site, therefore the ultimate need to improve the existing procedures lead to 
other versions of ACI. 
2.4.2. Matrix-assisted autologous chondrocyte implantation 
Matrix-assisted ACI (MACI) was first described by Behrens et al. in 1999 [100]. 
The CACI and MACI procedures were very similar (both utilizing collagen I/III 
membrane instead of a periosteal flap), however the critical difference that made MACI 
more mainstream today was the way cells were delivered; in CACI the chondrocytes 
were injected beneath the collagen membrane in a suspension (similar to ACI) whereas 
in MACI the chondrocytes were harvested from monolayer then seeded and cultured on 
the membrane for an additional 3 days before implantation [101]. In MACI, the collagen 
scaffold with chondrocytes was fixed to the defect site only with fibrin glue and no 
suturing or watertight sealing was required because the cells had already adhered to the 
collagen membrane (Fig. 10B).  With MACI, the invasiveness and the operation length 
were dramatically reduced. After ACI, MACI was another breakthrough because the 
tissue engineering techniques (chondrocytes seeded and cultured on a biomaterial) were 
used to treat cartilage defects for the first time. MACI is widely applied in orthopedics 
as a routine procedure with successful results in Europe and Australia [101-107] but not 
yet in USA (pending Food and Drug Administration approval) [108]. However, the risk 
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of disease transmission by porcine derived collagen membrane, intensive cost and the 
long duration of cartilage regeneration by monolayer expanded chondrocytes (up to 24 
months[106]) are the drawbacks of the technique, all of which are reasons stimulating 
further improvement of the existing procedures. 
2.4.3. Autologous matrix-induced chondrogenesis 
Another method called Autologous Matrix-Induced Chondrogenesis (AMIC) 
using the same collagen I/III membrane was introduced by again Behrens et al. at the 
end of a MACI follow-up report [101]. Authors drew attention to the cost-intensiveness 
of the MACI procedure and changed their strategy of using monolayer expanded 
chondrocytes (which causes the cost-intensiveness) into utilizing bone marrow derived 
cells similar to marrow stimulating techniques. In this method, microfracture technique 
was combined with the use of a collagen membrane.  First, microfracture was performed 
recruiting the cells from the bone marrow to the defect site, and then the collagen 
membrane was fixed into “bleeding” defect with fibrin glue (Fig. 10C). The advantages 
of implanting a collagen membrane into the defect after microfracture were more 
homogenous defect filling, additional mechanical strength and chondrogenic induction 
of marrow derived cells [109]. When compared to MACI, this one-step technique 
successfully prevented donor site morbidity and increased the practicality and cost 
effectiveness of the procedure. The follow up study with a mean of 37 months revealed 
promising results [109], however the histological assessment of the repair tissue and 
long term follow up reports are required in order to demonstrate effectiveness of the 
technique.   
2.4.4. Autologous chondrocyte spheroid implantation 
Another autologous chondrocyte implantation method was developed by co.don 
(Germany). In this method, the chondrocytes are harvested and expanded similar to ACI 
procedure, however the expanded cells are then used to form spheroids of 200,000 cells 
each (termed as chondrosphere®), cultured in patient’s own serum, then implanted into 
the defect site arthroscopically (Fig. 10D) [110]. The use of animal derived or synthetic 
materials is purposely avoided to offer a complete autologous, biological procedure. The 
culture of chondrocytes in 3D spheroids before implantation is critical because it helps 
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the chondrocytes to redifferentiate and regain their chondrogenic phenotype, which was 
diminished during monolayer expansion [111-113]. Additionally, the arthroscopic 
delivery of spheroids makes this procedure minimally invasive and provides faster 
recovery time. The company is recruiting patients for phase III clinical trials and 
pending approval from European Medicines Agency for this procedure to be routinely 
practiced in Europe.  
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Figure 10. Existing cell-based therapies to treat cartilage injuries. The critical steps and the 
differences of following procedures are demonstrated: Autologous Chondrocyte Implantation (A), Matrix-
assisted Chondrocyte Implantation (B), Autologous Matrix-induced Chondrogenesis (C) and 
chondrosphere (D). 
 
3. Cartilage tissue engineering 
The relative success of cell-based therapies is stimulating cartilage regeneration 
focused-tissue engineering research more than ever. There is also a tremendous 
commercial motivation in finding better treatment options for cartilage defects [114] 
since OA is considered to be an epidemic with increasing age. Therefore, numerous 
researchers from around the globe are seeking alternative ways to treat cartilage defects, 
which would ideally improve clinical outcomes. This led to the accumulation of a great 
body of work in cartilage tissue engineering of which a brief summary will be given in 
this section.  
There are three components considered as cornerstones of cartilage tissue 
engineering: cells, chondrogenic signals and scaffolds (Fig. 11). 
 





















Figure 11. Cartilage tissue engineering overview. In order to obtain an in vitro engineered cartilage 
graft generally cells (chondrocytes or MSC) are seeded on various scaffolds then cultured under chemical 
and mechanical stimuli. This project introduces a scaffold-free approach for in vitro cartilage tissue 
generation. 
 
3.1. Cell source 
3.1.1. Articular chondrocytes 
Autologous articular chondrocytes are often preferred on the basis that they are 
the cartilage-generating units of patient’s own tissue, which requires treatment. These 
cells are ideal because they have the right phenotype and capabilities to be used in 
cartilage regeneration. However, chondrocytes are obtained at a cost of introducing 
another minor injury to the non-healing cartilage and the hypocellular nature of the 
tissue causes low cell yield. This is why the harvested cells are generally expanded on 
monolayer but this process leads to an even more critical problem; rapid 
dedifferentiation and loss of chondrogenic phenotype [115]. It is noted that collagen II 
expression is substantially downregulated during the first few passages [116] and the 
spherical morphology is replaced by fibroblast-like shape [117]. Some studies focused 
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on redifferentiating the expanded chondrocytes in 3D culture environment with addition 
of growth factors [118], however the general notion is that the full chondrogenic 
capacity is never regained. Alternatively, the use of MSC in cartilage regeneration is 
also investigated.  
3.1.2. Mesenchymal stem/stromal cells (MSC) 
MSC are highly utilized in regenerative medicine mostly because of their relative 
ease of harvest, proliferation and differentiation capacity.  MSC can be isolated from 
various tissues [119] but generally bone marrow- and adipose-derived MSC are 
preferred in cartilage regeneration studies since some similarities are observed between 
these two cell populations [120,121]. However, comparative studies concluded that the 
proliferation capacity of adipose derived MSC is higher [122] whilst the chondrogenic 
and osteogenic differentiation capacity of bone marrow-derived MSC is found to be 
superior [123]. Epigenetic alterations studies in different origin MSC reveals that 
promoter DNA hypermethylation occurs at the progenitor state and that may restrict the 
expression of other lineage-specific genes limiting the generation of tissues other than 
the tissue of origin [124,125]. This epigenetic memory phenomenon, described as 
memory from the tissue of origin, supports the use of bone marrow derived MSC in 
cartilage regeneration since it has intrinsic chondrogenic and osteogenic differentiation 
capacity.  
The major challenge associated with the use of MSC in cartilage regeneration is 
the difficulty of obtaining and maintaining a chondrogenic phenotype. One of the 
reasons is the unique way the skeleton is generated from hyaline cartilage during 
development and then replaced by bone via a process called endochondral ossification 
(Development section) [126].  During this process chondrocytes arise from condensed 
MSC and generate a hyaline cartilage template then undergo hypertrophy and apoptosis 
that is synchronized with the ossification of the tissue resulted with the bone formation 
[127]. In theory, this process is mimicked for the chondrogenic differentiation of MSC; 
therefore the chondrogenic characteristics are generally transient and not stable enough 
to regenerate functional cartilage tissue. Numerous studies are still focusing on 
optimizing the culture conditions of MSC to enhance and stabilize chondrogenic 
differentiation and prevent hypertrophy [128-130].  
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Another drawback associated with MSC use is the heterogenic nature of the cell 
population isolated with plastic adherence method [131,132]. Either the presence of 
osteogenic cells in the initial cell population, or the monolayer expansion on a stiff 
plastic surface [133] is enhancing the osteogenic differentiation potential while 
simultaneously compromising the ability to obtain a homogenous chondrogenic 
population. In order to overcome this problem, some studies aimed to isolate more 
“stem-like” cells by sorting them according to the presence or absence of specific cell 
surface markers. However, the inconsistency in the selected markers in different studies 
increased the debate in the field. Finally, the International Society for Cellular Therapy 
published the minimal criteria for defining MSC [134] where the following requirements 
were listed: (1) plastic-adherence, (2) expression of CD 105, CD 73, CD 90 and lack of 
expression of CD 45, CD 34, CD 14 or CD 11b, CD 79α or CD 19 and HLA-DR surface 
molecules, (3) in vitro tri-lineage (chondrogenic, osteogenic, adipogenic) differentiation. 
This report emphasizes the importance of initiating differentiation studies with more 
homogenous and potent cell population in order to have better quality tissue 
regeneration. However, since the criteria above only define the mesenchymal stromal 
cells, the search for true “stemness” markers continues. One of the highly studied cell 
surface antigens is STRO-1 and fibroblast colony forming cells (CFU-F) were 
exclusively found in this STRO-1+ cell population [135]. Following studies revealed that 
the STRO-1+ cells were rich in osteogenic precursors [136], which suggests that STRO-
1 may be a marker for osteogenic lineage [137]. A recent study reported the presence of 
STRO-1 expression in tissues other than the bone marrow, and this finding may raise 
questions about the specificity of STRO-1 as the mesenchymal stem cell marker [138]. 
Another MSC marker Nestin was identified in mouse MSC and it is claimed that Nestin+ 
cells mostly contained self-renewing, CFU-F cells [139]. However, the intracellular 
localization of Nestin led to search for surface markers associated with the presence of 
Nestin. In a recent report, it is demonstrated that PDGFRα and CD51 surface markers 
can be used to identify Nestin+ MSC populations [139]. There are other studies 
suggesting that the Nestin+ cells may be biased towards neural fate [140,141]. Similarly, 
there is a search for a specific marker, which helps to identify the cells with higher 
chondrogenic differentiation potency. In one study, a subset of MSC (CD271bright 
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MSCA-1+ CD56+) were suggested to have higher chondrogenic differentiation capacity 
[142]. While the use of the discussed markers appear to enable enrichment for MSC 
populations, it is still not possible to definitively identify and isolate MSC. The next step 
after isolation is the expansion of MSC, which is also known to be critical. One of the 
factors that help maintaining the stemness and the differentiation capacity is the 
continuous provision of hypoxic atmosphere during cell expansion [143]. It is claimed 
that hypoxia mimics the native stem cell niche preserving the undifferentiated state of 
the stem cells. Another factor is the geometry of the culture. Expanding MSC in 3D 
culture has been trialed and the idea was to better mimic the developmental 
chondrogenesis process [144]. The undifferentiated state of MSC was preserved in 3D 
spheroids, however cell expansion rate was substantially lower in 3D culture when 
compared to 2D [145]. The expansion media composition is also known to be effective 
in the maintenance of the stemness and multipotency. Numerous studies suggested that 
serum free expansion medium is beneficial for preserving stemness and crucial for 
clinical applications [146,147]. One of the studies emphasized that the serum free MSC 
expansion enhances chondrogenic and adipogenic differentiation capacity [148]. In this 
project, MSC were not isolated based on surface marker profiles because of the limited 
access to clinical samples, however MSC expansion was performed under hypoxic 
conditions and the differentiation was facilitated in 3D micropellets in order to 
maximize the chondrogenic features of the generated tissues.   
3.1.3. Coculture of chondrocytes and MSC 
Since both chondrocytes and MSC have complementary advantages, some 
suggest combining the two cell populations to harness the benefits of both. The 
suggested mechanisms explaining how coculture enhances chondrogenesis are 
controversial. Some studies suggest that the trophic effects of MSC help proliferation 
and redifferentiation of chondrocytes whereas others argue that the presence of 
chondrocytes in the culture enhances chondrogenic differentiation and prevents 
hypertrophy of MSC [149-153]. Wu et al. demonstrated compelling evidence that 
presence of human bone marrow MSC enhanced bovine chondrocyte proliferation and 
matrix production, also they reported preferential MSC apoptosis within the first weeks 
of the coculture supplemented with serum containing proliferation media [154]. 
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However, when they repeat the coculture study with chondrogenic media, MSC 
apoptosis was decreased [155]. Therefore, the interplay between two cell types in 
accordance with the coculture microenvironment and the actual mechanisms driving the 
benefit of coculture remain to be elucidated.  Further studies need to investigate the 
effects of combining the two cells populations in order to justify the extra effort required 
to use both cells types in clinical applications.  
3.2. Chondrogenic signals 
Chondrocytes are highly differentiated and specialized cells that maintain the 
fine balance between the anabolism and catabolism of the unique ECM of hyaline 
cartilage. Similarly, MSC require very specific “directions” in order to acquire 
chondrogenic characteristics. In chondrogenic differentiation studies it is soon realized 
that obtaining and maintaining this specific phenotype requires more than an undefined, 
batch-to-batch varying serum containing medium. This realization led to the 
formulations of a serum-free, chemically-defined medium generically referred as 
“chondrogenic differentiation/induction medium” that combines specific growth factors 
and chemical species at specific concentrations [156,157]. There are also other factors 
such as oxygen concentration and mechanical stimuli that effects chondrogenesis.  
3.2.1. Growth factors 
Growth factors that are known to be critical during cartilage development are 
considered the most effective chondrogenic medium additive. Some of the well-known 
growth factors with chondroinductive effect are transforming growth factor beta (TGF-β 
1,3), bone morphogenic protein (BMP-2,4,7), basic fibroblast growth factor 
(bFGF/FGF-2) and insulin-like growth factor (IGF-1).  TGF-β 1 plays role in 
chondrocyte differentiation, maturation, proliferation and chondrogenic matrix synthesis 
[158-163]. Recently another isoform, TGF-β 3, has gained popularity in chondrocyte 
redifferentiation and chondrogenic differentiation of MSC [164-167]. BMP isoforms are 
known for upregulating N-cadherin expression required for MSC condensation before 
chondrogenic differentiation (BMP-2) [168], inducing Smad1 or Smad5 mediated 
chondrogenesis (BMP-4) [169] and increasing cartilage ECM synthesis whilst  
decreasing catabolic effects of interleukins and matrix metallopeptidases (BMP-7) [170]. 
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FGF-2 expansion medium supplementation has been shown to increase MSC 
proliferation and subsequent chondrogenic capacity [171]. IGF-1 was also reported to 
enhance both MSC chondrogenesis and prevent chondrocyte dedifferentiation [172,173] 
and additive effects were observed when used in combination with TGF-β 1 [172]. 
Generally, most studies start with investigating the chondrogenic effects of a single 
growth factor as a continuous supplement in culture medium, however it is more rational 
to think that the combination of growth factors, ideally with spatial and temporal control, 
would better mimic the well-orchestrated, strictly-regulated cartilage development 
process [34,174]. Additionally most of the growth factors of which chondrogenic effect 
is demonstrated in vitro, appear to have deleterious side effects such as synovial fibrosis 
and osteophyte formation when injected in vivo [174]. Therefore, more autologous and 
benign ways of concentrated growth factor delivery strategies, such as platelet-rich 
plasma (PRP)[175] or bone marrow concentrate (BMC)[176] injections, are being 
trialed, however more extensive research regarding those novel techniques is required in 
order to validate their effectiveness when compared to growth factor supplements.  
3.2.2. Oxygen concentration and other chemicals 
It is well-known that the oxygen concentration also affects chondrogenesis 
[177,178] and low oxygen (hypoxic) atmosphere (2-5% O2) is generally preferred since 
the oxygen concentration in native cartilage is low and the chondrocytes obtain energy 
through glycolysis [179]. It is shown that during both expansion and redifferentiation of 
chondrocytes, hypoxic atmosphere helps preserving chondrogenic properties [17,180]. 
Similarly, the chondrogenesis of the bone marrow MSC is enhanced when cultured 
under low oxygen atmosphere during both expansion and differentiation [18,181]. This 
effect is thought to be related to the original niche of MSC in the bone marrow being 
also hypoxic [182]. The chondrogenic effect of hypoxia is mediated via hypoxia-
inducible factor (HIF) molecules. HIF-1α is known to mediate chondrocyte growth 
arrest and survival in low oxygen microenvironment [183,184] whereas specifically 
HIF-2α is shown to mediate the upregulation of chondrogenic gene expression via SOX9 
dependent and independent pathways [185,186].  
Some other additives are suggested to further enhance chondrogenesis when 
supplemented in chondrogenic differentiation medium. The well-known additives are 
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dexamethasone, which upregulates cartilage ECM expression [187], ascorbic acid that 
takes role in collagen synthesis pathway [188], parathyroid hormone-related peptide, 
which is  shown to be critical in prevention of hypertrophy [189]. 
3.2.3. Mechanical stimulation 
 In addition to the chemical cues in the environment, engineered cartilage tissue is 
also known for its sensitivity to mechanical stimuli, which simulate the aspects of joint 
movement. Mechanical stimulation can be applied in different ways including direct 
mechanical compression [190-192], surface motion [193,194], hydrostatic pressure 
[195] or ultrasound [196,197]. However, it is critical to finely tune the magnitude, 
duration and the frequency of the mechanical stimuli because weak stimuli might fail to 
demonstrate any effect or strong stimuli might have deleterious effects on cultured cells 
and the tissue. The mechanical forces affect the cultured tissue in two ways; (1) by 
enhancing the diffusion of medium and its contents in a more dynamic 
microenvironment hence increasing cell viability, proliferation and matrix production 
[198], (2) by activating certain signaling pathways with a process called 
mechanotrunsduction,  which is critical in maintaining the integrity of the articular 
cartilage [199]. It is reported that the single cilium found in the chondrocytes act as a 
mechanoreceptor [200] and at a molecular level it is suggested that the integrins convey 
the mechanical forces to the inner cell activating critical pathways including mitogen-
activated protein (MAP) kinase/JNK pathway [201]. The exact details of this complex 
interaction between the cartilage ECM and the chondrocyte mediated via mechanical 
forces are not yet fully understood. Once these details are clarified, it may be possible to 
partly mimic the mechanotrunsduction effects by media supplements.  
Mechanical stimulation in cartilage tissue engineering studies will likely require 
a sterile closed system such as a bioreactor combined with the mechanical components, 
which might be costly and less practical. Additionally to be able to introduce forces to 
the culture, the tissue needs to be mature enough to endure the loadings, which may 
require longer culture duration increasing the cost intensiveness; therefore the clinical 
relevance of such applications is questionable. Nevertheless, these systems are useful 
tools in order to mimic the natural dynamics of an articulating joint in vitro to better 
understand the interplay between the cells and the biomechanical forces.  
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3.3. Scaffolds 
Scaffolds are commonly utilized in cartilage tissue engineering. The primary role 
of a scaffold is to provide a structure for cells to colonize. The use of a scaffold is also 
considered as a practical strategy to improve the mechanical properties of the engineered 
tissue that facilitates the manual handling during subsequent procedures. In addition, the 
specific characteristics of the selected scaffold may contribute to cell proliferation, 
differentiation and ECM production [202]. Ideally, scaffolds must meet the criteria of 
being non-toxic, non-immunogenic, biocompatible, biodegradable, reproducible, easily-
manufactured and mechanically strong to be appropriate for tissue engineering [203]. 
According to the origin of their materials scaffolds are classified as natural or synthetic 
and according to their manufacturing process and structure they can be 3D-printed, 
porous, nanofibrous, microspheres hydrogels or hybrids.  
3.3.1. Natural scaffolds 
Natural scaffolds are generally preferred because of their inherent 
biocompatibility, however they may still stimulate antigenic responses. The most 
commonly used protein-based natural materials are collagen, gelatin, fibrin and the 
carbohydrate-based ones are hyaluronic acid (HA), chitosan and alginate.  Collagen is 
widely used as it is naturally found in most of the tissues, biodegradable, cell adhesive 
with RGD (arginine-glycine-aspartic acid) peptide sequence and can easily be combined 
with other materials [204]. It can also be manufactured in different forms such as a 
porous sponge [205], a hydrogel [206] or a nanofibrous scaffold [207].  As collagen can 
easily modify surfaces, it is generally used to coat the other types of scaffolds to increase 
their biocompatibility [208,209].  Gelatin is the denatured form of collagen and has a 
thermo-reversible gelling ability, which makes it a practical and attractive hydrogel for 
encapsulation of cells in cartilage tissue engineering. However, the mechanical strength 
of gelatin is very low at body temperature, therefore functionalized versions of gelatin 
emerged mostly with the photocurable/photocross-linkable properties [210-212]. One of 
the methods introduces methacrylamide groups, which can be cross-linked with UV 
light yielding a gelatin hydrogel with tunable curing properties [213]. Fibrin glue is a 
biological hydrogel of which components (human fibrinogen and thrombin, critical 
elements of blood coagulation) are commercially available (Tissel, Austria) and widely 
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used in surgeries to stop local bleeding or immobilize/glue the biological implants in 
place [214]. It is generally used to encapsulate the cells in vitro [215,216] or to aid the 
precise and efficient delivery of the cells to the defect site in vivo  [217]. However, the 
rapid enzymatic degradation of the fibrin makes it only useful for short-term 
applications. Hyaluronic acid/hyaluronan (HA) is present in native cartilage and the 
synovial fluid, therefore, is a widely used scaffold material, however it is water soluble 
and lacks mechanical integrity in aqueous environment [218]. Fortunately, the hydroxyl 
and carboxyl-rich chemical structure allows different types of chemical or photo 
crosslinking to obtain water insoluble scaffolds [219,220]. The esterification of HA with 
different alcohols yielded an FDA-approved commercial HA product called HYAFF® 
(Italy), which was then used for cartilage tissue engineering applications and cell-based 
therapies [221,222]. In a HA-based scaffold, Jacobsen et al. showed that bone marrow 
MSC were able to express collagen II 600 times higher than the chondrocytes [223]. It is 
suggested that the highly porous, open microenvironment facilitates the condensation 
step required for MSC chondrogenesis [218], however that also leads to the escape of 
collagen II molecules to the culture media [223]. Chitosan derived from chitin (found in 
the exoskeleton of arthropods) is used in cartilage tissue engineering because of its 
extreme chemical structure similarity to the sGAG and HA found in native cartilage 
[224]. It is reported that the chondrocytes can maintain their spherical morphology when 
grown on a chitosan membrane and minimize the dedifferentiation at a cost of 4.7 times 
less growth when compared to tissue culture plastic [225]. Chitosan is soluble in acidic 
environment and the solution is freeze-dried to obtain a simple porous scaffold [226] or 
it can also be used as a stimulus-responsive “smart” injectable hydrogel [227]. Alginate, 
derived from brown seaweed, is a widely used, practical hydrogel that can be reversibly 
cured with the addition of a cation ion such as Ca2+ [228]. Alginate gained wide 
popularity in cell encapsulation studies after it is suggested that geometry of the cells 
affects their chondrogenic properties and spherical morphology is generally 
accompanied by enhanced chondrogenic characteristics [229,230]. However, alginate 
lacks cell adhesion sites and it is known that the cell-cell or cell-matrix interactions are 
critical for the communication between the cells and their microenvironment. Therefore, 
encapsulation of single cells in alginate may cause cell stress. Additionally, alginate is 
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not biodegradable; it is claimed that the mechanical strength is lost due to uncontrolled 
dissociation of Ca2+ ions overtime [231]. However, alginate is also used to reverse 
insulin-dependent diabetes with encapsulation of islet cells to prevent immunogenicity 
[232] and the long term success of this application indicates that alginate enables 
diffusion of molecules but physically stays intact in vivo, which could potentially 
compromise the regeneration of cartilage tissue in the defect site.  
Overall, batch-to-batch variation of the materials, no control over the 
biodegradation and mechanical weakness are the limitations of the natural scaffolds. 
3.3.2. Synthetic scaffolds 
Synthetic biodegradable polymers are used in cartilage tissue engineering to 
overcome some of the problems associated with the natural materials. Synthetic 
materials are relatively easier to reproduce, mass-produce and have uniform, predictable, 
robust, tunable mechanical properties. Some of the frequently used synthetic materials 
are linear aliphatic polyesters such as poly(lactic acid) (PLA), poly(glycolic acid) 
(PGA), and their copolymers poly(lactic acid-co-glycolic acid) (PLGA), 
polycaprolactone (PCL) and polyethers such as poly(ethylene glycol) (PEG) and 
poly(ethylene oxide) (PEO). PLA and PGA are degraded by hydrolysis producing lactic 
acid and glycolic acid, respectively, which increases the acidity of the microenvironment 
[233]. PLA is known to be more hydrophobic than PGA, therefore it degrades slower 
[234] and has milder toxicity on cells [235]. However, the slow degradation of the PLA 
delays the proliferation of cells compromising rapid regeneration of the tissue [236]. 
Therefore, copolymers of those materials are produced (PLGA) with varying PLA-PGA 
ratios to tailor the biodegradation rate and acidic by-product release. PLGA is an FDA 
approved material and is commonly used in cartilage tissue engineering as a scaffold in 
the form of microspheres [237,238], porous sponge [239,240] or fibrous mesh 
[241,242]. Polycaprolactone (PCL) is another type of polyester used in cartilage tissue 
engineering. It is one of the most commonly electrospun materials [243] and known to 
be non-toxic and inexpensive [244]. It is shown that by changing the modulus of the 
electrospun PCL scaffold, MSC can be differentiated in to chondrogenic or osteogenic 
lineages on soft or stiff scaffolds, respectively [245]. However, the low swelling and 
slow biodegradation (described in terms of years) are the shortcomings of this material 
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[243]. PEG and its high molecular weight version PEO are highly hydrophilic and 
generally used in the form of a hydrogel in cartilage tissue engineering applications. The 
hydroxyl end-groups and the overall chemical structure make PEG a widely chemically 
modified synthetic material so that the modification of therapeutic agents with PEG 
chains referred as “pegylation” [246,247]. For example, the biodegradation can be tuned 
with the incorporation of PLA whilst photocross-linking can be achieved with the 
addition of dimethacrylate groups yielding a biodegradable and photocurable PEG 
hydrogel to be used in cartilage regeneration studies [248,249]. Photopolymerizable 
PEG hydrogels are also used as injectable scaffolds delivered in a minimally invasive 
way and then cured in the defect with transdermal UV light exposure [250]. However, in 
addition to its lack of biodegradability, PEG is also biologically very inert with no cell 
attachment sites. To overcome this problem cell attachment sites, RGD peptides, can be 
chemically incorporated into the PEG hydrogels in varying concentrations [251].  
Overall, their high immunogenicity, lack of biological property/degradability and 
cytotoxic by-products are the limitations of the synthetic scaffolds.  
3.3.3. Hybrid scaffolds 
The natural scaffolds may be used on their own in clinical applications (collagen 
I/III membrane used in MACI), however most of the synthetic materials require some 
modifications to gain more biological properties and to hinder their immunogenic nature 
before implantation. Also, combining natural and synthetic materials may be necessary 
to finely tune the scaffold properties such as biodegradation rate, rigidity, pore size and 
biocompatibility. This leads to the common hybrids of natural/synthetic scaffolds used 
for cartilage regeneration [202,241,252]. The modification can take place in different 
ways such as simple mixing or blending, crosslinking the components or surface 
coating, layer-by-layer localizing the specific components. The PLGA/collagen 
scaffolds are common and it is shown that the chondrogenic properties of the tissue 
cultured on hybrid scaffolds were enhanced when compared to collagen or PLGA only 
scaffolds [241,253-256]. Similarly PCL/collagen/chondroitin sulfate scaffolds were able 
to increase the proliferation and ECM production of chondrocytes when compared to 
PCL only scaffolds [257]. More combinations with different types of natural and 
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synthetic materials need to be trialed, optimized and compared to be able to decide 
which scaffold is ideal for which tissue engineering approach.   
3.3.4. Decellularized cartilage  
The use of decellularized ECM as a scaffold is now a common strategy for a 
wide variety of organ/tissue engineering studies [258]. Autologous [259], allogeneic 
[260] or xenogeneic [261-265] ECM can be used for repairing the original tissue the 
ECM is derived from [261-263,265-267] or it can be used in a novel way to repair a 
different organ with similar biological properties [268-271]. Decellularized ECM use is 
even more prevalent in orthopedic tissue repair [272] since these tissues are endowed 
with resilient mechanical properties mainly by their ECM-rich structure. 
Decellularization and recellularization of articular cartilage has been described in some 
studies, however the intact, non-porous, ECM-rich tissue structure makes this process 
inefficient.  
The aim of decellularization step is to remove the foreign material that could 
cause infection, disease transmission or immune reaction [263]. Extensive research is 
focusing on optimizing decellularization of cartilage while preserving the mechanical 
strength of the native tissue [263,273-276]. Recellularization, however, is necessary to 
vitalize the tissue graft before implantation because repopulation of the implanted 
decellularized tissue by native chondrocytes is less likely since these cells have limited 
migration capacity. Recellularization of 1 mm thick cartilage pieces was shown to be 
limited to the periphery of the tissue [277,278] whereas cell penetration rate was 
increased when thinner tissue sections were used [279]. Based on these findings, 
powdered cartilage matrix use was trialed to enhance the repopulation of the 
decellularized tissue. In two studies, physically crushed donor cartilage particles were 
used to manufacture porous scaffolds [280,281]. Similarly, our group previously 
explained the benefits of using powdered microscopic donor cartilage particles referred 
as “cartilage dust”, where the cells and the cartilage dust were directly mixed and 
cocultured [282]. In Chapter 4, the use of cartilage dust in tissue engineering 
applications is further investigated where the incorporation of cartilage dust into MSC 
micropellets is reported. 
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3.3.5. Limitations of scaffolds 
In addition to their many advantageous properties, the scaffolds also have their 
downsides. Despite they are considered an essential component for cartilage tissue 
engineering; the problems associated with the use of a scaffold cannot be 
underestimated.  
The natural scaffolds such as collagen membranes are derived from xenogeneic 
sources, which is associated with disease transmission risks. Generally, porcine derived 
collagen is utilized, and the material is treated with strong alkaline solutions to inactivate 
any nucleic acid residue that may cause disease transmission [283]. Additionally, the 
telopeptide regions of collagen, which are known to be antigenic, are removed to prevent 
immune response [283]. However, the companies never assure the 100% safety of the 
product, therefore even low, there are immune response and disease transmission risks.  
The use of synthetic scaffolds is even more questionable since there are no 
effective strategies to prevent immune response when implanted in vivo. The surface 
modification with biological materials may serve as a short term solution effective only 
during the first weeks of the implantation [284].  Most of the synthetic materials lack 
biodegradability; therefore the implanted material may act as a barrier preventing the 
cell proliferation and new tissue formation. There are some synthetic materials with 
biodegradability, however the challenge in this case is to control the biodegradation rate 
because most of the common materials used in cartilage tissue engineering such as PLA, 
PLGA undergo bulk erosion rather than the ideal surface erosion [285]. This effect 
causes rapid loss of the mechanical strength but more importantly the accumulation of 
the acidic by-products decreases the pH in the microenvironment, which may diminish 
the cellular activity in surrounding tissue and can cause immune response [286]. The 
avascular nature is thought to provide cartilage an immune-privileged status, however it 
is the intact superficial layer preventing the infiltration of the immune cells from the 
synovial fluid and in the case of an injury this mechanism is impaired. Therefore, the 
biocompatibility and the control of biodegradation rate in synthetic scaffolds need 
further optimization before they are routinely used in clinical treatments.  
Most of the 3D printed or porous scaffolds are considered to be a pseudo-3D 
culture platform since they can only provide the cells a “surface” to attach to, similar to 
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monolayer culture. Specifically in low cell seeding densities, where the cell-cell 
interaction is limited, the cell morphology seems to be similar to the monolayer culture. 
Alternatively, hydrogels are preferred because the spherical cell morphology, one of the 
key characteristics of the chondrocytes, can easily be mimicked in such platforms. 
However, single cell encapsulation in a hydrogel almost completely blocks the cell-cell 
interactions, which are known to be essential for MSC chondrogenesis (see 1.5. 
Development section). At that point, the scaffolds seem inefficient in mimicking the 
critical elements of biological microenvironment.  
In conclusion, it is the lack of complete autologous and biological solutions that 
motivate the use of scaffolds in cartilage tissue engineering. The biological components 
such as cells on their own lack the strength to mimic the natural resilience of articular 
cartilage, therefore the scaffold use has a merit in order to provide a temporary support 
to the regenerating tissue. However, it is still important to search for more biological 
strategies and ideally eliminate the use of foreign materials in clinical treatments.  
3.4. Scaffold-free cartilage tissue engineering, micropellets as building blocks 
In order to engineer a tissue without the mechanical support of a scaffold, an 
entity reasonably greater than a single cell is required, because it is simply impractical 
trying to shape a tissue structure using the single cells as building blocks. Cell 
pellets/spheroids/aggregates, which contain certain number of cells attached with the 
help of cell-cell and/or cell-ECM interactions, are the ideal candidates for being building 
blocks in scaffold-free tissue engineering approaches.  
It is known that the chondrogenic differentiation of MSC and redifferentiation of 
expanded chondrocytes are enhanced when the cells obtain a round morphology similar 
to the chondrocytes in native cartilage [287-289]. It is also shown that the cell-cell 
interactions are essential in order to initiate MSC chondrogenesis. Hence a conventional 
method was first described by Johnstone et al. [157] where 200,000 MSC were 
centrifuged in a tube to form a 3D high-density cell aggregate, later this method was 
commonly referred as pellet culture. Despite still being the gold-standard method for 
MSC chondrogenesis and chondrocyte redifferentiation, pellet culture often yields a 
radially heterogenic histological appearance for matrix distribution. The common 
heterogeneity patterns are the uneven matrix distribution, necrotic core and fibrous outer 
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layer.  It is highly possible that the large pellet size (~1 mm diameter) causes diffusion 
gradients throughout the pellet and this effect is exacerbated with the accumulating 
cartilaginous matrix resulting in uneven matrix distribution [18]. The diffusion gradients 
may form for chondrogenic factors, metabolites, waste products and oxygen 
concentration. Using smaller size pellets can mitigate diffusion gradient formation and 
yield more homogenous chondrogenesis [18]. The small size pellets termed as 
micropellets in this study are made of 150-200 cells with a diameter of 100-200 µm 
each.  
The micron size pellets have some advantages when compared to traditional 
large pellets. It is anticipated that large pellets cultured under atmospheric oxygen have a 
decreasing oxygen gradient from surface to the core, yielding cartilaginous tissue in the 
interior region whereas the well-oxygenated outer layer has a fibrous appearance. It is 
assumed that the concentrations of both oxygen and chondrogenic factors are more 
predictable and less changing throughout the micropellets provided by their micron-
scale size. Therefore, micropellet culture is geometrically superior in providing more 
homogenous conditions while mimicking 3D culture microenvironment.  
Another challenge in cartilage regeneration is replicating the matrix abundant 
low cellularity of the native tissue. Hydrogel systems mimic the low cellularity too early 
by diluting single cells in a large volume of hydrogel, which is hardly ever replaced by 
cartilaginous matrix. The aggregation of fewer cells in individual micropellets may 
allow rapid matrix accumulation and increase in size, yielding low cellular and matrix 
rich chondrogenic building blocks of micropellets.  
Previously, our group showed that when reduced pellet size was coupled with 
low oxygen atmosphere MSC chondrogenesis was enhanced [18]. Similarly, in Chapter 
3, the enhancement of expanded chondrocyte redifferentiation in micropellets coupled 
with low oxygen is demonstrated. In Chapter 4, it is shown that the micropellets 
mediated more efficient incorporation of cartilage particles into the engineered tissue. 
Finally, in Chapter 5 osteogenic and chondrogenic micropellets are used as building 
blocks to engineer a composite osteochondral-like tissue. In this Thesis, I suggest that 
the chondrogenic micropellets can be arthroscopically delivered to fill non-uniform 
complex-geometry defects of articular cartilage. I also suggest and demonstrate that 
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various types of micropellets can be utilized as building blocks to engineer large and 
composite structures such as a biphasic tissue, bypassing the scaffold use (Fig. 11). In 
this Thesis, I report that micropellets with different characteristics can be manufactured 
and assembled in an organized fashion to be able to obtain continuous composite 
macrotissues.  
Next three chapters are independent research articles with significant common 
elements such as micropellet manufacturing and a subsequent assembly. Each one of 
these studies address one of the specific aims of this study, also represent an example of 
utilizing micropellets as building blocks.  
 
- Chapter 3 aims to test the micropellet approach in redifferentiation of 
monolayer expanded human articular chondrocytes 
- Chapter 4 aims to increase matrix content and defect filling properties of 
human bone marrow MSC micropellets with incorporation of donor cartilage 
particles 
- Chapter 5 aims to assemble osteogenic and chondrogenic micropellets in 
order to generate a scaffold-free osteochondral-like tissue 
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Chapter 3:  The interplay between chondrocyte redifferentiation pellet size 





Chondrocytes dedifferentiate during ex vivo expansion on 2-dimensional 
surfaces.  Aggregation of the expanded cells into 3-dimensional pellets, in the presence 
of induction factors, facilitates their redifferentiation and restoration of the chondrogenic 
phenotype.  Typically 1x105-5x105 chondrocytes are aggregated, resulting in “macro” 
pellets having diameters ranging from 1-2 mm. These macropellets are commonly used 
to study redifferentiation, and recently macropellets of autologous chondrocytes have 
been implanted directly into articular cartilage defects to facilitate their repair.  
However, diffusion of metabolites over the 1-2 mm pellet length-scales is inefficient, 
resulting in radial tissue heterogeneity.  Herein we demonstrate that the aggregation of 
2x105 human chondrocytes into micropellets of 166 cells each, rather than into larger 
single macropellets, enhances chondrogenic redifferentiation. In this study, we describe 
the development of a cost effective fabrication strategy to manufacture a microwell 
surface for the large-scale production of micropellets. The thousands of micropellets 
were manufactured using the microwell platform, which is an array of 360x360 µm 
microwells cast into polydimethylsiloxane (PDMS) that has been surface modified with 
an electrostatic multilayer of hyaluronic acid and chitosan to enhance micropellet 
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formation.  Such surface modification was essential to prevent chondrocyte spreading on 
the PDMS.  Sulfated glycosaminoglycan (sGAG) production and collagen II gene 
expression in chondrocyte micropellets increased significantly relative to macropellet 
controls, and redifferentiation was enhanced in both macro and micropellets with the 
provision of a hypoxic atmosphere (2% O2).  Once micropellet formation had been 
optimized, we demonstrated that micropellets could be assembled into larger cartilage 
tissues.  Our results indicate that micropellet amalgamation efficiency is inversely 
related to the time cultured as discrete micropellets. In summary, we describe a 
micropellet production platform that represents an efficient tool for studying 
chondrocyte redifferentiation and demonstrate that the micropellets could be assembled 
into larger tissues, potentially useful in cartilage defect repair. 
2. Introduction  
Cartilage is an avascular tissue with poor regenerative capacity.  Existing 
surgical repair strategies are limited in their efficacy [290-292], and largely function 
only to delay the onset of osteoarthritis [293,294].  It is envisaged that autologous cell-
based therapies will overcome these regenerative barriers, enabling defect repair and 
restoration of long-term joint function [93,295].  However, in practice, cell-based 
therapies have demonstrated only modest efficacy relative to less complex and less 
costly treatment protocols such as microfracture [296,297].  Nevertheless, the capacity 
of cell-based therapies to deliver more cells of an appropriate phenotype into defect sites 
is seen as a unique feature that will ultimately enable their efficacy.  Notably, 
manufacturing this ideal cell population remains a challenge [298].   
Clinically approved cell-based cartilage defect strategies utilize autologous 
chondrocytes harvested from non-weight bearing regions of the joint targeted for repair 
[93,299].  Selection of articular chondrocytes as a starting population is rational, as 
these cells have a phenotype appropriate for articular cartilage tissue formation.  
However, this “optimal” phenotype is lost when the finite number of donor 
chondrocytes is expanded using traditional 2-dimensional (2D) tissue culture 
methodologies [300,301].  A number of research groups have explored alternatives to 
conventional 2D expansion processes [302-304], but avoiding chondrocyte 
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dedifferentiation whilst also achieving the necessary expansion in a clinically relevant 
time frame has not yet been achieved.   
During in vitro studies, expanded chondrocytes are commonly redifferentiated 
through the aggregation of 1x105-5x105 cells into a 3-dimensional (3D) pellet in the 
presence of TGF-ß or other induction factors [305-310].  The resulting “macropellet” is 
macroscopic, having diameters of 1-2 mm.  Significant diffusion gradients develop over 
such length-scales and as a result the redifferentiation phenotype and matrix deposition 
vary radially through the pellet [306,311-313].  Despite this artefact, macropellet 
cultures remain the gold standard for studying chondrocyte redifferentiation in vitro, 
and in recent clinical trials they have been directly implanted into articular cartilage 
defects to facilitate tissue regeneration by co.don® AG (Teltow, Germany) [313,314].  
Macropellets’ popularity as a redifferentiation platform, and now potentially as a 
clinical tool, reflects the simple and robust methods used in their manufacture. The cells 
are easily pelleted via centrifugation in polypropylene tubes or v-bottom plates.  Whilst 
being an inexpensive process, the heterogeneous product derived from pellet cultures 
limits our capacity to investigate and optimize redifferentiation mechanisms for clinical 
application. 
In previous work we outlined how a commercial microwell product could be 
utilized to manufacture thousands of micropellets (166 cells each, diameters of ~100 µm 
each) of mesenchymal stem/stromal cells (MSC) and subsequently differentiate them 
into chondrocytes [18].  The reduced diameter of the micropellets mitigated diffusion 
gradients, enhanced MSC chondrogenic differentiation and generated a more uniform 
cell product [18].  We reasoned that a similar strategy should also enhance chondrocyte 
redifferentiation, and that optimized chondrocyte micropellets should be capable of 
subsequent assembly into larger tissues, thereby demonstrating their potential in tissue 
engineering applications. To further optimize the redifferentiation process, and to better 
understand the role of hypoxia in relation to pellet dimension, redifferentiation studies 
were performed in hypoxic (2% O2) and normoxic (20% O2) atmospheres.    
Identifying a cost effective platform for micropellet formation is essential for 
routine and thorough micropellet experimentation.  To address this need, an in-house 
process for the manufacture of a microwell platform from polydimethylsiloxane 
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(PDMS) was developed.  This custom PDMS microwell platform was then surface 
modified with an electrostatic multilayer of hyaluronic acid (HA) and chitosan (CHI) to 
promote micropellet formation.  Such surface modification was essential to prevent 
chondrocyte spreading on the PDMS, and the HA/CHI multilayer ensured robust 
micropellet formation.  Using this platform, the redifferentiation of 2x105 2D-expanded 
chondrocytes, either assembled into single macropellets or into 1200 micropellets (166 
cells each), in 2% and 20% oxygen atmospheres were contrasted over 14 days.  
Macropellets and micropellets were characterized for metabolic activity, total sulfated 
glycosaminoglycan (sGAG), DNA production, gene expression and histology.  In 
subsequent experiments, the optimal micropellet manufacturing protocol (2% O2) was 
utilized to characterize the capacity of micropellets of different maturity to amalgamate 
into a single cartilage tissue.  Micropellets from day 4, 8, 11 or 14 cultures were 
amalgamated up to 21 days, and integration was assessed via histology. 
3. Materials and methods 
All materials were purchased from SIGMA-ALDRICH® unless otherwise stated. 
 
Fabrication of microwell surface 
Soft lithography was used to prepare custom microwell surfaces [315]. A silica 
wafer having an array of microwells with the dimensions of 360 µm x 360 µm x 180 µm 
(Fig. 12A) was prepared via deep reactive ion etching [316] by the Australian National 
Fabrication Facility-Queensland (ANFF-Q).  PDMS (Slygard®, silicone elastomer kit) 
was used to generate a negative imprint of the microwell surface on the silica wafer (Fig. 
12A, B), as per the manufacturer’s protocol.  This PDMS negative was then used as a 
mold to generate a replica of the original microwell surface.  First, the PDMS negative 
was coated with a 5% solution of Pluronic-F127 to act as a release agent.  The Pluronic-
F127 coated surface was permitted to air-dry overnight.  It was then used to cast the 
replica surface in a 2 mm thick layer of PDMS (Fig. 12C).  This layer was cured at 60˚C 
for one hour and then pealed from the negative.  As this process was not sufficiently 
reproducible to enable reliable mass production of such surfaces, a hot embosser was 
used to cast this replica PDMS shape into polystyrene.  This polystyrene surface then 
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functioned as a mold that could be used repeatedly to cast microwell sheets (Fig. 12D, 
E). The polystyrene hot embossing was achieved by taking a sheet of polystyrene cut 
from a culture flask and pressing the PDMS replica surface into it (at 160˚C for 15 
minutes with minimal pressure, POWER TEAM hydraulic heat press), PDMS sheets 
with microwells were mass-produced (Fig. 12E), and 2 cm2 disks were punched from the 
PDMS sheets (Fig. 12F), which were inserted into 24-well plates (Nunc™).  
 
Surface modification of microwells 
We previously showed that cells cultured on unmodified PDMS microwell 
surfaces have a propensity to spread rather than form pellets [317], and this microwell 
platform exhibited similar problems when culturing chondrocytes in serum-free 
chondrogenic redifferentiation medium (Fig. 12H). To minimize cell attachment to the 
microwell surface (Fig. 12I), the PDMS insert surface was chemically modified using a 
variation of our electrostatic multilayer (ML) technique [318] (Fig. 12G).  Prior to ML 
deposition, a net negative charge was imparted on the PDMS microwell surface utilizing 
a hand-held high frequency plasma generator (Model BD-20, ETP) [319].  Immediately 
following plasma modification, the inserts were submerged in an electropositive poly-L-
lysine solution (50 µg/mL in MES buffer, pH 5.5) and centrifuged at 4000xg for 5 
minutes to ensure that the fluid entered the microwells.  The poly-L-lysine was adsorbed 
onto the PDMS surface for 30 minutes at room temperature (RT).  The wells were then 
rinsed twice with MES buffer, and ML deposition was initiated by adsorbing 
electronegative hyaluronic acid (HA) (50 µg/mL in MES buffer, pH 5.5) plus 1:100 
dilution of fresh cross-linker stock.  N-Hydroxysuccinimide (NHS) and N-Ethyl-N′-(3-
dimethylaminopropyl) carbodiimide hydrochloride (EDAC) cross-linker stock solution 
contained 50 mg/mL EDAC plus 70 mg/mL NHS in DMSO.  We found that the DMSO 
stock solution could be effectively frozen and stored at -20ºC in aliquots as long as the 
aliquots were used immediately upon thawing.  The HA layers were adsorbed and cross-
linked to the poly-L-Lysine for 20 minutes, and then the surfaces were washed twice 
with MES.  Next, a layer of electropositive chitosan (CHI, 50 µg/mL CHI in MES 
buffer) was adsorbed to the HA layer for 20 minutes at RT. This process was repeated 
until 4 bilayers of HA-CHI were deposited, with the top layer being HA. The inserts 
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were then sterilized overnight in 70% ethanol, washed three times with PBS, placed into 
sterile 24-well cell culture plates and kept hydrated in PBS at 4ºC overnight. 
The stability of the multilayer was tested by incubating multilayered and non-
multilayered flat PDMS disks under different conditions and assessing cell attachment. 
Briefly, disks were incubated in 100% ethanol, 70% ethanol, acetone, liquid nitrogen, 
air, distilled water, PBS, boiling water for 24 hours, then ventilated for 15 minutes. The 
cells were seeded at a density of 3000 per cm2, incubated overnight in chondrogenic 
redifferentiation media. The next day, cell attachment was assessed (Fig. 19). For further 
information regarding characteristics of HA-CHI multilayer please see references 
[320,321].   
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Figure 12. Fabrication of the microwell surface from PDMS replica molding and surface 
modification. A silica wafer having an array pattern of microwells was formed via deep reactive ion 
etching.  The dimensions of the microwells on silica wafer were 360 x 360 x 180 (depth) µm (A). This 
surface was used to cast PDMS, generating a negative surface. PDMS mold having an inverted microwell 
pattern (B). This surface was then coated in 5% pluronic acid solution, which functioned as a release 
agent. The coated surface was used to cast a 2 mm thick PDMS sheet having a microarray pattern identical 
to the original silica wafer (C). Because PDMS-PDMS casting was not reproducible, the PDMS sheet with 
the microwells was cast with a polystyrene sheet to obtain a plastic mold (D). Using polystyrene mold 
PDMS sheets with microwells were produced (E). A punch was used to create 2 cm2 discs, which fit 
snuggly into the bottom of a 24-well plate (F). Individual microwell inserts were subsequently surface 
modified using a CHI/HA electrostatic multilayer; see text for details (G). The chondrocytes spreading on 
non-modified PDMS microwell surface (cell layers marked with arrowheads) (H). Robust micropellet 
formation on CHI/HA multilayered PDMS surface (I). Scale bar: 200 µm. 
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Human articular chondrocyte isolation and expansion 
Articular chondrocytes were isolated from intact articular cartilage tissue 
remaining on the knee joints donated following total joint replacement surgery. Ethical 
approval for this tissue recovery was granted through the Queensland University of 
Technology Ethics Committee and the Prince Charles Hospital in accordance with the 
Australian National Health and Medical Research Council’s Statement on Ethical 
Conduct in Research Involving Humans. Articular cartilage was minced into 3-4 mm 
pieces using a sterile scalpel.  Tissue pieces were washed 3 times in phosphate-buffered 
saline (PBS; Gibco®). Pieces were suspended in 200 U/mL of Collagenase (Gibco®) 
diluted in low glucose Dulbecco’s modified Eagle’s medium (DMEM-LG; Gibco®), 
and then incubated overnight at 37ºC.  The digest was filtered through a 40 µm cell 
strainer (BD Falcon™) to separate tissue fragments.  The filtered suspension was 
washed 3 times, each in 10 mL of DMEM-LG. 
Chondrocytes were expanded in monolayer using T175 cm2 culture flasks 
(Nunc™) in 35 mL/flask volume of medium composed of DMEM-LG (Gibco®) 
supplemented with 10% fetal bovine serum (FBS; Gibco®), 100 U/mL penicillin and 
100 µg/mL streptomycin (1% PS, Gibco®), 1% Glutamax (Gibco®), 40 µM ascorbic 
acid 2-phosphate, 40 µg/mL L-proline, in a humidified incubator having a 2% O2 and 
5% CO2 atmosphere at 37ºC.  For the first two passages, 50 µg/mL gentamicin 
(Amersham Biociences©) and 2% PS were added to the medium. When monolayer 
cultures approached 80% confluence, the cells were harvested via 5-minute incubation 
with 3 mL 0.25% trypsin (Trypsin-EDTA; Gibco®) at 37ºC. To inactivate the trypsin, 9 
mL of expansion media containing 10% FBS and 1% PS was added. The cell suspension 
was centrifuged at 500xg for 5 minutes, the supernatant was discarded, and the cells 
were diluted into 3 times the previous growth medium volume and seeded into 3 T175 
cm2 flasks, giving a split ratio of 1:3. The experiment was repeated with three different 
donor chondrocytes, and passage 3 cells were used.  
 
Chondrogenic redifferentiation medium  
Chondrogenic redifferentiation medium was composed of high-glucose DMEM 
(DMEM-HG; Gibco®), 10 ng/mL recombinant human Transforming Growth Factor- β1 
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(TGF-β1, Gibco®), 10−7 M dexamethasone, 200 µM ascorbic acid 2-phosphate, 100 
µg/mL sodium pyruvate, 40 µg/mL L-proline, 1% ITS-X (Gibco®) and 1% PS. 
 
Formation of macropellets  
Macropellets were formed using a conventional pellet culture method [18].  In 
brief, 2x105 cells were suspended in 1 mL of chondrogenic induction medium, then 
centrifuged in a 15 mL tube (LabServ®) at 500xg for 5 minutes, and then placed into a 
2% or 20% O2 - 5% CO2 cell culture incubator at 37ºC with the tube lid loosened to 
facilitate gas exchange.   
 
Formation of micropellets 
Micropellets were formed as described previously [18,19,317]. This design was 
modeled after work described by Ungrin et al. [322]. In brief, microscopic pellets of 
approximately 166 cells were formed using the patterned surface having 600 
microwells/cm2 (described in Fig. 12). Approximately 1200 micropellets were formed 
from 2x105 cells by suspending these cells in 1 mL of chondrogenic induction medium 
over 2 cm2 microwell inserts in the bottom of 24-well plates.  Plates were centrifuged for 
5 minutes at 500xg to facilitate pellet formation.  Following centrifugation, an even 
distribution of cells within the microwells was confirmed via microscopy, and the plates 
were carefully transferred to a cell culture incubator set at 5% CO2 and either 2% or 
20% O2 at 37ºC. 
 
Assembly of micropellets 
The micropellets were transferred into a 15 mL tube then centrifuged at 500xg 
for 5 minutes to facilitate assembly after the culture of discrete micropellets, in 
microwells, for 4, 7, 11 or 14 days.  The total culture time, including both micropellet 
culture and assembled culture, was 21 days. This part of the study was performed in only 
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Sulfated glycosaminoglycan (sGAG) quantification  
Chondrogenic medium was exchanged twice weekly, and the medium from the 
macropellet and micropellet cultures was collected and stored at -80ºC.  When the 
culture was terminated, the recovered macropellets and micropellets were digested by 
adding 25 µg papain per sample directly to each tube or microwell plate then the 
pellet/enzyme mixtures were incubated at 60ºC overnight.  DMB dye (1,9-Dimethyl-
Methylene Blue zinc chloride double salt) was used to quantify the sGAG content in the 
collected media and digested tissues using an established protocol [323]. In brief, a 30 
µL volume of each sample of was dispensed into a single well of a 96-well clear plate 
(Nunc™), followed by the addition of 170 µL of DMB dye. The amount of sGAG was 
quantified by measuring the blue to purple color shift at 530 nm and 590 nm, 
respectively, in a plate reader (Benchmark Plus plate reader, Bio-Rad). Shark cartilage 
extract was used to generate a standard curve.   
 
Metabolic activity assay 
AlamarBlue® (Invitrogen™) was used to assess the metabolic activity of the 
pellets as per the manufacturer’s protocol. The 10X alamarBlue® solution was diluted in 
the culture media of the pellets and incubated for 3 hours. Then the medium was 
removed and analyzed in a plate reader (POLARstar OPTIMA, BMG Labtech) at an 
excitation and emission of 544 nm and 590 nm, respectively.  
 
DNA quantification  
A Quant-iT™ PicoGreen® dsDNA Reagent and Kit (Invitrogen™) was used to 
determine DNA content in the cultures, as per the manufacturer’s protocol. In brief, 50 
µL of papain digest was mixed with 50 µL of PicoGreen dye in a fluorescence plate 
(Nunc™) and analyzed in a plate reader (POLARstar OPTIMA, BMG Labtech) at an 
excitation and emission of 480 nm and 520 nm, respectively.  
 
Relative gene expression analysis  
TRIzol® (Invitrogen™) was used for RNA extraction, as per the manufacturer’s 
protocol.  RNA concentration was determined using a Nanodrop ND-1000 
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spectrophotometer (Bio-Lab). cDNA was synthesized from RNA template using 
SuperScript III RT and oligo(dT)20 (Invitrogen™) as per the manufacturer’s protocol, 
and stored at -80ºC until analysis. Real-time polymerase chain reaction (qPCR) was 
performed using Platinum® SYBR® Green qPCR SuperMix-UDG (Invitrogen™) using 
the primer sequences shown in Table 1 (Geneworks). The master mix was dispensed 
into the 384-well reaction plate and combined with cDNA samples using an epMotion 
5057 (Eppendorf) liquid handling robot. The plates were processed in a 7900HT Fast 
Real-Time PCR System (Applied Biosystems). PCR cycling parameters were 50ºC for 2 
minutes, 95ºC for 3 minutes, 95ºC for 15 seconds and 60ºC for 30 seconds, repeated for 
a total of 40 cycles. The results were analyzed using the ΔCt method normalized to the 
geometric mean of two housekeeping genes (cyclophilin A and glyceraldehyde 3-
phosphate dehydrogenase (GAPDH)) [324]. 
 
Histological analysis 
Harvested tissues were embedded in optimum cutting temperature compound 
(OCT, Tissue-Tek®), and stored at -80ºC. 10 µm-thick sections of samples were 
generated using a microtome-cryostat (Leica®), and then adsorbed onto poly-lysine 
glass slides (Thermo Fisher Scientific) and stored at -20ºC until further analysis.  
For Alcian blue staining, the slides were fixed with 4% paraformaldehyde for 20 
minutes at RT then rinsed with PBS 3 times. Following rinsing, slides were dried and the 
sections submerged in fresh filtered 1% Alcian blue solubilized in 3% acetic acid (pH 
2.5) for 10 minutes. The slides were then rinsed thoroughly with PBS and observed 
under Laborlux S microscope (Leitz®) using bright field illumination. For 
immunofluorescence (IF), the slides were fixed with 4% paraformaldehyde for 20 
minutes at RT, and then rinsed with PBS 3 times. The slides were dried and borders 
drawn around sections using a PAP pen. The sections were blocked (3% goat serum, 
0.3% Triton X-100 in 1% BSA/PBS) for 20 minutes at RT.  The blocked sections were 
incubated with collagen I, II and X primary antibodies (raised in mouse, rabbit and 
rabbit respectively, Abcam®) at 4ºC overnight in a humidity chamber. The slides were 
washed with 0.3% Triton X-100 in PBS for 3 minutes, and then rinsed with PBS.  The 
sections were incubated with corresponding secondary antibodies (FITC conjugated anti 
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mouse IgG2b and Cy-3 conjugated anti rabbit IgG, Abcam®) for 30 minutes at RT.  
Slides were washed twice with 0.3% Triton X-100 in 1% BSA/PBS and once with PBS. 
Coverslips were mounted onto slides using the ProLong Gold Antifade Reagent 
(Invitrogen™), and assessed under an Eclipse TE2000-U (Nikon) fluorescence 
microscope using NIS Elements (F 3.2) software.  
 
Statistical analysis 
All experiments contained n = 4 biological replicates.  Studies were repeated 
using chondrocytes derived from three donors. Data were represented as mean ± 
standard deviation. Data were analyzed using SPSS (statistical software package: 
SPSS® Inc.) and one-way analysis of variance (ANOVA) with Tukey post-hoc tests to 
identify statistical significance, (*) represents p < 0.05 and (***) represents p < 0.001. 
4. Results 
Morphology and size of the pellets 
Chondrocytes aggregated into micropellets within 24 hours (data not shown).  At 
day 14 of culture, both hypoxic macropellet and micropellet diameters were greater than 
normoxic pellet diameters (Fig. 13A, B). The estimated average diameter of the hypoxic 
micropellets was 193 ± 20 µm (n = 20), whilst the normoxic micropellets had an 
estimated average diameter of 87 ± 10 µm  (n = 20). 
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Figure 13. Morphology and size of the pellets. At the end of the 14-day culture, both hypoxic 
macropellets (A) and micropellets (B) were bigger than the normoxic pellets. The estimated mean 
diameter for hypoxic micropellets was  193 ± 20 µm (n = 20) whilst the estimated mean diameter of the 
normoxic micropellets was 87 ± 10 µm (n = 20). Scale bars: 1 mm. 
 
Metabolic activity, DNA and sGAG production 
Hypoxic micropellets were significantly more metabolically active than the other 
pellets over the culture period, as assessed by alamarBlue® (Fig. 14A). DNA 
quantification demonstrated that the proliferation of the cells did not differ significantly 
in different conditions (Fig. 14B). To assess the recovery of the chondrogenic 
phenotype, the amount of sGAG secreted into the medium over the culture duration and 
in the final tissues was quantified. The amount of the sGAG retained inside the pellet 
was significantly higher for the hypoxic macropellets at day 7, 11 and 14 (Fig. 14C). 
However, the amount of sGAG released into the media was highest for the hypoxic 
micropellets at all time points (Fig. 14D). The sGAG/DNA ratio was calculated by 
dividing the total amount of sGAG produced during the culture to the amount of DNA 
measured at the end of the culture. Hypoxic micropellets had the greatest ratio when 
compared to other pellets; hypoxic macropellets also had a significantly higher ratio 
than normoxic pellets (Fig. 14E). The amount of total sGAG measured in the media was 
higher than the amount measured in the pellets for all conditions (Fig. 14F). The 
retained sGAG was the highest for the hypoxic macropellets; whilst the overall 
produced sGAG was greater for the hypoxic micropellets (Fig. 14F). 
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Figure 14. Metabolic activity, growth and sGAG production in pellets. AlamarBlue® graph for 
metabolic activity (A), DNA quantification (B), sGAG in construct (C) and sGAG in media (D) 
measurements on days 4, 7, 11, 14. The sGAG/DNA ratio (calculated by dividing the total amount of 
sGAG produced during the culture to the amount of DNA measured on day 14) (E) and the total sGAG 
graph demonstrating the total sGAG in media and in construct separately (F). 
 
Chondrogenic and hypertrophic gene expression 
Chondrocyte-associated expression of Sox9, aggrecan and collagen II and 
hypertrophy associated expression of Runx2, collagen I, collagen X, osteocalcin, 
versican [18] were assessed. Key matrix genes like aggrecan and collagen II had the 
highest expression in the hypoxic micropellets (Fig. 15A, B).  Collagen I was 
significantly downregulated in macropellets, but remained unchanged in micropellet 
cultures relative to day 0 controls (Fig. 15C).  Runx2 (Fig. 15F) expression was greater 
in normoxic micropellets, as was collagen X expression in hypoxic micropellets (Fig. 
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15D).  Sox9 expression was lower in hypoxic macropellets (Fig. 15E). Macropellets 
maintained in a normoxic atmosphere had the highest expression of versican (Fig. 15G) 
and osteocalcin (Fig. 15F). 
 
Figure 15. Gene expression in pellets. Aggrecan (A), collagen II (B), collagen I (C), collagen X (D), 
Sox9 (E), Runx2 (F), versican (G), and osteocalcin (H) expressions relative to the geometric mean of 
housekeeping genes cyclophilin A and GAPDH 
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Chondrogenic and hypertrophic matrix deposition and distribution  
To visualize the distribution of the ECM molecules within the macro and 
micropellets, Alcian blue staining and IF analysis for collagen I, II and X were 
performed. DAPI staining was used to visualize the nuclei (Fig. 16A). Collagen I 
accumulation was minimal in all conditions, but appeared even lower in hypoxic 
cultures (Fig. 16B). Collagen X was more intense in normoxic cultures relative to 
cultures maintained in hypoxic atmospheres (Fig. 16C).  By contrast, collagen II 
staining was stronger in hypoxic cultures. Collagen II matrix distribution in hypoxic 
macropellets appeared non-uniform, whilst individual micropellets were stained more 
homogeneously (Fig. 16D). Alcian blue staining revealed that sGAG was lower in 
normoxic macropellets and staining was more homogeneous in micropellets relative to 
macropellets (Fig. 16E).  
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Figure 16. Cell and matrix localization throughout pellets following 14 days of culture. DAPI staining 
of nuclei in pellets (A).Immunofluorescence images for collagen I (B), collagen X (C), and collagen II 
(D), Alcian blue staining for sGAG (E). Scale bars: 100 µm. 
 
Micropellet assembly into macrotissues 
To assess the interaction between individual micropellets, they were collected 
from the microwell surface and centrifuged into a single aggregate at different time 
points during the chondrogenic redifferentiation process.  Micropellets collected from 
day 4 cultures that were assembled into larger tissue constructs integrated in a uniform 
manner, such that discrete micropellets were virtually indistinguishable via Alcian blue 
staining.  By contrast, it was still possible to identify individual micropellets collected 
from day 14 cultures that had been assembled into larger tissue constructs, indicating 
that full integration had not yet occurred in these constructs (Fig. 17). 
 
 
Figure 17. Hypoxic micropellets assembled into macrotissues. Alcian blue staining for hypoxic 
micropellets assembled at different time points (indicated days). The total culture duration was 21 days. 
Scale bars: 100 µm. 
 
5. Discussion 
A number of strategies are available to facilitate cell aggregate manufacture 
(reviewed in [325]), including hanging drop and various rotary bioreactors.  Our group 
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favors microwells, as they offer an unparalleled capacity to facilitate robust and precise 
high-throughput cell aggregate manufacture. Previous studies utilized a commercial 
microwell product (AggrewellTM, STEMCELL Technologies) to efficiently manufacture 
micropellets [18,19,317]. However, if the unmodified PDMS microwell surface is 
utilized directly in micropellet manufacture, the chondrocytes will adhere to the surface 
rather than form micropellets (Fig. 12H).  In our studies, modifying the surface to 
prevent cell attachment further enhanced the performance of AggrewellTM.  Minimizing 
cell attachment favored aggregate formation and facilitated aggregate harvest.  As a cost 
effective strategy, also to enable full control and to ease the optimization of the surface 
properties, we designed and fabricated our own microwell surface.  Figure 12 outlines 
the fabrication process that was used to generate PDMS microwell inserts that fit into 
24-well plates.  Following surface modification with the HA/CHI ML (Fig. 12G), the 
microwell surface enabled robust chondrocyte micropellet formation and harvest (Fig. 
12I).  Additionally, the stability of the multilayer was tested, and the surface 
modification remained functional even after 24 hour incubation in 100% ethanol, 70% 
ethanol, liquid nitrogen, air, distilled water, PBS or boiling water (Fig. 19).  
Other available microwell platforms are also suitable for chondrocyte micropellet 
manufacture.  For example, the development of a microwell platform in which the 
microwells were cast in an agarose gel rather than PDMS was recently described [326].  
In this clever strategy, the agarose surface promoted cell aggregate formation by 
resisting protein adsorption and subsequent cell attachment to the agarose surface.  
However, a more mechanically robust PDMS microwell platform is compatible with 
centrifugation, which enables more rapid and efficient micropellet manufacture than the 
gravity settling method required with an agarose platform.  Additionally, there is 
comparatively less risk of damaging the PDMS microwell structure during medium 
exchange or culture manipulation processes.   
Enhanced sGAG synthesis is critical for effective cartilage tissue regeneration, 
as the sGAG content endows cartilage with its compressive strength [18]. The sGAG 
outputs in both micropellet and macropellet cultures were significantly enhanced when 
these cultures were maintained in hypoxic atmospheres (Fig. 14E).  These results are 
consistent with previous studies demonstrating that hypoxia enhances chondrocyte 
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redifferentiation by stabilizing the hypoxia inducible factor 1 alpha (HIF-1α), which is 
translocated into nucleus and activates chondrogenic gene expression [327,328].  
However, this is the first study comparing the sGAG production between micropellets 
and macropellets, under both hypoxic and normoxic environments. Consistent greater 
sGAG production is observed in hypoxic micropellets, whilst greater sGAG retention 
occurs in the hypoxic macropellets (Fig. 14F). The loss of the sGAG to the medium is a 
commonly reported challenge in cartilage tissue engineering, and solutions have been 
suggested in previous papers [329,330]. The high surface-area-to-volume ratio in the 
micropellets contributes to the significant loss of sGAG to the medium. However the 
greater sGAG production and superior gene expression indicate that the chondrocyte 
redifferentiation was enhanced in hypoxic micropellets. If it is possible to improve the 
quality of the redifferentiation process, then this short term in vitro loss of sGAG should 
be insignificant relative to the overall clinical benefits. The retention of sGAG would 
likely be enhanced during a cartilage repair procedure where a large number of 
micropellets would be implanted into a sealed cartilage defect (Fig. 18A). 
Consistent with the sGAG results, chondrogenic gene expression also indicated 
that the redifferentiation was enhanced in hypoxic micropellets. No significant 
difference was observed in hypoxic micropellet expression profile for collagen I, Sox9, 
Runx2, versican and osteocalcin when compared to day 0 measurements (Fig. 15C, E, 
F, G, H). The expression of some osteogenic genes was elevated in the day 0 cultures, 
and this reflects the fact that the chondrocytes used in this study were all derived from 
tissue discards harvested from elderly patients suffering from severe osteoarthritis. 
Whilst collagen X expression was significantly upregulated in hypoxic micropellets, the 
overall magnitude of the expression was very low (0.0012 times) relative to the 
expression of housekeeping genes (Fig. 15D).  By comparison, collagen II gene 
expression was ~10-fold greater in the hypoxic micropellet cultures than the 
housekeeping gene expression (Fig. 15B).  Despite having some hypertrophic 
properties, the hypoxic micropellets exhibit superior redifferentiation when data are 
considered cumulatively.  The hypoxic micropellets had a larger volume (Fig. 13B), 
greater metabolic activity, sGAG production (Fig. 14A, E) and higher collagen II 
expression (Fig. 15B).  Importantly, the deposition of the collagen II and sGAG was 
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more uniform in the micropellets relative to macropellets (Fig. 16D, E). More uniform 
cell behavior is consistent with a smaller diameter pellet with reduced diffusion 
gradients. These data mirror our previously reported results indicating that the 
micropellet strategy enhanced uniformity in MSC chondrogenic cultures [18].   
Co.don® AG (Teltow, Germany) is currently evaluating the potential of 
macropellets for cartilage defect repair in on-going trials [313,314].  We suggest that 
there may be legitimate benefits in using micropellets rather than macropellets, as this 
should provide for a more uniform and potent clinical product.  Additionally, because of 
their smaller geometry, micropellets may be able to accommodate more complex defect 
geometries and ultimately produce a smoother articular surface.  This is a rational 
expectation, as smaller diameter spheres will always more uniformly fill a void than 
larger diameter spheres.  A prerequisite to such applications is that micropellets must 
demonstrate the capacity to amalgamate into a contiguous repair tissue.  Here we tested 
the amalgamation efficiency of cartilage micropellets that had been cultured for 4, 7, 11 
or 14 days.  The amalgamation efficiency depended on the time that the micropellets 
had been cultured before assembly (Fig. 17), and the most primitive day 4 micropellets 
proved the most efficient.  This outcome is also rational, as temporal matrix deposition 
in the micropellets would be expected to stabilize with time.  These results reflect only 
short-term observation, and it may be possible to observe excellent integration of even 
day 14 micropellets over an extended time period.  Given that micropellets contain 
significant matrix content, we reason that they may be superior to single cell 
suspensions lacking any legitimate matrix component, as in procedures like Autologous 
Chondrocyte Implantation (ACI). Unlike macropellets, micropellets could easily be 
injected under ACI-type membranes, thus facilitating delivery.  
Using our microwell system, it is possible to generate 36,000 cartilage 
micropellets in a single 6-well plate.  This manufacturing efficiency enables the 
evaluation of micropellets either in the direct repair of cartilage defects (Fig. 18A), or as 
a building block in the in vitro assembly of complex zonal osteochondral tissues (Fig. 
18B).  Typically, osteochondral tissues have been made from single cell suspensions 
seeded into gels or onto solid scaffolds [331-334], although a recent study used 
spheroids of rabbit MSCs differentiated into osteoblasts and chondrocytes, which were 
 68 Chapter 3: The interplay between chondrocyte redifferentiation pellet size and oxygen concentration 
subsequently assembled into a zonal tissue [335].  In this study, the spheroids were 
manufactured by manually dispensing cells in collagen droplets. Our more efficient 
manufacturing process should enable more sophisticated zonal tissues such as those 
shown schematically in Figure 18B.  Data from our group indicated that a similar 
micropellet manufacturing strategy enabled enhanced MSC osteogenesis and the 
generation of bone spheroids [19] ideal for the assembly of an osteochondral tissue.  
Ultimately, the small dimensions of micropellets make them ideal for identifying the 
culture conditions necessary to recapitulate the various zonal tissues found in cartilage 
[336], and therefore, micropellets will likely become the preferred building blocks for 
reconstructing such tissues.    
 
 
Figure 18. Potential applications of the chondrocyte micropellets.  The direct use of chondrocyte 
micropellets in articular cartilage defect repair (A). The use of cartilage micropellets in the manufacture of 
osteochondral tissues in vitro (B). 
 
6. Conclusion 
Herein we describe the fabrication of a custom microwell system and a surface 
modification that enables the efficient manufacture of thousands of cartilage 
micropellets.  Hypoxic micropellet culture was shown to be a superior chondrocyte 
redifferentiation platform, relative to traditional macropellet cultures. We rationalized 
that the micropellets might offer a unique strategy for enhanced cartilage defect repair, 
and to investigate this potential the efficiency of the micropellet amalgamation was 
examined. Micropellets that had been cultured for 4-7 days most efficiently 
amalgamated, and the composite tissue was nearly seamless at the end of the 21-day 
culture. Cumulatively, our results indicate that the redifferentiation of expanded human 
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articular chondrocytes can be enhanced using micropellet culture, and that these 
micropellets can be assembled into larger more clinically relevant dimensions.  
 
 
Figure 19. Surface modification testing. To assess the stability and functionality of the surface 
modification after incubation in ethanol and PBS, a testing platform was set up as follows: flat 24 well 
plate PDMS disks were produced and half of them were multilayered as explained in the Materials and 
Methods section. The disks were incubated under conditions stated (in 100% ethanol, in 70% ethanol, in 
acetone, in liquid nitrogen, in air, in distilled water, in PBS, in boiling water) for 24 hours and the 
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functionality of the surface was assessed by imaging cell attachment. After 15 minutes of ventilation, cells 
were seeded at a density of 3000/cm2, incubated in chondrogenic redifferentiation media overnight. 
Surface modification was not affected by any of the conditions. However acetone sensibly decreased the 
transparency of the PDMS itself, therefore the cell attachment could not be assessed. For all other 
conditions the cell spreading was observed for the surface with no multilayer whereas the cells were not 
spreading on the surfaces with multilayer. 
 
Gene	  (Amplicon	  size	  in	  basepair)	   Primers	  
	   	  
Cyclophilin	  A	  (164)	   Forward	  	  CTCGAATAAGTTTGACTTGTGTTT	  
Reverse	  	  	  CTAGGCATGGGAGGGAACA	  
GAPDH	  (119)	   Forward	  	  ATGGGGAAGGTGAAGGTCG	  
Reverse	  	  	  TAAAAGCAGCCCTGGTGACC	  
SOX9	  (77)	   Forward	  	  TTCCGCGACGTGGACAT	  
Reverse	  	  	  TCAAACTCGTTGACATCGAAGGT	  
Aggrecan	  (85)	   Forward	  	  TCGAGGACAGCGAGGCC	  
Reverse	  	  	  TCGAGGGTGTAGCGTGTAGAGA	  
Collagen	  II,	  COL2A1	  (79)	   Forward	  	  GGCAATAGCAGGTTCACGTACA	  
Reverse	  	  	  CGATAACAGTCTTGCCCCACTT	  
Collagen	  I,	  COL1A1	  (83)	   Forward	  	  CAGCCGCTTCACCTACAGC	  
Reverse	  	  	  TTTTGTATTCAATCACTGTCTTGCC	  
Versican	  (98)	   Forward	  	  TGGAATGATGTTCCCTGCAA	  
Reverse	  	  	  AAGGTCTTGGCATTTTCTACAACAG	  
Collagen	  X,	  COL10A1	  (70)	   Forward	  	  CAAGGCACCATCTCCAGGAA	  
Reverse	  	  	  AAAGGGTATTTGTGGCAGCATATT	  
Runx2	  (113)	   Forward	  	  GGAGTGGACGAGGCAAGAGTTT	  
Reverse	  	  	  AGCTTCTGTCTGTGCCTTCTGG	  
Osteocalcin	  (70)	   Forward	  	  GAAGCCCAGCGGTGCA	  
Reverse	  	  	  CACTACCTCGCTGCCCTCC	  
	  
 
Table 1. Primers used for gene expression analysis. 
 
 Chapter 4: Statement of Contribution of Co-Authors for Thesis by Published Paper 71 
Chapter 4:  Statement of Contribution of Co-Authors for Thesis by Published Paper 
In the case of this chapter 
Title: The rapid manufacture of uniform composite multicellular-biomaterial micropellets, 
their assembly into macroscopic organized tissues, and potential applications in cartilage 
tissue engineering  
 
Date, status, journal: January 2015, Submitted, PLOS ONE 
 
 
Contributor Statement of contribution 
Betul Kul Babur 
Signature   
Date           20.01.2015 
wrote the manuscript (M),  
experimental design (D),  
conducted experiments (E),  
and data analysis (A) 
Mahboubeh Kabiri aided with D, E 
William B. Lott aided with M, A 
Travis Klein aided with M, D, A 
Michael Robert Doran aided with M, D, A and materials 
 
 
Principal Supervisor Confirmation  
  
I have sighted email or other correspondence from all Co-authors confirming their certifying 
authorship.  
  
Michael Robert Doran     20.01.2015  
Name             Signature    Date 
 

 Chapter 4: The rapid manufacture of uniform composite multicellular-biomaterial micropellets, their assembly into 
macroscopic organized tissues, and potential applications in cartilage tissue engineering 73 





Chapter 4:  The rapid manufacture of uniform composite multicellular-
biomaterial micropellets, their assembly into macroscopic organized tissues, 





We and others have published on the rapid manufacture of micropellet tissues, 
typically formed from 100-500 cells each.  The micropellet geometry enhances cellular 
biological properties, and in many cases the micropellets can subsequently be utilized as 
building blocks to assemble complex macrotissues.  Generally, micropellets are formed 
from cells alone, however when replicating matrix-rich tissues such as cartilage it would 
be ideal if matrix or biomaterials supplements could be incorporated directly into the 
micropellet during the manufacturing process.  Herein we describe a method to 
efficiently incorporate donor cartilage matrix into tissue engineered cartilage 
micropellets.  We lyophilized bovine cartilage matrix, and then shattered it into 
microscopic pieces having average dimensions < 10 µm diameter; we termed this 
microscopic donor matrix “cartilage dust (CD)”.  Using a microwell platform, we show 
that ~0.83 µg CD can be rapidly and efficiently incorporated into single multicellular 
aggregates formed from 180 bone marrow mesenchymal stem/stromal cells (MSC) each.  
The microwell platform enabled the rapid manufacture of thousands of replica 
composite micropellets, with each micropellet having a material/CD core and a cellular 
surface.  This micropellet organization enabled the rapid bulking up of the micropellet 
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core matrix content, and left an adhesive cellular outer surface.  This morphological 
organization enabled the ready assembly of the composite micropellets into macroscopic 
tissues.  Generically, this is a versatile method that enables the rapid and uniform 
integration of biomaterials into multicellular micropellets that can then be used as tissue 
building blocks.  In this study, the addition of CD resulted in an approximate 8-fold 
volume increase in the micropellets, with the donor matrix functioning to contribute to 
an increase in total cartilage matrix content.  Composite micropellets were readily 
assembled into macroscopic cartilage tissues; the incorporation of CD enhanced tissue 
size and matrix content, but did not enhance chondrogenic gene expression. 
2. Introduction 
Cartilage tissue lacks reliable self-repair. Consequently, cartilage injuries often 
further degenerate rather than healing spontaneously. The tendency to degenerate makes 
osteoarthritis (OA) the leading cause of pain and disability in developed nations [2,337-
339]. Currently, the repair of osteoarthritic lesions is not possible and joint replacements 
are the only surgical interventions that successfully restore OA joint function [340].  
However, surgical repair of acute cartilage injuries and delayed onset of OA is possible 
to a limited extent.  A range of surgical methodologies has been developed and the most 
promising methods utilize cell-based tissue engineering approaches.  
The two clinically approved tissue engineering methodologies are Autologous 
Chondrocyte Implantation (ACI) [93] and Matrix-Assisted Chondrocyte Implantation 
(MACI) [341].  In both ACI and MACI, autologous chondrocytes are isolated from a 
biopsy of a non-load bearing site of the damaged cartilage.  The isolated chondrocytes 
are then expanded ex vivo, before being transplanted into the primary defect site beneath 
a periosteum membrane isolated from the patient’s tibia (ACI) or on a manufactured 
type I/III collagen membrane (MACI).  In both cases, the initial repair tissue lacks any 
cartilage matrix and is extremely fragile; typically the repaired joint is protected from 
full weight bearing for 2-3 months [342-344].  
The initial fragility of the ACI/MACI repair tissue is related to the lack of mature 
cartilage ECM at the time of implantation. To overcome this problem a number of 
groups have explored strategies that involve the direct incorporation of mature cartilage 
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matrix into engineered tissue. Peretti et al. assessed the bonding of 1 mm thick cartilage 
slices or chips with expanded chondrocytes; the bonding was successful however the 
repopulation of the cartilage pieces was inefficient [277,278,345].  The dense ECM 
network in donor cartilage matrix prevents effective cell infiltration, and as a result the 
repopulation of the 1 mm thick cartilage pieces was only successful on the superficial or 
in regions adjacent to outer exposed areas [277,278,345]. Using a refined approach 
Gong et al. combined thinner (10-30 µm) sections of donor cartilage and chondrocytes 
[279].  They reported that the repopulation of the cartilage sections was significantly 
enhanced in 10 µm thick sections even relative to the 30 µm thick sections [279].  This 
body of work indicated that donor cartilage matrix might not be efficiently repopulated 
unless used in units with dimensions approaching 10 µm in thickness.  This 
characteristic suggests that unlike tissues such as skin, large pieces of donor cartilage 
matrix cannot be used to provide a template for the effective generation of larger 3D 
tissue structures.   
An alternative to using large pieces of donor cartilage to provide macroscopic 
structure is the incorporation of cartilage matrix particles into scaffolds formed via 
conventional scaffold manufacture.  Yang et al. described the fabrication of a natural 
porous ECM derived scaffold made of physically crushed, lyophilized and cross-linked 
native cartilage tissue [280]. Similarly, Zheng et al. compared porous scaffolds made of 
PLGA versus porous scaffolds made of pulverized cartilage versus a composition of 
both [281]. They identified the composite scaffold as optimal, and suggested that this 
was related to the combination of biomimetic natural nanofibrous cartilage pieces and 
the mechanically strong PLGA component [281]. Additionally, Shin et al. used a freezer 
mill to crush porcine cartilage pieces, then cross-linked the particles to obtain a porous 
scaffold which was then seeded with chondrocytes for tracheal implantation in a rabbit 
model [346]. The use of donor matrix to enhance engineered cartilage tissue quality 
appears to be a rational and promising approach.   
Our team has previously utilized micropellet cultures to generate cartilage-like 
tissue [17,18].  Micropellets differ from conventional pellets, with micropellets typically 
having 100-1000 cells each, whilst macropellets typically have 100,000-500,000 cells 
each.  Chondrogenesis appears to be enhanced and more homogeneous in micropellets, 
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and this likely reflects the improved mass transport enabled by their smaller diameter 
[18].  Whilst chondrogenesis appears to be improved in the micropellet system, relative 
to conventional pellet cultures, the rapid formation of cartilage matrix equivalent to 
native tissue remains challenging.  We reasoned that the incorporation of microparticles 
of donor matrix into micropellets would provide a mechanism to rapidly increase the 
cartilage-like matrix volume of the micropellets, and ultimately enhance the tissue 
quality.   
Herein we describe the optimization of a method to incorporate lyophilized 
donor bovine matrix particles into microtissues or macrotissues formed from bone 
marrow-derived mesenchymal stem/stromal cells (MSC).  Hereafter we call the cartilage 
matrix particles Cartilage Dust (CD).  We contrasted the volume contribution and 
chondrogenic induction capacity enabled through the incorporation of CD into 
microtissues or macrotissues formed from 180 cells or 200,000 cells each, respectively.  
To demonstrate the potential utility of this concepts in tissue engineering applications, 
we used a high throughput microwell system to manufacture thousands of micropellets 
containing CD, and demonstrated that these tissues could be amalgamated into larger 
tissues in a manner that might have utility in the engineering of larger repair tissues or 
perhaps in direct cartilage defect filling. 
3. Materials and Methods 
Microwell fabrication and surface modification  
In previous work we outlined detailed methods for microwell insert manufacture 
[17]. In brief, using deep reactive ion etching a silica wafer was etched to have a 
microwell pattern of 600 microwells/cm2. Individual microwells had dimensions of 
360x360x180 µm (Fig. 26).  Polydimethylsiloxane (PDMS) replica molding was used to 
generate a negative that was then heat pressed into a sheet of polystyrene. The resulting 
polystyrene mold was used to manufacture PDMS sheets of microwells surfaces, from 
which discs were punched out to use as inserts within 24-well plates [17]. The 2 cm2 
discs containing microwells were fit and glued with PDMS into 24-well plates (Fig. 26). 
Each 24-well plate insert contained 1200 microwells. The plates with microwell inserts 
were sterilized for 1 hour in 70% ethanol then rinsed multiple times with sterile PBS. 
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Before cells were seeded, the inserts were treated with 5% pluronic acid (Sigma) 
solution for 5 minutes to block protein adhesion and prevent cell attachment to the 
PDMS surface. Then, the inserts were rinsed again with PBS and the cells were seeded 
into the wells containing the microwell inserts.  
 
Human bone marrow MSC isolation and expansion 
Ethics: Bone marrow aspirate was collected from the iliac crest of healthy donors 
with full informed written consent in all cases. Mater Health Services Human Research 
Ethics Committee approved the consent procedure and held the consent documents. All 
tissue samples were provided to the research team in a de-identified manner. Ethical 
approval for this research was granted through the Mater Health Services Human 
Research Ethics Committee (Ethics number: 1541A) and the Queensland University of 
Technology Ethics Committee in accordance with the Australian National Statement on 
Ethical Conduct in Human Research.  
Bone marrow MSCs were isolated directly from bone marrow aspirates. The 
collected bone marrow aspirate was diluted 1:1 with PBS and underlayed with 12 mL 
Ficoll Paque Plus (GE healthcare). The solution was centrifuged at 535xg for 20 
minutes. Interface cells were collected, washed and resuspended in low glucose DMEM 
(DMEM-LG, Invitrogen) with PS and 10% fetal bovine serum (FBS, Invitrogen), then 
seeded in tissue culture flasks (T175, Nunc). After 48 hours, the non-adherent cells were 
removed and the adherent cells were further cultured to 80% confluence with medium 
changes every 3-4 days.  
MSCs were expanded in monolayer in DMEM-LG supplemented with 10% FBS 
and PS in an incubator with 2% O2 and 5% CO2 atmosphere at 37°C. The cells were 
dissociated via 5-minute incubation with 0.25% TrypLE (Invitrogen) at 37°C when they 
reached confluence. The cells dissociated from one flask were divided equally into four 
and then seeded into new flasks until passage 3, and then the cells were used in the 
described studies. 
 
Chondrogenic differentiation medium 
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Chondrogenic medium was composed of DMEM-HG with 110 µg/mL sodium 
pyruvate (Invitrogen), 10 ng/mL recombinant human Transforming Growth Factor β1 
(TGF- β1, Peprotech), 10-7 M dexamethasone (Sigma), 200 µM ascorbic acid 2-
phosphate (Sigma), 40 µg/mL L-proline (Sigma), 1% Insulin-Transferrin-Selenium-
Ethanolamine (ITS-X, Invitrogen) and PS. The chondrogenic medium was changed 75% 
every second day, the collected media was stored at -20°C for sulfated 
glycosaminoglycan (sGAG) analysis. 
 
Cartilage dust preparation 
Bovine knee articular cartilage (obtained from a local butcher, animals were ~12 
month-old) was used to generate cartilage dust. The cartilage tissue was harvested 
aseptically from femoral condyle as thin sections. The collected tissue was washed three 
times with sterile phosphate-buffered saline (PBS, Invitrogen) containing 100 U/mL 
penicillin and 100 µg/mL streptomycin (PS, Invitrogen). The tissue was frozen at -80°C 
overnight then lyophilized (Christ Alpha 1-2 LDplus). The lyophilized tissue was 
aseptically pulverized into a powder using a marble pestle and mortar (10 cm inner 
diameter) by vigorous crushing for 30 minutes. The powdered cartilage was stored dry at 
-20°C until use. The powdered cartilage was suspended in high glucose Dulbecco’s 
modified Eagle’s medium (DMEM-HG, Invitrogen) with PS immediately prior to 
initiating cultures, and the wetted cartilage pieces were filtered using a 40 µm cell 
strainer (BD Falcon) to eliminate pieces larger than 40 µm. The filtered micron size 
fraction of the powdered cartilage, referred as cartilage dust (CD), was washed twice 
with DMEM-HG including PS to generate a concentrated CD solution (~20 mg/mL). A 
50 µL sample of that solution was added to each CD-containing macro or micropellets 
delivering ~1 mg (dry weight) CD per culture. Monochrome phase contrast images of 
the CD on a glass slide were taken with a Nikon DS-Qi1Mc camera using ECLIPSE Ti 
microscope at 4X magnification (Nikon, Japan). Cartilage dust particle size was 
measured using Feret’s diameter (ImageJ, NIH, USA).  
 
Macropellet formation 
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Macropellets were formed in 15-mL tubes (BD Falcon) using the conventional 
method. MSC macropellets contained only 2.2 x 105 MSCs in 1mL chondrogenic media 
in tubes. MSC+CD macropellets contained both 2.2 x 105 MSCs in 1 mL chondrogenic 
media and 1 mg CD, described in previous section, in tubes. CD macropellets contained 
only 1 mg CD in 1 mL chondrogenic media in tubes. Then the tubes were centrifuged at 
400xg for 5 minutes. The macropellets were cultured in a 2% O2 and 5% CO2 incubator 
at 37°C for 14 days with loosened lids to enable gas exchange. 
 
Micropellet formation 
Micropellets of ~180 cells each (a total of 2.2x105 cells in 1200 micropellets) 
were formed using microwell PDMS discs in 24-well plates (Nunc) (Fig. 26) [17]. Each 
disc contained 1200 microwells therefore a single macropellet described in previous 
section was equivalent and compared to 1200 micropellets. Similar to macropellets, 
MSC micropellets contained only 2.2 x 105 MSCs in 1mL chondrogenic media in wells. 
MSC+CD micropellets contained both 2.2 x 105 MSCs in 1mL chondrogenic media and 
1mg CD in wells. CD micropellets contained only 1mg CD in 1mL chondrogenic media 
in wells. Then the plates were centrifuged at 400xg for 5 minutes. The micropellets were 
cultured in a 2% O2 and 5% CO2 incubator at 37°C for 14 days. Monochrome phase 
contrast images of the cultures at day 1 and 14 were taken with a Nikon DS-Qi1Mc 
camera using ECLIPSE Ti microscope (Nikon, Japan). The diameters of the micropellets 
were then estimated from the images using ImageJ software.    
 
Micropellet assembly 
In the second part of the study, the micropellets were assembled at different time 
points. Day 0 assembly was equivalent to macropellet formation. The other cultures 
were initiated as micropellets and subsequently assembled after either day 4, 7, 10 or 14 
of culture as discrete micropellets. The assembly process was achieved by dislodging the 
micropellets from the microwells, via pipette aspiration, and pelleting the micropellets in 
a 15-mL tube by centrifuging at 400xg for 5 minutes. The assembled micropellets were 
then cultured in a 2% O2 and 5% CO2 incubator at 37°C with loosened lids to enable gas 
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exchange. The total duration of chondrogenic culture was 22 days for the assembled 
tissues in this study.  
 
Sulfated glycosaminoglycan (sGAG) and DNA quantification 
Tissues were digested through the addition of 0.25 mg papain (Sigma) solution 
directly to each tube or well followed by overnight incubation at 60°C. The digest was 
used to quantify both the DNA and the sGAG in tissue constructs. The medium collected 
during the medium exchanges was analyzed to determine the quantity of secreted sGAG. 
1,9 Dimethyl methylene blue zinc chloride double salt (DMB, Sigma) was used for 
sGAG quantification. Digests or culture medium were dispensed in clear 96-well plates 
(Nunc), then DMB dye was added and the signal was measured at 590 using a plate 
reader (MULTISKAN GO, Thermo Fischer).  Shark chondroitin sulfate (Sigma) was 
used to generate a standard curve.  
PicoGreen dsDNA Reagent and Kit (Invitrogen) was used to quantify the DNA 
content in the micropellet digests.  The papain digest and the PicoGreen solution was 
mixed in a black 96-well plate (half-area, Costar) and measured in a plate reader 
(FLUOstar OMEGA, BMG Labtech) at an excitation and emission of 480 nm and 520 
nm, respectively. 
 
Gene expression  
Trizol (Invitrogen) was used to extract mRNA from pellets as per the 
manufacturer’s protocol. The RNA concentration was measured using 
spectrophotometer (Nanodrop 1000, Thermo Scientific). Complementary DNA (cDNA) 
was synthesized from the mRNA template using SuperScript III RT and oligo(dT)20  kit 
(Invitrogen) as per the manufacturer’s instructions. The quantitative polymerase chain 
reaction (qPCR) was performed using Platinum SYBR Green qPCR SuperMix-UDG kit 
(Invitrogen). The primers (5’ to 3’, Geneworks) listed in Table 2 were used. 
The qPCR reactions mixes were aliquoted using a liquid handler (epMotion 
M5073, Eppendorf). SYBR Green master mix was dispensed into 384-well plates 
(Applied Biosystems) and combined with cDNA template. The qPCR reaction was 
performed using ViiA real time PCR system (Applied Biosystems). The qPCR reaction 
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was initiated with a 2-minute 50°C hold, followed by a 3-minute 95°C hold, and then 
proceeded with 40 cycles of 15-second at 95°C, 30-second at 60°C. The qPCR results 
were analyzed using ΔCt method and the gene expression was normalized to the 
geometric mean of two housekeeping genes (cyclophilin A and glyceraldehyde 3-
phosphate dehydrogenase (GAPDH)).  
 
Histology 
Cultured tissues were fixed in 4% paraformaldehyde (PFA, Sigma) for 30 
minutes. Then collected in micro centrifuge tubes and embedded in optimum cutting 
temperature compound (OCT, Tissue-Tek) and frozen at -20°C. Embedded frozen 
tissues were sectioned in 10 µm thickness using a cryostat (Leica) then the sections were 
adsorbed on poly-lysine glass slides (Thermo Fisher), dried at room temperature, stored 
at -20°C. Before staining, the slides were brought to room temperature and the sections 
were fixed with 4% PFA for 20 minutes then rinsed with PBS.  
For alcian blue staining, the sections were covered with filtered 1% alcian blue 
(Sigma) dissolved in 3% acetic acid with pH of 2.5 for 10 minutes. Then the slides were 
rinsed with PBS until the excess alcian blue was removed from the slides. The sections 
were counter stained using 4’, 6 diamidino-2-phenylindole (DAPI, Sigma). The sections 
were imaged using a Nikon ECLIPSE Ti microscope and images were taken using a 
Nikon DS-Fi1 camera. Alcian blue and DAPI images were merged using Photoshop 
(Adobe CS5) software.  
For immunofluorescence (IF) staining, the slides were dried and borders were 
drawn around the sections using a hydrophobic PAP pen (Sigma). Then the sections 
were blocked using 3% goat serum (Invitrogen), 0.3% Triton X-100 (Sigma) in 1% BSA 
(Sigma) for 20 minutes at room temperature. Then the sections were incubated with 
primary antibodies for human collagen II and X both 1:100 dilution and raised in rabbit 
(Abcam) at 4°C overnight in a humidified chamber. Then the slides were washed twice 
with 0.3% Triton X-100 in PBS for 3 minutes, then rinsed once with PBS. Next, the 
sections were incubated with the secondary antibody (Cy-3 conjugated anti rabbit IgG, 
Abcam) diluted 1:500 in 1% BSA for 30 minutes at room temperature. The slides were 
washed twice with 0.3% Triton X-100 in PBS for 3 minutes, counter stained with DAPI 
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then rinsed once with PBS. The sections were mounted using CC/Mount (Sigma) and 
cover slipped. The slides were imaged using an ECLIPSE Ti epifluorescent microscope 
(Nikon, Japan) and monochrome images were taken with a Nikon DS-Qi1Mc camera, 
and then colored using NIS Elements BR 3.2 software. The images were merged using 
Photoshop (Adobe CS5) software.  
 
Live imaging 
A parallel 24-well plate containing MSC micropellets and MSC+CD 
micropellets was prepared and live imaging was utilized to track the assembly of the 
micropellets over the first 92 hours of culture. Medium was not changed during imaging 
and micropellets were cultured at 37°C under 5% CO2 and atmospheric oxygen instead 
of 2% O2. All live imaging was performed on a Live cell microscope (ZEISS, Germany), 
and image stacks were converted to AVI format using ImageJ software, then the videos 




All experiments were performed with n = 4 biological replicates. Studies were 
repeated using 3 different donor MSCs. Data in graphs were represented as mean + 
standard deviation (SD). The significance was analyzed using SPSS software (SPSS 
Statistics 21, IBM, USA) and one-way analysis of variance (ANOVA) with Tukey’s 
post-hoc test was used to identify the statistical significance with a p-value smaller than 
0.05. The significance was indicated using Roman numerals or symbols on the 
corresponding graphs, any two groups with same numerals or symbols were statistically 
equivalent and the groups not marked with the same numerals or symbols were 
statistically different. 
4. Results and Discussion 
Cartilage dust  
CD particle size was first characterized via image analysis.  A gradient in particle 
size was observed in cartilage dust (Fig. 20A), and overall size distribution graph 
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indicated that particle size was mainly less than 10 µm (Fig. 20B). However even in low 
numbers, there were still particles greater than 10 µm since CD solution was filtered 
with a 40 µm cell strainer. In total 10,000 particles were characterized. The overall 
particle size average was estimated to be 5.53 ± 6.02 µm (Fig. 20B) and the median 
particle size was 3.73 µm.  
Devitalized xenogeneic matrix has been utilized in tissue engineering previously, 
but this particular approach has never been described.  Here we pulverized lyophilized 
bovine cartilage and used only micron size particles, which provided efficient cell 
infiltration and repopulation of the donor matrix [282], since the size of the CD particles 
was in the same range with the mammalian cell size. The individual collagen fibers in 
CD particles might still be intact, however the overall collagen fiber organization was 
likely to be abolished during pulverization. Our pulverization method yielded different 
sizes of particles in CD (Fig. 20A, B). The smaller particles tend to rapidly lose both the 
unwanted residual DNA as well as leach the desired sGAG molecules.  The release of 
both DNA and sGAG increases proportionally to the increased surface area to volume 
ratio that occurs as the particle diameter is reduced.  This phenomenon was noted nearly 
three decades ago; although at the time pulverizing cartilage into microparticles was 
done purposefully to enhance the extraction of sGAG from cartilage [347]. In our hands, 
it was necessary to store the CD dry and frozen to prevent loss of sGAG and only rinse it 
immediately before use to remove the bulk of the residual DNA. 
 
Pellet size 
The addition of CD during the manufacturing of MSC+CD macro and 
micropellets always resulted in a significant increase in the pellet size, and this relative 
increase in size was maintained over the 14-day culture period (Fig. 20C). The average 
diameters of the MSC micropellets and MSC+CD micropellets on day 1 were 100.8 ± 
7.8 µm and 176.1 ± 9.9 µm, respectively. On day 14, the average diameters of the MSC 
micropellets and MSC+CD micropellets were 82.6 ± 10.8 µm and 183.8 ± 16.2 µm, 
respectively. The addition of CD to the tissue effectively doubled the diameter, 
significantly increasing the micropellet volume. The MSC micropellets were slightly 
smaller following 2 weeks of culture compared to day 1, whereas MSC+CD micropellets 
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were slightly larger in size following 2 weeks of culture. MSC+CD micropellets 
appeared to have a darker core in phase contrast images at day 14 (Fig. 20C). The CD 
appeared to be homogenously distributed within the MSC+CD micropellets at day 1, 
however CD was increasingly concentrated within the core of the micropellets 
throughout the culture (Fig. 20C). MSC and MSC+CD micropellet formation was 
captured for the first 92 hours and the mechanism of MSC/CD self-assembly was 
documented in Video 1 [348] and Video 2 [349]. In videos, it is seen that the micropellet 
formation was completed within the first 4 hours, and that cell proliferation occurred at 
the periphery of the micropellets following micropellet assembly.  Perhaps the most 
interesting outcome from this paper is the impressive mechanism by which the 
micropellet rolls around the microwell, attaches to the biomaterial/matrix, and then 
internalizes it.  This feature may have potential utility in a number of tissue engineering 
and micropellet tissue mimic applications.  It is foreseeable that this technology could 
readily be used to incorporate biomaterial particles that elute chondrogenic induction 
factors or other signal molecules.  Alternatively, this approach could be used to rapidly 
incorporate bone matrix, for example, into micropellets to enable the rapid formation of 
bone tissue mimics for in vitro study or in vivo tissue repair.   
The substantial volume increase in MSC+CD macro and micropellets supports 
the concept of using CD as an agent to rapidly increase the matrix content of engineered 
cartilage tissue.  Utilizing CD, larger cartilage defects could be filled with reduced total 
number of cells. This would enable the rapid filling of defects with matrix-rich artificial 
tissue that had cell density and matrix composition similar to native cartilage tissue. A 
fortunate outcome of having the CD localize within the core is that the cellular surface 
of the MSC+CD micropellet makes individual micropellets very adhesive and readily 
assembled into larger tissues. Based on these observations, we reason that assembling 
MSC+CD micropellets will enhance the capacity of this concept to have utility in 
cartilage defect repair. 
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Figure 20. Cartilage dust (CD) characterization and micropellet morphology. Phase contrast image of 
CD demonstrated a gradient in particles size (A). The particles size distribution indicated that most of the 
particles had a size smaller than 10 µm and the average particle size was estimated to be 5.53 µm (B). 
Phase contrast images of MSC and MSC+CD micropellets on day 1 and 14 and macroscopic images of 
MSC and MSC+CD macropellets (C), the average diameters for MSC micropellets on day 1 was 100.8 ± 
7.8 µm and on day 14 was 82.6 ± 10.8 µm, the average diameters for MSC+CD micropellets on day 1 was 
176.1 ± 9.9 µm and on day 14 was 183.8 ± 16.2 µm Overall, MSC+CD macro and micropellets were 
greater in size. Abbreviations: MSC, cell only control; MSC+CD, composite (cell and cartilage dust). 
Scale bars: 500 µm. 
 
DNA and sGAG production 
There was residual DNA retained within CD only control samples (Fig. 21B). At 
day 14 MSC micropellets had increased total DNA compared to day 0, indicating some 
cell proliferation.  By contrast, there was no increase in DNA content in the MSC+CD 
macro and micropellets when compared to day 0 (Fig. 21B).   
Some DNA is retained possibly in greater size CD particles. In previous work, 
using human-derived CD, we were able to exclusively generate particles less than 10 µm 
in size and the human material retained only trace quantities of residual DNA [282].  In 
this study, the bovine cartilage was less malleable and tended not to be as easily 
pulverized, resulting in greater retention of DNA.  Residual DNA could be removed 
through DNAse treatment, however additional processing of the CD would have also 
 86 Chapter 4: The rapid manufacture of uniform composite multicellular-biomaterial micropellets, their 
assembly into macroscopic organized tissues, and potential applications in cartilage tissue engineering 
depleted sGAG content and chondrogenic cues therefore CD was minimally processed 
and not decellularized to maximize its biological potential on MSC chondrogenesis.  
The quantity of sGAG measured in the media for the CD and MSC+CD macro 
and micropellets was greater during the early days of the culture (Fig. 21A).  The elution 
profiles from CD macro and micropellet controls indicate that the sGAG content in the 
medium over the first few days for MSC+CD macro and micropellets largely reflects 
elution from the CD rather than de novo sGAG synthesis by the MSC. Similarly, this 
time course also indicates that the sGAG elution from CD is completed by the end of the 
first week of culture (day 8).  By contrast, MSC micropellets continuously increased 
their sGAG secretions over the first and second week of culture.  It is clear that the 
sGAG secretion profile of the micropellets (MSC and MSC+CD) is superior to the 
macropellets (MSC and MSC+CD) in the second week of culture (Fig. 21A). 
Figure 21C outlines the total sGAG content in each of the tissue constructs. The 
sGAG values represent the actual quantity of sGAG produced by MSC and as well as 
the sGAG content that originated from CD.  The calculations used to estimate these 
values accounted for the fact that we only performed a 75% volume medium exchange 
(rather than 100% exchange) every second day. CD macro and micropellets were able to 
retain the majority of their sGAG within the constructs while both MSC and MSC+CD 
micropellets eluted approximately twice as much sGAG as they retained (Fig. 21C). 
Nevertheless, the overall sGAG retained and released to the media was significantly 
greater in micropellets relative to macropellets (Fig. 21C). The loss of sGAG into bulk 
media only occurs during the micropellet culture and ceases when the micropellets are 
assembled (see “Micropellet assembly” section).  
The total quantity of sGAG (both in media and in the tissue digest) from each 
sample was normalized to the total DNA. The greatest sGAG/DNA content was found in 
the MSC+CD micropellets followed by MSC micropellets (Fig. 21D).  The total sGAG 
content in these constructs was equivalent to the summation of the sGAG in the MSC 
micropellet plus the CD controls (Fig. 21D).  Previously published studies have reported 
synergistic benefits through the incorporation of donor cartilage matrix [350-352].  In 
our micropellet system the sGAG production is upregulated by 3-4 fold relative to the 
macropellet.  It is possible that the increase in chondrogenesis resulting from the 
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micropellet culture and TGFβ supplementation superseded the more subtle changes 
reported to be induced by the inclusion of donor matrix.  Additionally, bovine-derived 
cartilage matrix was used in this study rather than human-derived cartilage matrix as 
described previously [282].  In our system, it appears that the increase in MSC+CD 
tissue volume and sGAG quantity represents the primary contribution of the CD to the 
cultures.   
 
 
Figure 21. DNA quantification and chondrogenic differentiation.  The quantity of sGAG in the media 
throughout the culture was higher for micropellets in general (A). The quantity of DNA at day 14 was the 
greatest for MSC micropellets and residual DNA was detected in CD macro and micropellets (B). The 
overall sGAG quantification in digest and in media demonstrated that the greatest quantity of sGAG was 
contained and eluted by MSC and MSC+CD micropellets (C). Total sGAG/DNA was calculated by 
dividing the quantity of the total sGAG (in digest and media) by DNA and this ratio was the greatest for 
MSC+CD micropellets (D). Abbreviations: CD, cartilage dust only control; MSC, cell only control; 
MSC+CD, composite (cell and cartilage dust); macro, macropellet; micro, micropellet. 
 
Matrix deposition and distribution 
Alcian blue staining demonstrated that all macro and micropellets contained 
sGAG (Fig. 22). MSC macropellets demonstrated a heterogeneous sGAG distribution 
where some parts of the pellets were more intensely stained than others, and DAPI 
staining revealed that the less stained areas had more concentrated nuclei than sGAG 
 88 Chapter 4: The rapid manufacture of uniform composite multicellular-biomaterial micropellets, their 
assembly into macroscopic organized tissues, and potential applications in cartilage tissue engineering 
rich areas (Fig. 22). MSC+CD macropellet had less intense staining, reduced number of 
nuclei and the tissue structure appeared to be less intact (Fig. 22). The staining for MSC 
and MSC+CD micropellets appeared similar, although it was evident that MSC+CD 
micropellets had a greater overall diameter.   
Collagen II immunolocalizing suggested that CD itself was rich in collagen II, 
and MSC+CD macro and micropellets stained intensely for collagen II (Fig. 22). The 
antibody manufacturer indicates that their human anti-collagen II antibody cross-reacts 
with bovine collagen II and we expected to be able to visualize the contribution of the 
bovine collagen. MSC macro and micropellets also stained positively for collagen II, 
however the intensity of the staining was substantially lower than the MSC+CD macro 
and micropellets indicating that the increase in collagen II content is mainly provided by 
the CD incorporation rather than de novo collagen II biosynthesis.  Collagen X staining 
was relatively weak and similar for all conditions (Fig. 22). The legitimate next step in 
future studies is the biomechanical characterization of generated tissues in order to 
measure the additional mechanical strength provided by CD incorporation. 
 
Gene expression 
A panel of chondrogenic, hypertrophic and osteogenic (aggrecan, versican, 
SOX9, RUNX2, collagen II, collagen I, collagen X, osteocalcin) gene expression was 
assessed for samples on day 0, day 7 and day 14 (Fig. 23). Aggrecan expression was 
greatest in MSC micropellets on both days 7 and 14 (Fig. 23A). Versican was 
significantly downregulated in all cultures relative to day 0, and the lowest expression 
was seen in the MSC+CD macropellets (Fig. 23B). SOX9 was upregulated in MSC 
macropellets on day 7 (Fig. 23C). RUNX2 was upregulated in MSC+CD macropellet 
and MSC micropellets on day 7 (Fig. 23D). Collagen II expression was only upregulated 
in MSC micropellets on both day 7 and 14, being significantly higher on day 14 than on 
day 7 (Fig. 23E). The low collagen II expression in MSC+CD micropellets also supports 
that the increase in collagen II content of these tissues (Fig. 22) was mainly provided by 
the incorporation of CD. Collagen I expression was the lowest in MSC and MSC+CD 
macropellets (Fig. 23F).  The greatest relative collagen I expression was observed in 
MSC micropellets on day 7 (Fig. 23F). Collagen X expression, similar to collagen II, 
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was only upregulated in MSC micropellets on both day 7 and 14 (Fig. 23G).  
Osteocalcin expression was the highest in MSC micropellets on day 7 but was 
significantly downregulated on day 14 (Fig. 23H). 
Overall the chondrogenic gene expression was not elevated in MSC+CD 
micropellets as much as it was in MSC micropellets confirming the previous results; no 
chondroinductive effects were observed as a result of CD supplementation (Fig. 23). 
This observation suggests that chondrogenic factor supplement is superior to CD 
addition in inducing chondrogenic differentiation. 
 
Figure 22. Histological assessment of MSC and MSC+CD macro and micropellets at day 14. The 
alcian blue staining demonstrated that MSC+CD macropellet was less intact when compared to MSC 
macropellet. Collagen II staining was stronger in MSC+CD macro and micropellets when compared to 
MSC macro and micropellets indicating that CD itself contained high quantity of collagen II. Collagen X 
staining was similar in all conditions. All the images were overlayed with DAPI staining. Abbreviations: 
MSC, cell only control; MSC+CD, composite (cell and cartilage dust); macro, macropellet; micro, 
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Figure 23. Gene expression analysis of MSC and MSC+CD macro and micropellets at day 7 and 14. 
Aggrecan (A), Versican (B), SOX9 (C), RUNX2 (D), Collagen II (E), Collagen I (F), Collagen X (G) and 
Osteocalcin (H) gene expressions were analyzed to assess the chondrogenic, hypertrophic and osteogenic 
characteristics of the generated macro and micropellets. Abbreviations: MSC, cell only control; MSC+CD, 
composite (cell and cartilage dust); macro, macropellet; micro, micropellet; d7, day 7; d14, day 14. 
 
Micropellet assembly 
Assembly of macropellets is previously utilized in order to engineer macroscopic 
cartilage tissues [353,354]. Similarly in this study, the relative capacity of micropellets 
to be assembled into macroscopic tissues was compared at multiple time points in order 
to help predict the time point that would enable optimal tissue integration in defect 
repair applications.  Specifically, MSC micropellets and MSC+CD micropellets were 
assembled into macrotissues following 4, 7, 10, or 14 days of culture as discrete 
micropellets. The assembled macrotissues were then matured in culture until day 22. 
Alcian blue staining revealed that MSC-only micropellets appeared to be more 
efficiently integrated into continuous and seamless macrotissues relative to MSC+CD 
micropellets (Fig. 24).  MSC+CD micropellet integration appeared to be more efficient 
at early time points (Fig. 24).  This is consistent with our previously published results, 
which demonstrated that the more mature a cartilage micropellet was, the less efficient it 
was at seamlessly integrating with other micropellet into a continuous macrotissue [17]. 
The collagen II staining confirmed the rich collagen II content of CD and if 
assembled at early time points, MSC+CD micropellets could form a collagen II rich 
cartilaginous tissue (Fig. 24). Additionally, DAPI staining showed that few nuclei were 
observed for the day 0 MSC+CD assembly when compared to later assembly time points 
(Fig. 24). Therefore, first generating composite MSC+CD micropellets then assembling 
them into macroscopic constructs can enhance revitalization of CD with MSC. 
The macroscopic appearance indicated that MSC+CD assembled tissues were 
more opaque while the MSC assembled tissues appeared more transparent (Fig 25A). 
Day 0 assembled MSC tissue was noticeably smaller than the other assembled MSC 
tissues (Fig 25A). This observation may indicate that MSC micropellets can rapidly 
increase their size resulting in a greater total tissue volume relative to tissues formed 
immediately through the pelleting of a single cell suspension.  
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The quantity of sGAG released into the media was measured before and after the 
assembly of micropellets.  Previously, it has been reported that the retention of sGAG is 
enhanced when chondrocyte macropellets are assembled into larger constructs [354]. 
Similarly, we observed that when MSC micropellets were assembled into macroscopic 
constructs, their sGAG elution slowed after the assembly time point (Fig. 25B).  This 
result is rational, as the surface area to volume ratio, from which the sGAG is eluted, 
decreases when larger tissues are formed.  However elution pattern was different for 
MSC+CD micropellet assembly where a high quantity of sGAG was released to the 
media during the first week (Fig. 25C), which suggest that the gradual sGAG loss was 
mainly originating from CD itself. Nevertheless, the elution of sGAG from both MSC 
and MSC+CD micropellets appears to be a transient event occurring during the early 
stage of discrete micropellet culture.  
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Figure 24. Histological assessment of the assembled tissues. Alcian blue staining showed inefficient 
integration of the CD particles in day 0 MSC+CD assembly (equivalent to MSC+CD macropellets) and 
decreasing integration efficiency was observed when the assembly day increased. Collagen II staining 
confirmed that the quantity of collagen II in MSC+CD assembled tissues was higher than the collagen II 
in MSC assembled tissues. Abbreviations: MSC, cell only control; MSC+CD, composite (cell and 
cartilage dust); d0, day 0; d4, day 4; d7, day 7; d10, day 10; d14, day 14. Scale bars: 100 µm. 
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Figure 25. Morphology of the assembled tissue and quantification of the sGAG in media during 
assembly. MSC assembled tissues looked transparent whereas MSC+CD assembled tissues were more 
opaque and the day 0 MSC tissue was smaller than the rest of the assembled tissues. (A). The graph of 
sGAG in media during assembly of the MSC micropellets showed that the sGAG release to the media was 
diminished after assembly time points (B). The sGAG in media for the MSC+CD assembled tissues 
showed a decreasing trend in the first week, which is mostly the sGAG originating from CD (C). 
Abbreviations: MSC, cell only control; MSC+CD, composite (cell and cartilage dust); d0, day 0; d4, day 
4; d7, day 7; d10, day 10; d14, day 14. Scale bar: 1 mm. 
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5. Conclusion 
Replicating native cartilage tissue ECM properties in tissue engineered cartilage 
remains a significant challenge in the field [355]. In approved therapies, such as ACI, 
chondrocytes are implanted into defects without the benefit of any previously 
established mature cartilage matrix. A cartilage defect site is a challenging 
microenvironment for tissue regeneration and expecting the rapid and efficient 
generation of functional repair tissue may not be rational, and thus successful cartilage 
defect repair strategies may require the combined use of donor and de novo cartilage 
matrix.  Here we have described a novel strategy to incorporate mature donor cartilage 
matrix into engineered cartilage tissue. By supplying donor cartilage matrix in the form 
of microscopic cartilage dust (CD) we were able to overcome previously reported 
limitations in cell penetration and repopulation of larger dimension donor cartilage 
matrix pieces.  To enable the uniform CD distribution in the engineered tissue, we first 
manufactured composite MSC+CD micropellets.  Composite micropellets self-
assembled into structures with a core of CD, and a cellular surface that facilitated the 
bridging of micropellets into macrotissues when they were in contact with each other. 
The logical next step in future studies is to assess biomechanical features of the 
generated tissues to further verify the benefits of utilizing CD in cartilage repair.   Whilst 
the addition of CD did not enhance MSC chondrogenic differentiation, this delivery 
strategy resulted in uniform and rapid loading of donor cartilage matrix particles into 
MSC micropellets that may offer a mechanism to enhance cartilage defect repair. In a 
clinical setting, xenogeneic CD can be used as an off-the-shelf product, and the patient’s 
own bone marrow MSC can be harvested and expanded for two weeks, then MSC+CD 
micropellets can be manufactured within a week. Three weeks after the bone marrow 
harvest, the prepared micropellets can be injected into the defect site where CD will 
provide temporary mechanical support and MSC will contribute to de novo tissue 
regeneration. The exploitation of the described micropellet and biomaterial composite 
strategy may offer a unique template for the addition of other nano/microparticles 
capable of enhancing chondrogenesis through the release of growth factors or other 
signal molecules.  Such strategies could enable control over cellular organization and the 
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continued release of induction factors following implantation of the micropellets in 
vitro. 
 
Gene	  (Amplicon	  size	  in	  basepair)	   Primers	  
	   	  
Cyclophilin	  A	  (164)	   Forward	  	  CTCGAATAAGTTTGACTTGTGTT	  
Reverse	  	  	  CTAGGCATGGGAGGGAACA	  
GAPDH	  (119)	   Forward	  	  ATGGGGAAGGTGAAGGTCG	  
Reverse	  	  	  TAAAAGCAGCCCTGGTGACC	  
SOX9	  (77)	   Forward	  	  TTCCGCGACGTGGACAT	  
Reverse	  	  	  TCAAACTCGTTGACATCGAAGGT	  
Aggrecan	  (85)	   Forward	  	  TCGAGGACAGCGAGGCC	  
Reverse	  	  	  TCGAGGGTGTAGCGTGTAGAGA	  
Collagen	  II,	  COL2A1	  (79)	   Forward	  	  GGCAATAGCAGGTTCACTGACA	  
Reverse	  	  	  CGATAACAGTCTTGCCCCACTT	  
Collagen	  I,	  COL1A1	  (83)	   Forward	  	  CAGCCGCTTCACCTACAGC	  
Reverse	  	  	  TTTTGTATTCAATCACTGTCTTGCC	  
Versican	  (98)	   Forward	  	  TGGAATGATGTTCCCTGCAA	  
Reverse	  	  	  AAGGTCTTGGCATTTTCTACAAAG	  
Collagen	  X,	  COL10A1	  (70)	   Forward	  	  CAAGGCACCATCTCCAGGAA	  
Reverse	  	  	  AAAGGGTATTTGTGGCAGCATATT	  
Runx2	  (113)	   Forward	  	  GGAGTGGACGAGGCAAGAGTTT	  
Reverse	  	  	  AGCTTCTGTCTGTGCCTTCTGG	  
Osteocalcin	  (70)	   Forward	  	  GAAGCCCAGCGGTGCA	  
Reverse	  	  	  CACTACCTCGCTGCCCTCC	  
	    
Table 2. Primers used for gene expression analysis. 
 
 
Figure 26. Schematic demonstrating the details of the microwell discs. 
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CD#size#distribution#(Fig.#20B)
Particle)size)(μm))0)x)axis 1 2 3 4 5 6 7 8 9 10
Number)of)particles)0)y)axis 2442 1561 1178 1021 550 616 501 246 239 197
Particle)size)(μm))0)x)axis 11 12 13 14 15 16 17 18 19 20
Number)of)particles)0)y)axis 139 97 101 61 41 69 39 42 42 44
Particle)size)(μm))0)x)axis 21 22 23 24 25 26 27 28 29 30
Number)of)particles)0)y)axis 31 34 26 21 28 31 18 17 18 13
Particle)size)(μm))0)x)axis 31 32 33 34 35 36 37 38 39 40
Number)of)particles)0)y)axis 13 15 15 10 20 9 13 8 7 10
sGAG#in#media#(Fig.#21A)
Conditions)0)y)axis sGAG)in)media)Mean
Days)0)x)axis CD)macro CD)micro MSC)macro MSC)micro MSC+CD)macro MSC+CD)micro
2 2.972776688 3.883592156 0 1.226780719 5.265261938 9.558345375
4 0.692260781 0.799397156 0 2.264625188 2.124713344 5.377400719
6 0.283911187 0.551493844 0.090084656 5.120479687 1.982941875 5.912734219
8 0.17647575 0.215379 0.620349 5.22804675 0.253215 3.99003675
10 0.001620469 0.775510313 0.119172656 5.256480938 0.160095938 4.99909125
12 0 0 0 5.762797219 0 4.425272813
14 0.204325 0.088777 0.018327 9.836309 0 7.283201
sGAG)in)media)SD
2 0 0.854370616 0.407338812 0.494253765 0.408157058 0.452246709
4 0 0.608513382 0.451093882 0.382822206 0.71632335 0.278875603
6 0.097730741 0.754601956 0.653538162 0.285388063 0.403931717 0.559003326
8 0.476292951 0.305559777 0.551041477 0.466649088 0.25605942 0.159225068
10 0.154942238 0.320191875 1.141370398 0.947978112 0.003240938 0.547090903
12 0 0 0.732053943 1.465343649 0 0
14 0.036654 0 1.46614287 1.159650656 0.315444511 0.177554  
DNA$(Fig.$21B)
Conditions()(x(axis day(0 CD((macro MSC((macro MSC+CD((macro CD((micro MSC((micro MSC+CD((micro
DNA(Mean()(y(axis( 1.776973608 0.981319964 1.368836081 1.79034104 1.38973187 2.210923494 1.594000115
DNA(SD 0.13290329 0.093223984 0.086063894 0.087508626 0.03777488 0.152798852 0.10530326
Total$sGAG$(Fig.$21C)
Total(sGAG(Mean
Conditions()(x(axis day(0 CD((macro MSC((macro MSC+CD((macro CD((micro MSC((micro MSC+CD((micro
sGAG(in(digest()(y(axis((black) 3.66803625 10.78598725 5.296019625 7.731108125 10.14415963 16.1244505 17.127134
sGAG(in(media()(y(axis((grey) 0 4.331369875 0.847933312 9.786228094 6.243503125 34.6955195 41.54608213
Total(sGAG(SD
0.830490886 0.722895338 0.539372176 0.73675105 0.317742541 0.912076263 0.992807002
0 1.211719974 0.582689347 2.341712726 1.104154892 2.788330602 2.398654515
Total$sGAG/$DNA$(Fig.$21D)
Conditions()(x(axis day(0 CD((macro MSC((macro MSC+CD((macro CD((micro MSC((micro MSC+CD((micro
Total(sGAG/DNA(Mean()(y(axis 2.051542897 15.40735177 4.503288236 9.793679776 11.81423028 23.04989717 36.92345935
Total(sGAG/DNA(SD 0.338739052 0.83104324 0.333145192 1.372414077 1.2331806 1.99606069 2.870746073
Gene$expression$(Fig.$23)
Relative(gene(expression()(x(axis Gene(expression(Mean
Conditions()(y(axis Aggrecan((Fig.(23A) Versican((Fig.(23B) Sox(9((Fig.(23C) Runx2((Fig.(23D) Col(I((Fig.(23F) Col(II((Fig.(23E) Col(X((Fig.(23G) Osteocalcin((Fig.(23H)
MSC+CD(micro(d14 0.041249167 0.15928649 0.013168423 0.00450951 19.66655951 0.018971088 0.049431972 0.000777859
MSC+CD(micro(d7 0.019395302 0.117070141 0.015580249 0.011074219 16.05265291 0.002091582 0.030437476 0.001391523
MSC(micro(d14 0.119628577 0.135985124 0.016742476 0.009356104 16.61536192 0.61077304 0.325578793 0.000772288
MSC(micro(d7 0.147984306 0.203332614 0.029137531 0.01377469 26.33207606 0.249702151 0.381665587 0.001872898
MSC+CD(macro(d14 0.005928658 0.044775999 0.016692754 0.00892704 2.780884598 1.52953E)05 0.000122195 0.001098905
MSC+CD(macro(d7 0.005962409 0.068159876 0.032001645 0.014240243 1.854222295 1.65041E)05 0.000236096 0.00133397
MSC(macro(d14 0.050808842 0.128836997 0.022237641 0.005328402 5.454949455 0.058810946 0.013399238 0.000510641
MSC(macro(d7 0.008345466 0.14363354 0.039774719 0.007207111 3.24478076 0.000154071 0.000186668 0.001201627
d0 0.028472483 0.296021537 0.007151873 0.005362364 8.191271934 2.66049E)06 4.84755E)06 0.001037553
Gene(expression(SD
MSC+CD(micro(d14 0.01893115 0.031584641 0.003418478 0.00169978 8.061006451 0.017428758 0.034844207 0.000421305
MSC+CD(micro(d7 0.004931078 0.004167333 0.002424744 0.001584744 1.917623165 0.000205975 0.007043007 0.000270851
MSC(micro(d14 0.032391112 0.029240949 0.003994321 0.002984179 4.821128418 0.069743272 0.091456497 0.000408488
MSC(micro(d7 0.030407047 0.028560114 0.004028969 0.003286186 2.616840634 0.028348308 0.0359078 0.000308233
MSC+CD(macro(d14 0.001443255 0.005731784 0.002933673 0.000630861 0.49530209 7.06622E)06 6.44366E)05 0.000205159
MSC+CD(macro(d7 0.001536055 0.009671057 0.004106253 0.001337315 0.381987334 1.15132E)06 0.00017071 0.000129575
MSC(macro(d14 0.026408797 0.028656881 0.005923434 0.001029282 2.60054007 0.078083635 0.014394629 0.000276827
MSC(macro(d7 0.00134004 0.025235375 0.009365887 0.001943515 0.46696334 0.00012397 0.000100374 0.000279366
d0 0.002844536 0.061189478 0.00115335 0.000875945 4.676250324 2.95025E)06 7.16061E)06 0.000752905  
Table 3. Data used to generate Figures 20, 21, 23.  
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sGAG$elution$during$MSC$micropellet$assembly$(Fig.$25B)
sGAG$elution$,$y$axis$ sGAG$elution$Mean
Days$,$x$axis 2 4 6 8 10 12 14 16 18 20 22
Assembly$time$points$,$linesd0 0.004468 0 0.09467 0.003169 1.545339 0.450282 0.592758 0 0.232364 0 0.353014
d4 1.368675 3.122325 1.955823 1.638867 2.344224 1.266054 3.435384 2.562456 3.293793 3.172986 4.383654
d7 1.450512 2.798874 4.356375 4.968204 3.174285 1.490781 2.484516 1.99869 3.699081 3.153501 3.815991
d10 1.655754 2.841741 4.229073 5.35011 7.803921 4.069296 2.135085 2.978136 4.299219 4.044615 6.660801
d14 1.343994 2.510496 4.365468 5.650179 7.810416 8.368986 10.655226 6.171078 4.417428 3.315876 4.885068
sGAG$elution$SD
d0 0.0077388 0 0.1427927 0.00548887 0.39860678 0.0390349 0.82193299 0 0.40246625 0 0.30772435
d4 0.14299034 0.54293383 0.30793698 0.19902698 0.45650379 0.23704526 0.33673177 0.28669669 0.35224943 0.33761008 0.9719793
d7 0.19814754 0.59623251 0.27426132 0.4662252 0.60343549 0.24325314 0.27129204 0.30052415 0.29551322 0.1384578 0.21238948
d10 0.019485 1.11447614 0.37887846 0.15173299 0.24960075 0.0250542 0.35398405 0.40046929 0.52656147 0.42867 0.9167922
d14 0.43672488 0.3158574 0.31499076 0.36885882 0.49708268 0.44525392 0.46902355 0.89104488 0.31616977 0.65138212 0.66233334
sGAG$elution$during$MSC+CD$micropellet$assembly$(Fig.$25C)
sGAG$elution$,$y$axis sGAG$elution$Mean
Days$,$x$axis 2 4 6 8 10 12 14 16 18 20 22
Assembly$time$points$,$linesd0 5.243592 2.54427 1.62198 0.598368 1.156938 0.39531 0.372499 0.016159 0.793375 0.316799 0.316642
d4 9.680976 6.15549 3.491241 1.7259 1.974009 0.185443 0 0 0.990823 0.7609 0.103763
d7 9.848547 6.081447 5.325429 3.810795 2.513094 0.804338 0.06869 0 0.310304 0.212308 0.038085
d10 9.97455 6.793299 4.964307 4.722693 5.330625 3.157398 0.477561 0.194693 0.516531 0 0.5568
d14 9.842052 6.19446 6.446466 4.070595 4.11606 4.96041 5.183838 3.356145 1.840212 0.307549 0.415937
sGAG$elution$SD
d0 0.24752342 0.19237922 0.09682562 0.23046178 0.26280924 0.53566618 0.39278156 0.02798821 0.6966341 0.54871196 0.14251641
d4 0.68002743 0.27238144 1.11852047 0.20049677 0.14267136 0.21977757 0 0 0.8580978 0.67065468 0.10827582
d7 0.14277777 0.14420655 0.8009765 0.25339491 0.44060234 0.66555579 0.10435064 0 0.38292403 0.36772824 0.00811225
d10 0.51248637 0.32357618 0.82927391 0.83168773 0.42776565 0.73141544 0.17236609 0.18045381 0.33799221 0 0.48316514
d14 0.38310371 0.01190553 0.50524922 0.45287991 0.29722982 0.61745011 0.51063094 0.68627413 0.20703061 0.14872859 0.36765448  
Table 4. Data used to generate Figure 25.  
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1. Abstract  
Engineered biphasic osteochondral tissues may have utility in cartilage defect 
repair.  As bone marrow-derived mesenchymal stem/stromal cells (MSC) have the 
capacity to make both bone-like and cartilage-like tissues, they are an ideal cell 
population for use in the manufacture of osteochondral tissues.  Effective differentiation 
of MSC to bone-like and cartilage-like tissues requires two unique medium 
formulations, and this presents a challenge in both in achieving initial MSC 
differentiation and in maintaining tissue stability when the unified osteochondral tissue 
is subsequently cultured in a single medium formulation.  In this proof-of-principle 
study we used an in-house fabricated microwell platform to manufacture thousands of 
micropellets formed from 166 MSC each.  We then characterized the development of 
bone-like and cartilage-like tissue formation in the micropellets maintained for 8 to 14-
days in sequential combinations of osteogenic or chondrogenic induction medium.  Our 
data indicate that bone-like and cartilage-like micropellets induced for only 8-days 
displayed significant phenotypic changes when the osteogenic or chondrogenic 
induction medium, respectively, was swapped.  Based on these data we developed an 
extended 14-day protocol for the pre-culture of bone-like and cartilage-like micropellets 
in their respective induction medium.  A unified osteochondral tissue was then formed 
by layering 12,000 osteogenic micropellets and 12,000 chondrogenic micropellets into a 
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biphasic structure and cultured in chondrogenic induction medium.  The assembled 
tissue was cultured for a further 8-days and then characterized via histology. The 
micropellets had amalgamated into a continuous structure with distinctive bone-like and 
cartilage-like regions.  This proof-of-concept study demonstrates the feasibility of 
micropellet assembly for the formation of osteochondral-like tissues that may have 
utility in osteochondral defect repair. 
2. Introduction 
Articular cartilage has limited intrinsic regeneration capacity. The degeneration 
of articular cartilage leads to osteoarthritis (OA), which is the most common form of 
joint disease and one of the leading causes of disability worldwide [2,337-339].  The 
capacity to effectively repair acute cartilage defects could delay or prevent the 
development of OA for many patients.  A number of acute cartilage defect repair 
strategies have been proposed and these range from filling of the defect with cells, with 
natural/synthetic hydrogels/scaffolds, or combinations of both [93,101,110].  There are a 
number of challenges associated with any cartilage defect repair, and perhaps most 
significant is the effective integration of the repair tissue with the adjacent native tissue 
[356,357].  Because chondrocytes are low in number and have a limited capacity to 
migrate through cartilage matrix at wound edges, the borders surrounding the repair 
tissue may not be iteratively remodeled and effectively integrated into the adjacent 
repair tissue.  Additionally, the underlying bone often incurs simultaneous damage 
during the initial injury, and building new tissue on this damaged foundation can be 
problematic [358].  In procedures such as mosaicplasty, the underlying bone and 
associated cartilage is harvested from a donor location and transplanted into a critical 
defect site [83].  The inclusion of the bone layer is essential as it facilitates tissue 
integration and provides a foundation for the donor cartilage tissue [90].  Whilst the 
bone layer rapidly and iteratively remodels, the integration of the cartilage layer can be 
delayed or even remain incomplete.  A ring of dead tissue can often be observed around 
the perimeter of a mosaicplasty tissue plug [90].  Nevertheless, the inclusion of the bone 
layer does enhance integration and the probability of a successful repair.  A fundamental 
drawback in mosaicplasty is the limited supply of autologous donor tissue available for 
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harvest and the associated damage at the donor site.  These limitations are driving the 
development of tissue engineering solutions that will enable the manufacture of either 
synthetic or biosynthetic osteochondral tissues.  
Approaches trialed in the manufacture of artificial osteochondral tissues include 
the use of bilayer scaffolds, separate scaffolds for bony and chondral layers, scaffold for 
bony layer scaffold-free for chondral layer, and single homogenous or heterogeneous 
scaffolds [359]. There are also cell-free studies that utilize scaffolds to fill the defect 
site, with the anticipation that biological “cues” incorporated into the scaffold will direct 
host cells to repopulate the scaffold in a useful and organized manner [360-362].  This 
cell-free approach is likely not suitable for large chondral defects for reasons similar to 
the failure of mosaicplasty plugs to integrate; because chondrocytes have limited 
capacity to migrate from the dense matrix in the adjacent native tissue, the probability 
that cells would be able to populate a large scaffold is remote. For this reason, cell-free 
studies are often coupled with microfracture technique, which stimulates bleeding and 
recruits cells from within the underlying bone marrow [109,363,364].  Additionally, 
most scaffold approaches aim to use the scaffolds as a temporary extracellular matrix 
(ECM) support and assume that the scaffold biodegradation will be synchronized with 
the de novo tissue formation.  This synchronization is technically challenging when the 
scaffold has multiple phases or components. Other studies have explored repairing full-
thickness osteochondral defects with scaffold-free approaches.  However, in such cases 
the repair tissue only includes a cartilage phase [365,366], and the de novo tissue relies 
on the existing bone to function as both the tissue foundation and interface.  
Bone marrow-derived mesenchymal stem/stromal cells (MSC) are frequently 
utilized in osteochondral defect studies [367-370], because it is assumed that these cells 
have the potential to differentiate into either chondrocyte or osteoblast-like cells.  The 
chondrogenic or osteogenic phenotype derived from MSC populations is very sensitive 
to the medium formulation, and chondrogenic or osteogenic medium traditionally has 
different formulations [371].  Constructing a continuous osteochondral tissue in vitro 
presents a very real challenge as it obligates the culture of both tissue types in a single 
medium cocktail.  Some groups have attempted to overcome this challenge by culturing 
composite tissues in custom-made double chamber bioreactors that aim to physically 
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isolate each tissue type in their unique medium formulations [372,373]. We reason that a 
more rational approach might be to manufacture MSC micropellets, and induce 
chondrogenic or osteogenic differentiation in discrete culture systems, and then 
assemble the partially mature micropellet into a biphasic tissue in a common culture.  
Based on this rationale, we described the method for high throughput manufacture of 
discrete bone-like and cartilage-like micropellets with the subsequent assembly of the 
micropellets into a biphasic osteochondral-like tissue.   
Bone-like and cartilage-like micropellets were manufactured using a modified 
microwell platform previously described by our group [18,19].  Using this modified 
method, we systematically characterized the phenotypic change of bone marrow-derived 
MSC micropellets exposed sequentially to osteogenic and/or chondrogenic medium.  
Following characterization and optimization of this process, we assembled bone-like and 
cartilage-like micropellets into an osteochondral tissue and cultured this construct in a 
single medium formulation. 
3. Materials and Methods 
Experimental design 
This study has two parts. In the first part, the phenotypic characteristics of 
micropellets formed from human bone marrow-derived MSC cultured for 14 days under 
four different sequential medium conditions were characterized.  The medium conditions 
are described in Table 5, and defined using the following abbreviations: CC 
(chondrogenic media for 14 days), CO (chondrogenic media for first 8 days and 
osteogenic media for last 6 days), OC (osteogenic media for first 8 days and 
chondrogenic media for last 6 days), OO (osteogenic media for 14 days).  After 14 day 
exposure to osteogenic and/or chondrogenic media, micropellets were assessed for 
DNA, chondrogenic and osteogenic differentiation, histological features and gene 
expression. In the second part of the study, chondrogenic and osteogenic micropellets 
were assembled at different time points to form a continuous biphasic osteochondral-like 
tissue as depicted in Figure 30. The biphasic tissue was assessed for cartilage and bone 
histological features.  
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   Abbreviation	   Medium-­‐first	  8	  days	   Medium-­‐last	  6	  days	  
CC	   Chondrogenic	   Chondrogenic	  
CO	   Chondrogenic	   Osteogenic	  
OC	   Osteogenic	   Chondrogenic	  




Table 5. The abbreviations used in the study. According to the media type, and culture duration, each 
condition is stated with two letters. The first letter “C” or “O” indicates the culture medium formulation 
over the first 8 days of culture, and the second letter “C” or “O” indicates the culture medium formulation 
over the subsequent 6 days of culture. The media types were swapped at day 8 but not 7 because the media 
was changed every second day throughout the culture. 
 
 
Microwell fabrication and surface modification 
We used an in-house fabricated microwell surface to efficiently manufacture 
micropellets [17]. In brief, a polystyrene microwell mold having an array of microwells 
(each with dimensions of 360x360x180 µm, and 600 microwells per cm2) was used to 
generate sheets of polydimethylsiloxane (PDMS, Slygard) with microwells.  The process 
of fabricating the mold is described in detail here [17]. Discs (2 cm2 or 10 cm2) were 
punched from the sheets of PDMS and used to make multiwell inserts with 1200 and 
6000 microwells, respectively.  The PDMS discs were glued (Silicone Glue) into 24-
well plates and 6-well plates (Nunc), respectively. The plates with the microwell inserts 
were sterilized in 70% ethanol for 1 hour and then rinsed with sterile phosphate-buffered 
saline (PBS, Invitrogen). To prevent cell attachment, the surface was treated with 
surfactant, 5% pluronic F-127 (Sigma) solution, for 5 minutes then rinsed with sterile 
PBS once before the cells were seeded. 
 
Human bone marrow MSC isolation and expansion 
Ethics: Bone marrow aspirates were obtained from the iliac crest of volunteer 
donors with written consent. This documentation is held by the ethics committee and all 
tissue samples were provided to the research team in a de-identified manner. Mater 
Health Services approved this consent procedure. Ethical approval for these studies was 
granted by the Mater Health Services Human Research Ethics Committee (Ethics 
number: 1541A) and the Queensland University of Technology Human Research Ethics 
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Committee in accordance with the Australian National Statement on Ethical Conduct in 
Human Research.  
The bone marrow aspirates were processed as described previously [18].  
Aspirates (~20 mL) were diluted 1:1 using sterile PBS, and 12 mL Ficoll Paque Plus 
(GE Healthcare) was underlayed beneath the diluted aspirates. The Ficoll and bone 
marrow mixture was centrifuged at 535xg for 20 minutes. The cells accumulated at the 
interface of the Ficoll and bone marrow were aspirated carefully and washed with sterile 
PBS. The cells were resuspended in low glucose Dulbecco’s modified Eagle’s medium 
(LG DMEM, Invitrogen) with 100 U/mL penicillin and 100 µg/mL streptomycin (PS, 
Invitrogen) and 10% fetal bovine serum (FBS, Invitrogen) and seeded in T175 flasks 
(Nunc) and incubated for 48 hours before removing the non-adherent cells. The plastic 
adherent cells (MSC) were cultured until confluent with media changes every 3-4 days 
and passaged with 1:4 ratio three times (until passage 3), and then used in micropellet 
studies. MSC were expanded at 37°C in a hypoxic incubator (2% O2 and 5% CO2 
atmosphere) as this has been previously demonstrated to enhance proliferation and 
differentiation capacity [143,374].  Passage 2 expanded cells were characterized for their 
expression of CD marker profiles associated with MSC [375].  Specifically, we 
confirmed that the cell populations used were CD90, CD73, CD105, CD44 and CD146 
positive, and CD45, CD34, and HLA-DR negative.  Antibodies were purchased from 
Miltenyi Biotech and used as per the manufacturers instructions.  Stained cells were 
analyzed on a BD LSR-II flow cytometer. 
 
Micropellet formation 
Micropellets were formed in the multi-well plates containing microwell inserts. 
In the first part of the study 24-well plates containing 2 cm2 microwell inserts each 
containing 1200 microwells were used. For each sample, 1 mL medium containing 
2x105 human MSC was dispensed to each well (166 cells/microwell) and settled for 
micropellet formation inside the incubator. In the second part of the study 6-well plates 
containing 10 cm2 microwell inserts each containing 6000 microwells were used. For 
each well 5 mL medium containing 1 million human MSC was dispensed to each well 
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(166 cells/microwell) and then transferred into the incubator. Micropellet formation was 
confirmed via microscopy the following day.  
 
Chondrogenic and osteogenic differentiation 
Chondrogenic media contained high glucose (HG) DMEM with 110 µg/mL 
sodium pyruvate (Invitrogen), PS, 10-7 M dexamethasone (Sigma), 200 µM ascorbic 
acid 2-phosphate (Sigma), 40 µg/mL L-proline (Sigma), 1% insulin-transferrin-
selenium-ethanolamine (ITS-X, Invitrogen) and 10 ng/mL recombinant human 
Transforming Growth Factor β1 (TGF β1, Peprotech). Cultures containing chondrogenic 
media were incubated in a 2% O2 5% CO2 atmosphere at 37°C.   
Osteogenic media contained HG DMEM (Invitrogen), PS, 10% FBS, 10-7 M 
dexamethasone, 50 µM ascorbic acid 2-phosphate, 10 mM β-glycerol phosphate 
(Sigma). Cultures containing osteogenic media were incubated in a 20% O2 5% CO2 
atmosphere at 37°C.  
In the first part of the study, the media was exchanged 75% every second day for 
14 days except at day 8.  At day 8, the media was exchanged 100% in all samples.  This 
is because at day 8 the media type was switched (i.e. osteogenic to chondrogenic) and 
cultures were placed into different incubators at different oxygen concentrations 
appropriate for the medium type and corresponding differentiation process. 
 
Biphasic tissue assembly 
In the second part of the study, the MSC micropellets were differentiated in 
chondrogenic and osteogenic media separately, and then assembled at different time 
points to form a continuous osteochondral-like tissue. The chondrogenic media was 
exchanged 75% every second day until day 8, and the chondrogenic micropellets were 
assembled to form a macroscopic chondrogenic tissue on day 8.  Similarly, the 
osteogenic media was exchanged 75% every second day until day 14, and then the 
osteogenic micropellets were assembled on top of the macroscopic chondrogenic tissue 
to form a biphasic tissue.  The assembly of micropellets into larger tissues was achieved 
using customized PDMS funnel and layering cylinder shown schematically in Figure 30.  
This device was formed using the tip of a 10 mL syringe (Terumo) inside a 6-well plate 
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as a mold to cast PDMS around. The tip of the syringe was cut and glued to the middle 
of the well and the outer space left between the syringe and the well was filled with 
PDMS and cured (Fig. 33) then the extra PDMS around the edges of the mold was 
removed to accommodate more medium in the same well. The mold was sterilized in 
70% ethanol for 1 hour, and then rinsed repeatedly with sterile PBS prior to use in 
biphasic tissue formation. On day 8, chondrogenic micropellets (12,000) were 
concentrated in 2 mL media then transferred into the funnel mold in two steps (1 mL 
each time, followed by 300xg centrifugation for 2 minutes and removal of excess 
media). The accumulation of micropellets at the bottom of the funnel mold was visually 
confirmed and the remaining portion of the well was then filled with 5mL chondrogenic 
media. Following the first assembly step, the assembled tissue was cultured in a 20% O2 
5% CO2 atmosphere at 37°C with 75% of the medium volume exchanged daily. On day 
14 osteogenic micropellets (12,000) were transferred into the funnel mold using the 
above approach in order to generate a layer of bone tissue. Following the addition of 
osteogenic micropellets, the amalgamating tissue was cultured in chondrogenic media 
for 2 more days in the funnel mold, and then gently relocated into a 6-well plate.  This 6 
well plate was coated with PDMS and treated with 5% pluronic F-127 to prevent cell 
attachment to the underlying tissue culture treated polystyrene, but otherwise had a 
standard geometry.  The biphasic tissue was cultured for a further 6 days in 
chondrogenic media and then characterized via histology. 
 
Chondrogenic and osteogenic analyses 
Each sample for the first part of the study consisted of 2x105 cells (initially) in 
the form of 1200 micropellets. DNA, sGAG, calcium, alkaline phosphatase activity and 
gene expression quantifications were performed on ~1200 micropellets to obtain a single 
measurement. sGAG quantification in media was performed on 0.75 mL media collected 
after each media change on every second day.  
For DNA quantification the micropellets were digested in 0.25 mg/mL papain 
(Sigma) solution at 60°C overnight. DNA was quantified using PicoGreen dsDNA 
Reagent and Kit (Invitrogen) according to the manufacturer’s protocol. The signal was 
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measured using a fluorescent plate reader (BMG Labtech) with the excitation of 480 nm 
and emission of 520 nm.  
The quantity of sulfated glycosaminoglycan (sGAG) in the micropellets was 
measured from the papain digests and sGAG in media was measured from the media 
collected during culture.  The media or digest was mixed with 1,9 Dimethyl methylene 
blue zinc chloride double salt (DMB, Sigma) and the color change was measured using a 
plate reader (Thermo Fischer) at 590 nm. Shark chondroitin sulfate (Sigma) was used to 
generate a standard curve.  
Calcium quantification of the micropellets was achieved by incubating the 
tissues overnight in a tube shaker (Eppendorf) at 900 rpm in 10% acetic acid (RCI 
Labscan) at room temperature. A 1 mg/mL o-Cresolphthalein Complexone (OCPC, 
Sigma) solution was combined with 14.8 M ethanolamine-boric acid buffer (pH 11, 
Sigma) and 8-hydroxyquinoline (50 mg/mL in 95% ethanol, Merck) in following ratios 
5:5:2, then diluted 10X with ddH2O. The samples were mixed with OCPC solution, 
incubated at room temperature for 10 minutes and measured using a plate reader at 575 
nm. A standard curve was generated using serial dilutions of pure CaCl2 (Sigma).  
Alkaline phosphatase activity was quantified in the micropellets by first lysing 
them in a 0.1% Triton X-100 (Sigma) Tris buffer solution (pH 10.1, Sigma) contained in 
a tube placed in a shaker at 900 rpm for 1 hour at room temperature. The recovered 
lysate was mixed with substrate solution (1 mg/mL P-Nitrophenyl phosphate disodium 
salt, Sigma) and incubated at room temperature for 30 minutes in the dark.  The 
absorption of the incubated solution was measured in a plate reader at 405 nm.  
 
Gene expression analyses 
RNA was extracted from micropellets using Trizol (Invitrogen) as per the 
manufacturer’s suggested protocol. The isolated RNA was quantified with Nanodrop 
1000 (Thermo Scientific).  Reverse transcription was performed with SuperScript III RT 
and oligo(dT)20 kit (Invitrogen) as per the manufacturer’s protocol to obtain 
complementary DNA (cDNA).  Platinum SYBR Green qPCR SuperMix-UDG kit 
(Invitrogen) was used to perform quantitative polymerase chain reaction (qPCR). The 
primer sequences (5’ to 3’, Geneworks) in Table 6 were used to perform the qPCR.  
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SYBR Green master mix and cDNA were combined in a 384-well plate (Applied 
Biosystems) using liquid handler (epMotion M 5073, Eppendorf).  The qPCR reaction 
was initiated with 2 minutes hold at 50°C, continued with 3 minutes hold at 95°C, then 
continued with 40 cycles of 95°C for 15 seconds, and 60°C for 30 seconds.  This 
reaction was completed in a ViiA real time PCR machine (Applied Biosystems). The 
gene expression was quantified using ΔCt method and the relative gene expression was 
calculated by normalizing the gene expression with the geometric mean of two 
housekeeping genes (Cyclophillin A and GAPDH).  
 
Histological analyses 
The micropellets and the biphasic tissues analyzed via histology were first fixed 
in 4% paraformaldehyde (PFA, Sigma) for 30 minutes to preserve the tissue structure, 
then embedded in optimum cutting temperature compound (OCT, Tissue-Tek) then 
frozen at -20°C prior to sectioning. Using a cryostat (Leica) at -25°C, 10 µm thick 
sections were cut. The sections were captured on poly-lysine slides (Thermo Fischer), 
dried at room temperature, and then stored at -20°C. For staining, the sections were 
brought to room temperature and to prevent detachment, the sections were fixed second 
time onto glass slides with 4% PFA for 20 minutes then rinsed with PBS.  
Alcian blue staining was performed to identify the presence of sGAG in the 
tissues. Sections were covered and incubated for 10 minutes with 1% alcian blue 
(Sigma) solution in 3% acetic acid (pH 2.5).  Then the sections were rinsed with PBS 
and counterstained with 4’,6 diamidino-2-phenylindole (DAPI, Sigma) for 5 minutes, 
rinsed with PBS and mounted (CC/mount, Sigma) for imaging.  
Alizarin red staining was performed to assess osteogenic matrix deposition. The 
sections were rinsed with ddH2O then dried at 37°C for 10 minutes.  Slides were 
incubated with Alizarin Red S stain (Sigma) for 10 minutes then washed with PBS, and 
counterstained with DAPI for 5 minutes. Sections were washed with PBS and then 
mounted for imaging. 
For immunofluorescence (IF) analyses, borders were drawn around the sections 
with a PAP pen (Sigma). A solution of 3% goat serum (Invitrogen), 0.3% Triton X-100 
in 1% bovine serum albumin (BSA, Sigma) was used to block sections for 20 minutes. 
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The sections were incubated in primary antibody dilutions for human Collagen type I, II 
and X (raised in mouse, rabbit, rabbit respectively, Abcam) overnight at 4°C in a 
humidified environment. Negative controls for collagen type I, II and X were treated the 
same except their solution did not contain any primary antibody. Next day, the primary 
antibody solution was washed with 0.3% Triton X-100 for 3 minutes twice then rinsed 
with PBS once. Then, the corresponding secondary antibody solutions (Cy-3 conjugated 
anti rabbit IgG, FITC conjugated anti mouse IgG2b, Abcam) were added on sections and 
incubated for 30 minutes at room temperature, washed with 0.3% Triton X-100 for 3 
minutes twice counterstained with DAPI for 5 minutes, then rinsed with PBS. The 
sections were then mounted for imaging.  
 OsteoImage mineralization assay (Lonza) was used as per the manufacturer’s 
protocol to specifically stain the inorganic hydroxyapatite component of bone matrix. 
For the biphasic tissues, the sections were stained and imaged.  For micropellet tissues 
the whole micropellets were stained and imaged via confocal microscope. All samples 
were counterstained with DAPI. 
 
Microscopy 
The imaging of sections was performed using an ECLIPSE Ti epifluorescent 
microscope (Nikon, Japan) and assessed with NIS Elements BR 3.2 software. The 
micropellet images and fluorescent histology images were taken with a Nikon DS-
Qi1Mc camera whereas the color images (alcian blue and alizarin red staining) were 
taken by Nikon DS-Fi1 camera. The 3D images of whole micropellets stained with 
OsteoImage were acquired using a confocal microscope (ZEISS, Germany).  
 
Statistical analyses 
The experiments were repeated with 3 different MSC donor populations, some 
differences in differentiation efficiency were observed for different donors however the 
relations between different experimental groups were reproducible therefore a 
representative data set is presented. In each experiment, each condition had n = 4 
biological replicates.  Data were represented in graphs as mean + standard deviation 
(SD). The significance analyses were performed using SPSS Statistics 21 (IBM, USA), 
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one-way analysis of variance (ANOVA) with Tukey’s post-hoc tests.  For multiple 
comparisons, a p-value smaller than 0.05 was represented as significantly different. The 
significance was indicated with Roman numerals, the groups indicated with same 
numerals were statistically similar whereas the groups indicated with different numerals 
were statistically different.  
4. Results and Discussion 
Flow cytometry characterization of MSC 
MSC from four different de-identified bone marrow donations were utilized in 
this study. Donations were received from a 55 year old male, a 20 year old male, and a 
23 year old female. Two donations from the same 55 year old donor were collected at 
different times.  The CD marker expression for donor MSC at Passage 2 are displayed in 
Figure 32.  All MSC cultures contained <5% populations positive for either CD45, 
CD34 or HLA-DR.  All MSC cultures contained >95% populations positive for CD90, 
CD73, CD105, CD44 and CD146.   
 
Chondrogenic and osteogenic features of micropellets 
The size of the CC and OO micropellets were noticeably different following 14 
days of culture (Fig. 27A). OO micropellets were smaller and had opaque cores, whereas 
CC micropellets were greater in size. When compared to OO, OC micropellets had 
relatively greater size and less opaque cores (Fig. 27A). DNA quantification revealed 
that all cultures had less DNA than the day 0 samples. However, the cultures initiated 
with osteogenic media, OC and OO, had significantly less DNA than the cultures 
initiated with chondrogenic media, CC and CO (Fig. 27B).  DNA content is not the only 
factor affecting the micropellet size; the accumulation of matrix can also vary size of the 
micropellets. In this case however both the micropellet size and DNA content are lower 
in OC and OO micropellets, which may suggest that greater cell death occurred in those 
micropellets.  
The quantity of sGAG in the micropellets and the culture medium was measured, 
as this is a common approach used to indirectly quantify chondrogenesis. Figure 27C 
was plotted using the sGAG quantity found in the media after each media exchange 
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therefore it demonstrates the elution pattern of sGAG into the media over the two week 
culture.  The quantity of sGAG in medium was incrementally increased in CC and CO 
micropellets, while it was lower and constant for OC and OO micropellets over the first 
8 days (Fig. 27C). Following day 8, OC and OO micropellets continued to elute only 
minor quantities of sGAG into the media. Over the second week of the culture, sGAG 
elution in CO micropellets tapered slowly at first and then significantly at day 12 
because of the switch to osteogenic medium (Fig. 27C). Figure 27D demonstrates the 
sGAG found in the tissue on day 14 (sGAG in digest) and the accumulation of sGAG 
eluted into the media, which is the summation of sGAG quantities found in the media 
after media exchanges (sGAG in media). The quantity of sGAG retained in the 
micropellets was the greatest for CC, although the total quantity of sGAG eluted into the 
culture medium was similar for both CO and CC micropellet cultures (Fig. 27D). Figure 
27E demonstrates the ratio of the total sGAG quantity (which is summation of sGAG in 
digest and total sGAG in media) to the corresponding DNA quantity for each sample. 
The sGAG/DNA ratio was the greatest for CC and CO micropellets, and lesser for OC 
and OO micropellets (Fig. 27E). Overall, DNA and sGAG/DNA data indicated that the 
cultures initiated with a similar media type over the first 8 days had similar phenotype 
following 14 days total culture. 
In contrast to chondrogenic characterization, osteogenic characterization 
provided greater resolution and indicated that the change in medium composition did 
influence micropellet phenotype substantially. The calcium/DNA ratio was the greatest 
for OO micropellets, significantly lower for OC micropellets, and it was the lowest for 
CC and CO micropellets (Fig. 27F). Interestingly, the alkaline phosphatase (ALP) 
activity/DNA ratio was markedly greater in the CO micropellets (Fig. 27G).  ALP is 
considered a key early indicator of osteogenesis, and it is upregulated during early 
osteogenesis, and then ALP activity is diminished as the cells continue to mature [376]. 
The elevated ALP activity observed in the CO micropellets may suggest that these 
tissues acquire a pre-osteogenic phenotype in response to the change from chondrogenic 
to osteogenic medium. 
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Figure 27. Morphology of micropellets, chondrogenic/osteogenic differentiation and DNA content 
assessment. The size of the micropellets was greatest for CC and smallest for OO micropellets. The core 
of OO micropellets appeared more opaque (A). The quantity of DNA was lower than day 0 control in all 
conditions, and it was significantly reduced for the cultures initiated with osteogenic medium; OC and OO 
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(B). Elution of sGAG into the media was monitored throughout the culture; sGAG in media followed an 
increasing pattern for micropellets initiated with chondrogenic media (CC, CO), whereas it was lower and 
steady for OC and OO micropellets (C). The quantity of sGAG retained in the tissue at the end of day 14 
(sGAG in digest) was the greatest for CC micropellets, however the quantity of total sGAG eluted into the 
media (sGAG in media) was substantially greater than the quantity retained within the micropellets (D). 
The total sGAG/DNA ratio, which is equal to (sGAG in digest + sGAG in media) / DNA, indicated that 
cultures initiated with chondrogenic media, CC and CO, were able to produce greater quantity of sGAG 
during the two week culture (E). Calcium/DNA ratio indicated that OO micropellets had the greatest 
calcium content (F) whereas alkaline phosphatase activity was significantly greater only in CO 
micropellets (G). Data were represented in graphs as mean + SD, n = 4. Scale bars = 200 µm. 
 
Histological features of micropellets  
Alcian blue staining indicated that all micropellets contained sGAG, whereas a 
lack of alizarin red staining indicated that there was no mineralization in CC or CO 
micropellets (Fig. 28). Positive alcian blue staining of OC and OO micropellets likely 
reflects the expression of sGAG molecules commonly found in the bone (chondroitin 
sulfate), and the fact that the biphasic tissue had been cultured in chondrogenic induction 
medium for 8 days [377,378].  As expected, alizarin red staining was the most intense 
for OO micropellets (Fig. 28). The presence of mineralized matrix in OO micropellets 
was further validated with OsteoImage fluorescent stain, which is specific to 
hydroxyapatite portion of bone matrix (Fig. 28). OC micropellets also stained positive 
with OsteoImage, marking very small and localized hydroxyapatite nucleation points 
(Fig. 28) indicating that when the media was changed to chondrogenic their osteogenic 
differentiation was brought to a halt. Collagen II was present in CC, CO and OC 
micropellets, which suggests that chondrogenic media exposure may be required for 
collagen II accumulation therefore OO micropellets were stained less intense for 
collagen II (Fig. 28). Collagen X was present in all micropellets, which indicates that 
MSC micropellets were hypertrophic regardless of media type (Fig. 28). Collagen I was 
present in CO, OC and OO micropellets, which suggests that osteogenic media exposure 
may be necessary to trigger collagen I accumulation therefore CC micropellets had less 
intense collagen I staining.  
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Figure 28. Histological assessment of micropellets. Alcian blue staining was similar for all conditions, 
whereas alizarin red staining indicated that calcification only occurred in OO micropellets. Accumulation 
of collagen II was less in OO micropellets, whereas collagen X was present in all cultures. Collagen I 
staining was less intense in CC micropellets, and OsteoImage, specific for hydroxyapatite, intensely 
stained OO micropellets but only marked hydroxyapatite nucleation points in OC micropellets. Scale bars 
= 200 µm. 
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Gene expression in micropellets 
The gene expression for chondrogenic, hypertrophic and osteogenic markers 
(aggrecan, SOX9, collagen II and X, versican, RUNX2, collagen I, osteocalcin, ALP and 
BMP2) were assessed.  Aggrecan, SOX9 and collagen II were similarly upregulated at 
the end of 8-day chondrogenesis, and the expression of those genes was further elevated 
following 14 days of chondrogenic differentiation (Fig. 29A, C, E).  These results 
indicate that chondrogenesis continues to progress over the full 14 days of chondrogenic 
culture.  SOX9, but not the chondrogenic matrix molecules (aggrecan or collagen II), 
was upregulated in CO and OC micropellets exposed to chondrogenic differentiation 
media for the first 8 days or in the last 6 days, respectively. This suggests that the short 
term exposure to chondrogenic media may upregulate SOX9 expression but it is 
insufficient to generate a stable chondrogenic phenotype with high collagen II 
expression. This is parallel to a previous report where the lack of correlation between 
SOX9 and collagen II expressions was shown in articular chondrocytes [379]. Collagen 
X expression was upregulated during the first 8-day chondrogenic culture, and then 
remained at a similar level in CO micropellets but increased in CC micropellets (Fig. 
29G). Versican expression was significantly downregulated in micropellets initiated 
with chondrogenic media, CC and CO when compared to day 0.  By contrast, versican 
expression was similar to day 0 at the end of culture for tissues initiated in osteogenic 
media, OC and OO (Fig. 29B).  The expression of collagen I was elevated with 
chondrogenic media supplementation (Fig. 29F).  This pattern suggests that exposure to 
chondrogenic media in the culture directs collagen I expression. The TGF β1 contained 
in the chondrogenic medium is known to upregulate collagen I expression specifically 
during development in various tissues including bone [380-382].  RUNX2 was 
upregulated in CO and OO conditions (Fig. 29D). Osteocalcin, ALP and BMP2 
expressions had a similar pattern, significantly higher in CO micropellets when 
compared to others (Fig. 29H, I, J). This finding is quite interesting, because despite the 
lack of calcification in CO tissues when compared to OO, ALP activity and also gene 
expression for osteogenic factors such as ALP, BMP2, osteocalcin and RUNX2 were 
significantly elevated in CO micropellets.  This parallels recent findings [62,383,384], 
which suggest that pre-conditioning MSC with chondrogenic medium prior to 
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osteogenic differentiation may enhance bone formation by better mimicking the natural 
process of endochondral ossification. 
 
Figure 29. Gene expression analysis of micropellets. The gene expression was assessed at three 
different time points; day 0, day 8 and day 14. The lines connecting time points were colored either blue 
for chondrogenic media or red for osteogenic media. For example a continuous blue line represents CC 
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and a continuous red line represents OO. Aggrecan, SOX9, collagen II and X were upregulated in CC 
micropellets (A, C, E, G), and versican was downregulated in chondrogenic media initiated cultures (B). 
RUNX2 was greatest in CO micropellets (D) whereas collagen I was upregulated in CC, CO, OC 
micropellets (F). Osteocalcin, alkaline phosphatase and BMP2 expressions were significantly greater in 
CO micropellets at day 14 (H, I, J). Data were represented in graphs as mean + SD, n = 4. 
 
Biphasic tissue assembly and histology 
Results from the first part of our study indicated that an 8-day differentiation 
cycle was insufficient for MSC micropellets to acquire chondrogenic and osteogenic 
phenotypes required for use in the assembly of a biphasic tissue.  Specifically, whilst the 
OC micropellets did not demonstrate chondrogenic features after the media was 
swapped, they also did not achieve a similar state of tissue mineralization as the OO 
micropellets.  This implies that the osteogenic phenotype was not acquired after only 8 
days in osteogenic induction medium.  Similarly, the CO micropellets showed 
chondrogenic features after the first 8 days of culture, however when the media was 
altered from chondrogenic to osteogenic they rapidly became pre-osteogenic, parallel to 
previous findings [62,383,384].  This result implies that the chondrogenic phenotype is 
particularly unstable, and that exposure of early stage chondrogenic micropellets to 
osteogenic medium would result in osteogenic phenotype.  Based on these observations, 
we reasoned that the separate differentiation cultures would need to be maintained for 14 
days before assembling the micropellets into a biphasic tissue cultured in a common 
medium formulation.   
Our own work in this area indicates that the first phase of discrete culture cannot 
be drawn out indefinitely, as the capacity of cartilage micropellets to amalgamate is 
reduced as the tissues mature and matrix accumulates [17]. Similarly, more efficient 
fusion of human MSC conventional pellets at earlier days of chondrogenic culture was 
shown [353]. Taking these observations together, we elected to initiate the chondrogenic 
and osteogenic micropellet differentiation cultures on the same day (day 0), assemble the 
chondrogenic micropellets into a cartilage-only tissue at day 8 in chondrogenic induction 
medium, then layer the osteogenic micropellets onto the cartilage tissue at day 14, and 
continue the biphasic tissue culture in chondrogenic induction medium for an additional 
week (Fig. 30).  
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The PDMS mold used for osteochondral tissue formation had a diameter of 4 
mm and a total of 12,000 chondrogenic micropellets filled the mold to a height of 2 mm, 
and the same number of smaller osteogenic micropellets filled it an additional 0.5 mm 
high (Fig. 30). As the biphasic tissue matured the total diameter decreased slightly to ~3 
mm, although the chondrogenic layer remained ~2 mm deep, the osteogenic layer shrunk 
slightly to ~0.3 mm deep. The shrinkage in tissue size and deviation from a perfect 
cylinder in tissue morphology (Fig. 30) may be caused by MSC aggregate “compaction” 
phenomenon [385].  
The cross sectional area of the osteochondral tissue was assessed for histological 
features of bone and cartilage.  Alcian blue stained the tissue throughout (Fig. 31A, B).  
This staining highlighted individual micropellets, although discrete micropellets were 
much more visible in the cartilage portion of the tissue (Fig. 31A, B).  By contrast, the 
alizarin red exclusively stained the bony side of the tissue however staining revealed that 
mineralization was not always continuous (Fig. 31C, D).  In higher magnification 
images it is clear that individual cells are bridging the two tissue layers together (Fig. 
31B, D). Unexpectedly, the collagen II staining was more intense in the bony layer 
relative to the chondral layer (Fig. 31E).  This differs from the first part of our study 
where the micropellets were cultured for 14 days in discreet microwells, and exhibited 
minimal collagen II expression in OC medium combination (Fig. 29).  This difference 
suggests that the co-culture of the osteogenic and chondrogenic tissues drives this 
outcome.  One possible explanation is that chondrogenically induced cells from the 
cartilage micropellets migrated onto the osteogenic induced micropellets, forming a 
layer of cells that contributed to the observed intense collagen II staining.  An alternative 
possibility is that paracrine signals from the adjacent cartilage tissues modified the 
behavior of the initially osteogenically induced cells, resulting in their increased 
expression of collagen II.  There is precedent for a change in cell behavior in response to 
the fusion of pellets and for the signaling between adjacent fused pellets [386].  For 
example, Lehmann et al provide high resolution images demonstrating that the cells that 
form the layer that fuses pellets together contribute to a unique tissue layer with 
histological properties that differ from the pellets that were fused to generate the 
amalgamated tissue [386].  Further experiments will be required to elucidate the 
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mechanism that drives the enhanced collagen II staining observed in our osteogenic 
tissue layer.   
Collagen X (Fig. 31F) and I (Fig. 31G) stainings were present in both layers, but 
more intense in the bony layer (Fig. 31) revealing a lower collagen content in the 
chondral layer, and this was consistent with our expectations for bone-like tissue 
[62,383,384].  The hydroxyapatite-specific OsteoImage exclusively stained the bony 
layer suggesting there was not an accumulation of undesirable mineralization within the 
chondral layer (Fig. 31H). Our work builds on previous work demonstrating that discreet 
cartilage microtissues could be used to Whilst a previous publication demonstrated that 
cartilage macropellets could be fused together to form a cartilage-like core with a bone-
like exterior [387]. Specifically, our work demonstrates that it is possible to assemble 
cartilage-like micropellets and bone like-micropellets to make a structured bi-phasic 
tissue.  We believe that this capacity to assemble a complex layered tissue will 
contribute to efforts to repair or regenerate articular cartilage. 
 
Figure 30. Biphasic tissue construction with micropellets. The monolayer expanded MSC were used to 
form micropellets and cultured in chondrogenic and osteogenic media separately. The chondrogenic 
micropellets were assembled on day 8 then the osteogenic micropellets were layered on top at day 14 
using a custom-made PDMS mold. The biphasic tissue was cultured for another week then sectioned for 
histological analysis. 
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Figure 31. Histological assessment of osteochondral-like tissue. The upper section of the tissue is bony 
layer and the lower section is chondral layer. Alcian blue stained both chondral and bony layers (A, B), 
whereas alizarin red specifically stained the calcified region in the bony layer (C, D). At higher 
magnification, the cells migrating out of the individual micropellets and filling the void space between 
micropellets is visible (B, D). Collagen II (E), X (F) and I (G) were all accumulated more on bony side 
while being present in both sides whereas OsteoImage (H) stained exclusively bony side indicating lack of 
calcification on chondral layer. Scale bars = 200 µm. 
 
5. Conclusion 
Herein we described methods for the manufacture of osteogenic and 
chondrogenic micropellets as building blocks from bone marrow-derived MSC. Using 
the micropellet approach, we first assessed the impact of various medium conditions on 
osteogenic and chondrogenic differentiation of MSC. Then, a scaffold-free 
osteochondral tissue was assembled via layering osteogenic and chondrogenic 
micropellets in a tailored culture device.  The micropellets fused into a continuous tissue 
retaining the two distinct original layers.  Previously, the generation of an osteochondral 
tissue interface using collagen microencapsulated rabbit MSC spheroids was described 
[335]. To our knowledge, this is the first scaffold-free biphasic tissue built with a single 
cell type and our results are the first to demonstrate that a continuous bi-phasic structure 
can be generated without need for a hydrogel or polymer support structure. In future 
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studies, the use of micropellets should enable the precise layering of different 
micropellets and the more accurate replication of the complex zonal structure found in 
native cartilage. 
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Figure 32. Flow cytometry characterization of MSC. The MSC from all three donors used in these 




                            
Figure 33. Fabrication of conical mold used to assemble the biphasic tissue. The tip of a 10 mL 
syringe was cut and glued to the middle of a single well in a 6-well plate and the space between the 
syringe and the well was filled with PDMS and cured. Then the syringe tip was removed and the extra 





Figure 34. Negative controls for collagen staining in biphasic tissue. Negative control (no primary 
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Gene	  (Amplicon	  size	  in	  basepair)	   Primers	  
	   	  
Cyclophilin	  A	  (164)	   Forward	  	  CTCGAATAAGTTTGACTTGTGTT	  
Reverse	  	  	  CTAGGCATGGGAGGGAACA	  
GAPDH	  (119)	   Forward	  	  ATGGGGAAGGTGAAGGTCG	  
Reverse	  	  	  TAAAAGCAGCCCTGGTGACC	  
SOX9	  (77)	   Forward	  	  TTCCGCGACGTGGACAT	  
Reverse	  	  	  TCAAACTCGTTGACATCGAAGGT	  
Aggrecan	  (85)	   Forward	  	  TCGAGGACAGCGAGGCC	  
Reverse	  	  	  TCGAGGGTGTAGCGTGTAGAGA	  
Collagen	  II,	  COL2A1	  (79)	   Forward	  	  GGCAATAGCAGGTTCACTGACA	  
Reverse	  	  	  CGATAACAGTCTTGCCCCACTT	  
Collagen	  I,	  COL1A1	  (83)	   Forward	  	  CAGCCGCTTCACCTACAGC	  
Reverse	  	  	  TTTTGTATTCAATCACTGTCTTGCC	  
Versican	  (98)	   Forward	  	  TGGAATGATGTTCCCTGCAA	  
Reverse	  	  	  AAGGTCTTGGCATTTTCTACAAAG	  
Collagen	  X,	  COL10A1	  (70)	   Forward	  	  CAAGGCACCATCTCCAGGAA	  
Reverse	  	  	  AAAGGGTATTTGTGGCAGCATATT	  
Runx2	  (113)	   Forward	  	  GGAGTGGACGAGGCAAGAGTTT	  
Reverse	  	  	  AGCTTCTGTCTGTGCCTTCTGG	  
Osteocalcin	  (70)	   Forward	  	  GAAGCCCAGCGGTGCA	  
Reverse	  	  	  CACTACCTCGCTGCCCTCC	  
ALP	  (89)	   Forward	  	  CGTGGCTAAGAATGTCATCATGTT	  
	   Reverse	  	  	  TGGTGGAGCTGACCCTTGA	  
BMP2	  (72)	   Forward	  	  AAAACGTCAAGCCAAACACAAA	  
Reverse	  	  	  GTCCACGTACAAAGGGTCTCTCT	  
	    
Table 6. Primers used for gene expression analysis. 
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DNA! CC CO OC OO GAG/DNA CC CO OC OO
Donor!1 Mean 2.05027845 1.53101176 1.60205625 0.78183983 Donor!1 Mean 20.6563641 18.7179773 9.12596912 6.08157804
SD 0.04804959 0.10806467 0.13163035 0.13845745 SD 2.61542757 2.27685284 1.23568696 2.86672799
Donor!2 Mean 0.95427188 0.8400578 0.49003736 0.28210526 Donor!2 Mean 12.7202854 8.18542708 3.24924109 4.24861085
SD 0.0306942 0.08899185 0.05899807 0.02509655 SD 1.61921278 1.9768755 0.69832796 1.97352467
Donor!3 Mean 1.1430408 1.05114765 0.7589199 0.64725195 Donor!3 Mean 17.8826921 16.572193 11.7129252 11.0609929
SD 0.08491509 0.16789807 0.13159206 0.11291748 SD 0.77166998 2.51333078 3.11268637 3.92149979
Calcium/DNA CC CO OC OO ALP/DNA CC CO OC OO
Donor!1 Mean 1.50341292 1.62607294 7.35780659 37.3496861 Donor!1 Mean 0.34525251 0.97550356 0.15902119 0.39583005
SD 0.07353858 0.32040183 2.84599514 2.38748149 SD 0.05676371 0.24869783 0.02425738 0.08556182
Donor!2 Mean 1.98551634 2.2819932 4.53798928 7.01688636 Donor!2 Mean 0.7291289 2.83100532 1.65706733 2.22868417
SD 0.25351189 0.32326246 0.60788467 1.08531925 SD 0.26870077 0.29257218 0.46973419 1.10755395
Donor!3 Mean 2.02033467 2.51282267 7.57394161 41.8761768 Donor!3 Mean 0.09004894 0.10140167 0.14667912 0.25388274
SD 0.21036379 0.66713546 2.77745867 9.70076415 SD 0.00655811 0.01724498 0.02819844 0.01888155
Gene1Expression
Donor!1!7!Mean Aggrecan Versican Sox!9 Runx2 Col!I Col!II Col!X Osteocalcin ALP BMP2
CC 0.21955191 0.14585652 0.04585609 0.00837269 20.8005307 8.87748716 1.12968761 0.00172252 0.01246457 0.01707908
CO 0.01389272 0.1533135 0.01699134 0.01791073 27.5251347 0.35325963 0.22551608 0.01423678 0.03454933 0.1850758
OC 0.01090902 0.23711417 0.01698042 0.00882115 22.4280764 0.00861646 0.02539592 0.00186898 0.00056395 0.02004281
OO 0.00172744 0.21539093 0.00352271 0.01237596 3.32736075 0.00040256 0.00049373 0.00222714 0.0184183 0.01842759
Donor!1!7!SD Aggrecan Versican Sox!9 Runx2 Col!I Col!II Col!X Osteocalcin ALP BMP2
CC 0.02409777 0.01561786 0.00573684 0.00231887 3.28821875 1.06646603 0.16606624 0.00013968 0.00133337 0.00117961
CO 0.00467288 0.03783985 0.00495818 0.00178826 5.95518858 0.07932193 0.03685038 0.00409469 0.00249123 0.04229125
OC 0.00309143 0.01982998 0.00116547 0.00055289 1.21923081 0.00257982 0.00337702 0.00029038 0.00024561 0.0022704
OO 0.00057274 0.02796812 0.00020328 0.00209283 0.33458186 0.00011185 0.0002152 0.00051204 0.00227859 0.00281068
Donor!2!7!Mean Aggrecan Versican Sox!9 Runx2 Col!I Col!II Col!X Osteocalcin
CC 0.55481465 0.27347953 0.36787016 0.018063 114.376983 0.22957694 5.17348278 0.02114906
CO 0.01789334 0.10733799 0.19369808 0.01974532 9.8557614 0.0035489 0.36990735 0.03257208
OC 0.05416716 0.12972699 0.09293866 0.00807496 31.5223014 0.00132997 0.13917705 0.00284204
OO 0.00770769 0.04900125 0.21256182 0.02875966 3.58783203 0 0.00496683 0.06787841
Donor!2!7!SD Aggrecan Versican Sox!9 Runx2 Col!I Col!II Col!X Osteocalcin
CC 0.03771411 0.06170384 0.05158564 0.01058747 16.6371661 0.06069561 1.17127576 0.01001112
CO 0.01598521 0.03006616 0.05217068 0.02358799 1.2070421 0.0035489 0.06175311 0.00719858
OC 0.00709593 0.02880779 0.01202665 0.00282837 12.8749445 0.00040035 0.0156233 0.00354298
OO 0.00313174 0.09248764 0.04362818 0.00676642 1.05113912 0 0.00496683 0.01650715
Donor!3!7!Mean Aggrecan Versican Sox!9 Runx2 Col!I Col!II Col!X Osteocalcin
CC 0.05121239 0.21758045 0.01860672 0.01967495 30.1050171 0.13256745 0.26722254 0.00173912
CO 0.00337951 0.14556627 0.00849153 0.03011854 13.4566279 0.00048295 0.0308862 0.00237688
OC 0.0021321 0.22841739 0.01631144 0.01444447 22.332842 0.00018715 0.01008911 0.00154453
OO 0.00090629 0.08649819 0.00373291 0.02187094 1.72940737 4.6005E705 0.0002968 0.00204155
Donor!3!7!SD Aggrecan Versican Sox!9 Runx2 Col!I Col!II Col!X Osteocalcin
CC 0.00785923 0.02861342 0.00507095 0.00365585 2.77040255 0.03847362 0.05582532 0.00051511
CO 0.00117818 0.01411995 0.0019039 0.00316339 2.09405668 0.00032859 0.00253737 0.00070135
OC 0.00062988 0.04177663 0.00345912 0.00321145 2.57968835 0.00012091 0.0036955 0.00050897
OO 0.00069054 0.00281783 0.00107346 0.00598759 0.56003631 4.4756E705 0.00026189 0.00124196  
 
Table 7. Data obtained from three different donors. 
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Articular cartilage injuries are troublesome for both patients and orthopedic 
surgeons. If the injuries are not treated appropriately, the patients have the risk of living 
with constant joint pain or even disability. Surgeons have multiple options to treat the 
injuries, yet all treatments have substantial downsides and varying clinical outcomes 
(see Chapter 2). Overall, treatment effectiveness may depend on the surgeon’s decision 
making [388] and talent [389], which is not ideal and likely contributes to the varying 
success rates in clinics.  
The primary aim of cartilage tissue engineering studies is to improve the 
treatment procedures. During this process, a great amount of information about the 
biology of the cartilage tissue is also generated. Similarly, in this Thesis different ways 
of using micropellets in cartilage tissue engineering or cell-based therapies were 
investigated (Fig. 35) and at the same time, the effect of micropellet culture on different 
cells, under different culture conditions was reported.  
The cell-based treatment procedures such as ACI and MACI are facilitated with 
the monolayer expanded chondrocytes isolated from a biopsy of healthy cartilage. 
However, it is observed that once chondrocytes are stripped of their natural, matrix 
intense microenvironment and expanded on tissue culture plastic they obtain fibroblast-
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like characteristics and critically, their ability to generate cartilage tissue is significantly 
reduced with a process referred as “dedifferentiation” [116,390,391]. Therefore, some 
techniques are developed in order to restore the chondrogenic phenotype of 
chondrocytes referred as “redifferentiation” [288,392-394]. The pellet culture is one of 
the widely used redifferentiation methods because it helps the chondrocytes to re-obtain 
the 3D environment similar to native cartilage. However, the radial heterogeneity of the 
most pellets caused by the diffusion gradients is a concern since the chondrogenic 
properties are changing throughout the pellet. The use of micropellets was tested in 
order to overcome this heterogeneity problem. In Chapter 3, it was reported that 
redifferentiation of expanded articular chondrocytes was enhanced in micropellets when 
coupled with hypoxic microenvironment. These redifferentiated micropellets can be 
directly delivered into a partial-thickness defect site in order to mediate tissue 
regeneration (Fig. 35). Alternatively, generation of a greater size cartilaginous tissue 
with the assembly of chondrocyte micropellets was demonstrated, which can be useful in 
ex vivo cartilage tissue engineering applications. 
The few number of chondrocytes isolated from a small biopsy limits chondrocyte 
use in cell-based therapies, specifically in the case of greater size injuries. As an 
alternative, bone marrow MSC is preferred since these cells are easier to harvest, can 
proliferate and have the potential to differentiate into chondrogenic lineage. Our group 
has previously shown that MSC chondrogenesis is enhanced in micropellets when 
compared to conventional pellets under hypoxic atmosphere [18]. Building on this, in 
Chapter 4, the incorporation of donor cartilage particles, referred as cartilage dust, into 
MSC micropellets was investigated. The aim of this approach was to bulk up the 
micropellet size, and increase the defect filling capacity of micropellets. The composite 
micropellets had greater size and the addition of cartilage dust enriched the collagen II 
content of the generated tissue. This study suggests that the composite micropellets can 
be used as a defect-filling agent in greater size cartilage injuries (Fig. 35). 
In the case of osteochondral defects, it may be logical to exploit the nature of 
injury in order to facilitate better integration of the engineered construct to the defect 
site. In osteochondral graft transplantations, it is observed that the lateral integration 
occurs rapidly whereas the vertical integration mostly fails [395]. This is why in 
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mosaicplasty, even if the defect is not originally osteochondral, sometimes extra bone 
tissue is removed from subchondral region to facilitate better graft integration. Based on 
that, engineering an interface tissue between bone and cartilage is attempted in order to 
generate artificial osteochondral grafts to be implanted, eliminating the donor site 
morbidity associated with mosaicplasty. The most common approach is to use a biphasic 
scaffolds with properties mimicking the native bone and cartilage and the bone marrow 
MSC are preferred as a single cell source to engineer both layers. In Chapter 5, 
construction of a scaffold-free biphasic tissue was described where MSC derived 
chondrogenic and osteogenic micropellets were used as building blocks. To be able to 
build a biphasic tissue and culture it in a single media formulation, first the phenotypic 
change of MSC micropellets when cultured in chondrogenic or osteogenic media was 
tested. In this part of the study, chondrogenic and osteogenic characteristics of 
micropellets were assessed after the media were swapped from osteogenic to 
chondrogenic or chondrogenic to osteogenic. The exposure of chondrogenic 
micropellets to osteogenic medium significantly increased their osteogenic properties 
whereas the exposure of osteogenic micropellets to chondrogenic medium interrupted 
their osteogenic differentiation. Therefore, MSC micropellets were first separately 
differentiated into chondrogenic and osteogenic lineages, and then assembled to generate 
a ~2 mm thick osteochondral-like tissue. This is the first scaffold-free biphasic tissue 
and this method in particular embodies the idea of utilizing micropellets as building 
blocks in order to engineer composite tissue grafts (Fig. 35).  
All studies reported in this Thesis were performed in vitro. In order to assess the 
interaction between individual micropellets, they were assembled at varying time points. 
The next logical step is to test the benefits of this technique in vivo to be able to 
recommend micropellet use in clinical applications (Future perspectives section). 
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Figure 35. Utilizing micropellets as building blocks in cartilage tissue engineering. In Chapter 3, 
generation and assembly of chondrocyte micropellets was reported, which may lead to an efficient 
treatment method for partial-thickness defects. In Chapter 4, generation and assembly of bigger 
micropellets with addition of cartilage dust was reported, which may lead to an efficient defect filling 
strategy for full-thickness defects. In Chapter 5, using separately differentiated chondrogenic and 
osteogenic micropellets, a scaffold-free biphasic tissue was built, which may have a merit in osteochondral 
defect treatments. 
 
2. General discussion 
The primary aim of this project was to characterize different types of 
micropellets and explore their use in cartilage tissue engineering. Some significant 
findings were reported in three independent but theme-related studies. These studies 
revealed many advantages of micropellet use and also some limitations associated with 
it.  
The initial motivation for using micropellets was solely geometrical; by 
increasing the surface area to volume ratio, mass transport problems were minimized. 
Native human cartilage is 1-5 mm thick and devoid of blood vessels [28]. Glucose, 
oxygen and other factors are transported to chondrocytes via diffusion of the synovial 
fluid into the cartilage tissue. This tissue structure gives rise to a vertically aligned 
diffusion gradient pattern in the native cartilage. Ideally, once the engineered tissue is 
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implanted, it would develop such zonal diffusion gradients, which might help the tissue 
to acquire a desired zonal organization. However, the diffusion gradients observed in 
macropellets are radial because of the spherical tissue geometry. This radial diffusion 
pattern is dissimilar to native cartilage. Formation of such radial diffusion gradients was 
mitigated in each micropellet that had 100-200 µm diameter, therefore chondrogenic 
factors, metabolites and the oxygen concentrations were more homogenous and 
predictable throughout each individual micropellet. However, the increase in total 
surface area was also associated with an important drawback, elution of sGAG 
molecules to the culture medium. Sulfated GAG loss during in vitro culture is a common 
problem in chondrogenesis studies [330] and it is exacerbated in micropellet platform 
where the total surface area is increased [18]. One of the possible explanations for sGAG 
loss to the medium may be the delay in accumulation of other critical matrix 
components such as aggrecan and collagen II [330]. Elution of sGAG molecules can 
also be facilitated by a cross-linking defect since sGAG molecules are attached to 
aggrecan protein and aggrecan proteins are linked to hyaluronan via linking protein (Fig. 
2). Any defect interfering with these interactions may also contribute to sGAG elution. 
Additionally, formation of a cross-linked collagen II network is just as important 
because the components mentioned above are not cross-linked to collagen II molecules 
or attached to chondrocytes in native cartilage tissue. Therefore, their retention is solely 
based on the “entrapment” by the collagen network and the failure of establishing this 
structure can also contribute to the sGAG elution. It is now known that increasing 
collagen II content of the generated tissue is more challenging than upregulating sGAG 
production. Nevertheless, in Chapter 4 it was shown that after the assembly of 
micropellets the quantity of sGAG detected in the culture medium was rapidly reduced 
(Fig. 25). This indicates that a decrease in surface area may help retaining the produced 
sGAG molecules within the generated cartilage tissue [354].  
All three studies contained two parts: micropellet characterization and 
micropellet assembly. Micropellets were only assembled in an organized fashion in 
Chapter 5 where an osteochondral-like tissue with two distinct layers was generated. In 
Chapters 3 and 4, the assembly step was performed in order to investigate the 
amalgamation efficiency of the individual micropellets. Micropellets were able to fuse at 
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all time points and single cells liberated from micropellets were able to fill the void 
space between individual micropellets. However, tissue integration was not always 
optimal since the assembled tissues were cultured for relatively short time periods (1-2 
weeks). Once the micropellets were assembled into macroscopic tissues, diffusion 
gradient formation was mitigated because the increase in individual micropellet volume 
decreased the overall cell density of the generated tissue.   
In all three studies, collagen II gene expression was efficiently upregulated in 
micropellets. However, upregulation of collagen II expression was always coupled with 
upregulation of unwanted hypertrophic marker collagen X expression. According to the 
developmental process, the chondrogenic marker collagen II expression must be 
observed before the hypertrophic marker collagen X [157,396] since hypertrophy takes 
place after chondrogenesis during endochondral ossification (Fig. 3, 4). However, in 
some studies it is demonstrated that collagen X is expressed prior to collagen II [396], 
which seems contrary to the developmental process. Similarly, in Chapter 4 in 
micropellets without cartilage dust, collagen X was already being expressed higher than 
collagen II on day 7 (Fig. 23). This uncoupling in the order of specific collagen 
expressions observed during in vitro chondrogenesis may be one of the consequences of 
monolayer expansion that takes place prior to differentiation. In a chicken development 
model, it is demonstrated that during endochondral ossification there is a timeframe 
where chondrocytes proliferate and generate the cartilage skeleton template but do not 
express collagen X [50].  The hypertrophy is later initiated in the middle of the tissue 
first with Ihh expression followed by collagen X expression [50]. Replicating this pure 
chondrogenic phenotype without collagen X expression has proven to be challenging in 
most MSC chondrogenesis studies. Perhaps the standard chondrogenic differentiation 
medium needs improvements such as addition of the hypertrophy inhibitor, PTHrP, 
which is suggested to alleviate collagen X expression during MSC chondrogenesis 
[397]. The reason for PTHrP is not being a component of the standard chondrogenic 
medium is that its role as the hypertrophy inhibitor is not well established yet. Therefore, 
including PTHrP in chondrogenic media is still considered as experimental rather than 
standard.  
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In addition to collagen X, the high expression of collagen I has been a major 
problem in chondrogenesis studies. Both chondrocytes and MSC seem to increase 
collagen I expression specifically during the monolayer expansion process. Collagen I is 
abundant in fibrocartilage and bone, however it is only present in insignificant amounts 
in hyaline cartilage. Therefore, the success of chondrogenesis is not only related to 
upregulation of collagen II expression but also to effective downregulation of collagen I 
expression. One possible way to overcome this problem would be optimization of cell 
expansion conditions, such as continuous provision of hypoxic atmosphere (Oxygen 
concentration section in Chapter 2). Additionally, some studies are focusing on 
developing different surface modification techniques in order to maximize chondrogenic 
differentiation of both chondrocytes and MSC [398,399]. In this project, the collagen II 
expression upregulation in micropellets was associated with the elevation of collagen I 
expression. This undesired increase in collagen I expression may also be caused by 
TGF-β 1, which is the main chondrogenic factor in the differentiation medium since this 
factor is also associated with collagen I expression stimulation in various tissues during 
development [381,382]. The chondrogenic media repeatedly used in chondrogenesis 
studies is perhaps optimized for the standard pellet culture, whereas the overall geometry 
and the total surface area are substantially changed in the micropellet platform. 
Therefore, customizing the chondrogenic differentiation media components and their 
concentrations according to the specific needs of the micropellets may have merit in 
order to simultaneously elevate the chondrogenic gene expression and repress the 
unwanted collagen X and I expressions effectively.  
A recent study reported identification and specification of the mouse skeletal 
stem cells [400]. In this study, first a group of cells called postnatal skeletal stem cells 
were identified and then their specification was traced into cartilage, bone and stromal 
lineages. The researchers demonstrated that these skeletal stem cells can be expanded in 
the presence of BMP-2 and their osteogenic lineage commitment can be blocked via 
inhibition of VEGF signalling. Once the osteogenic lineage is blocked, these cells are 
able to form cartilage-like structures [400]. While being innovative, this study still must 
be validated with human cells. Until then, the closest adult human counterpart of these 
cells, bone marrow MSC, are extensively used in cartilage repair studies. In addition to 
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their role in contributing to the haematopoietic stem cell niche, MSC take place in long 
bone fracture healing process. During this process MSC are able to form a hyaline 
cartilage template in the fracture site, which is then replaced by newly forming bone 
tissue in a similar fashion observed during developmental endochondral ossification. To 
be able to routinely use bone marrow MSC in cartilage repair, their chondrogenic 
differentiation must be optimized and at the same time their hypertrophic features must 
be supressed [401]. 
The culture duration of the assembled tissues was relatively shorter (1-2 weeks) 
in all studies. Longer culture duration (i.e. few months) is not unusual in cartilage 
regeneration studies; however, the longer ex vivo culture duration would substantially 
increase the cost of a potential clinical application. Additionally, the tissue integration 
and maturation process may benefit from the early implantation of the micropellets or 
the generated tissues with provision of the true biochemical and biomechanical signals 
in the native cartilage microenvironment. As a result of the shorter culture period, at 
some cases assembled micropellets yielded an immature tissue structure and the 
micropellet impressions were still visible in the assembled tissues. Specifically, 
assembly of the osteochondral-like tissue in Chapter 5 was a worthy proof of concept 
demonstrating how to utilize micropellets as building blocks, but the tissue structure was 
suboptimal because of the deficiency in the collagen content of the chondral layer (Fig. 
31). Thus, the generated scaffold-free tissues were not mechanically tested. It is possible 
that the large tissue geometry and high cell density may have contributed to the 
suboptimal tissue structure observed in the chondral layer. In future studies, mechanical 
testing may be applied to assembled tissues that are cultured longer preferably under 
dynamic conditions or tissues that are matured in vivo.  
In general, collagen I expression was 100 times higher, collagen II expression 
was 10 times lower [300] and sGAG/DNA ratio was 200 times lower [402] in 
chondrogenic MSC micropellets when compared to native hyaline cartilage. The 
difference in relative ECM composition suggests that the MSC-derived cartilage tissue is 
deficient in cartilage-like matrix and maybe acquiring a bone-like matrix profile.  
Similar observations are often reported, and this reflects the current inability to 
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effectively differentiate MSC to enable the formation of hyaline cartilage and the 
mitigation of hypertrophy [401].  
In Chapter 4, cartilage dust use and micropellet strategies were combined. The 
most common approach for direct incorporation of ECM components to the generated 
tissue has been single cell encapsulation in various types of hydrogels. However, there 
are two major drawbacks associated with that strategy; (1) lack of cell-cell interactions 
in single cell encapsulation, (2) lack of mechanical strength in a hydrogel. Micropellet 
use provided cell-cell interactions and the use of microscopic cartilage pieces increased 
the ECM content of the generated tissue significantly. Therefore, it is highly possible 
that a tissue generated with cartilage dust incorporated micropellets would be more 
similar to native cartilage than a hydrogel with single cell encapsulation. In this cartilage 
dust study, it was observed that a significant quantity of residual DNA was retained 
within cartilage dust (CD) particles. It is known that unmethylated CpG motifs in 
bacterial DNA can stimulate inflammatory response and induce arthritis [403], however 
it is less likely that vertebrate DNA would cause a similar response since vertebrate 
DNA contains less frequent CpG motifs, which are mostly methylated [404]. However, 
elimination of all nucleic acid content of the material is required to minimize the disease 
transmission risks, therefore removal of all nucleic acids is a critical step in a clinical 
setting, where xenogeneic or allogeneic material is transplanted. A large number of 
researchers are focusing on optimizing this decellularization process [273,274]. In the 
case of cartilage dust, removal of the residual DNA is even easier since the cartilage 
tissue is already crushed into microscopic pieces. However, decellularization was 
purposely avoided in this study because of the previous observations regarding the rapid 
loss of sGAG molecules in such processes. The sGAG and collagen II content of the CD 
was preserved because the initial aim of the study was to validate the chondroinductive 
effect of such matrix molecules on MSC micropellet phenotype. According to previous 
reports the presence of sGAG possibly enhances chondrogenesis [257,350]. However, in 
micropellet platform this effect could not be reproduced because the upregulation of 
chondrogenic gene expression was impaired in micropellets in the presence of cartilage 
dust (Fig. 23). This may potentially be caused by the presence of CD hindering the 
initial cell-cell interactions within the micropellet.  This is parallel to previous findings 
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where superior chondrocyte redifferentiation with a significant upregulation of collagen 
II expression was observed in pellet culture but not in the alginate-based systems [111]. 
Similarly, these results may emphasize the importance of pellet culture, which allows 
cell-cell interactions and increases collagen II gene expression. Hence, the use of CD 
was promoted as a defect filling agent rather than a chondroinductive reagent in this 
study. 
Specifically in Chapter 5, a significant upregulation of osteogenic gene 
expression was observed in chondrogenic-osteogenic (CO) cultured micropellets (Fig. 
29). Similar effects were observed in recent studies where pre-conditioning or priming 
the MSC with chondrogenic medium was shown to enhance a subsequent osteogenic 
differentiation [62,383,384]. It was even suggested that chondrogenic priming could be 
exploited to accelerate tissue mineralization and bone formation after subcutaneous 
implantation [62,384]. This interesting finding may have the capacity to transform the 
traditional osteogenic differentiation methods in addition to raising questions regarding 
the possibility of optimizing MSC chondrogenesis. 
Using micropellets as building blocks may provide numerous advantages, 
however at present this relatively recent method also has some limitations. The future 
work addressing these limitations and testing micropellet use in vivo may provide insight 
about the potential exploitation of micropellets in cell-based clinical applications. 
3. Future perspectives 
3.1. In vivo experiments and animal defect models 
Before any novel approach is trialed in clinics, in vivo experimentation is 
routinely conducted in order to assure the safety of the procedure. In tissue engineering 
studies, the first step is generally the subcutaneous (SC) implantation of the generated 
tissue graft in immunodeficient mouse models. This method is widely used in order to 
assess the in vivo response to an in vitro generated tissue or biomaterial since the in vitro 
culture cannot always accurately mimic the in vivo conditions. As a result in SC 
implantation for most tissue types such as bone, the vascularization of the implanted 
tissue is a positive outcome since the new blood vessel formation throughout the newly 
generated tissue will be essential when the tissue is implanted into the defect site. 
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Controversially, the prevention of vascularization in SC implantation is a success for 
cartilaginous grafts since the native tissue does not bear any blood vessels. This 
technique is commonly used as an indicator of MSC chondrogenesis since in most cases 
MSC derived cartilaginous tissue is vascularized and mineralized whereas the native 
cartilage tissue or a tissue graft generated by chondrocytes have an intrinsic resistance to 
vascularization [397,405]. Therefore, it may be worthwhile to test the stability of 
chondrogenic phenotype in MSC micropellets via SC implantation method before 
moving to animal defect models.  
A second, and perhaps a more reliable, approach is to test a newly developed 
technique in an animal defect model. Articular cartilage defect model of rabbits (lapine 
model) is commonly used [406-410]. The Autologous Chondrocyte Implantation (ACI) 
was first tested in a rabbit defect model [411] before being translated into clinics. 
However, in most studies conducted on small animal models, the control groups also 
demonstrate self-healing to some extent, raising questions about the credibility of small 
animal models. The reason for self-healing effect in small animals is thought to be the 
relatively smaller dimensions of the tissue specifically the thickness, which is in the 
range of few cell layers whereas the human cartilage has a thickness of few millimeters 
(Fig. 36) [412]. The small animal defect models are cost effective and more practical but 
they are dimensionally inaccurate. This is why large animal defect models are preferred, 
when possible, for regeneration studies of orthopedic tissues such as bone and cartilage. 
Most commonly used large animal models are sheep (ovine model) [413-416], goat 
(caprine model) [417-419], pig (porcine model) [420-422] and horse (equine model) 
[203,423]. Even though the cartilage thickness for most of these animals does not match 
the human counterpart (Fig. 36), the in vivo results obtained via large animal models are 
thought to be more reliable. In conclusion, despite cost intensiveness and requirement of 
access to specialized animal facilities, large animal defect models are the critical 
intermediate testing step between the in vitro engineered construct and the clinical trials 
for orthopedic tissues. Therefore, it is necessary to test the use of chondrocyte 
micropellets (Chapter 3) and MSC micropellets with cartilage dust (Chapter 4) and the 
osteochondral-like tissue built with micropellets (Chapter 5) preferably in a large animal 
model in order to predict their clinical potential and applicability in the future. 
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Figure 36. Articular cartilage thickness comparison. Histology section of human (A), rabbit (B) and 
goat (C) articular cartilage are shown. Image is courtesy of WKH, taken from [424], see App. G for 
permission. 
 
3.2. Mass production of micropellets  
In order to utilize them at a clinical scale, micropellets need to be generated in 
large numbers. In a rough estimation, to be able to fill a small size, 1 cm3, cartilage 
defect ~418,000 micropellets will be required according to hexagonal close packing 
model (assuming that the micropellets are perfectly spherical and have a diameter of 150 
µm). With the existing platform, 36,000 micropellets can be generated in a single 6-well 
plate (6000 each well), however the static culture and manual handling of micropellets 
in multiwell plates is a labor-intensive and care-demanding technique. Therefore, mass 
production of micropellets can be achieved via closed bioreactor systems, which can 
provide dynamic culture conditions. Powers et al. introduced a similar concept in 2001 
where they described a closed perfusion bioreactor design with a microwell pattern 
inside, which provides dynamic culture conditions to liver cells in micropellets 
[425,426]. A similar, bigger scale, sterile and disposable bioreactor platform can be 
designed in order to generate large numbers of micropellets for clinical applications. 
Once the perfusion rate and media components are optimized, such platform will allow 
cell seeding, micropellet formation, differentiation and culture to be performed all 
together in an automated fashion reducing the handling and the cost of the micropellet 
mass production process.  
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3.3. Complex tissue engineering with micropellets 
Unlike cartilage tissue engineering, ex vivo generation of complex tissues such as 
kidney or lung requires multiple cell types, different tissue zones with different 
properties and critically blood vessels in order to facilitate cell and tissue survival ex 
vivo and in vivo. The ex vivo generation of small diameter vascular graft to be used in 
bypass surgeries is a hot topic itself. Forgacs et al. introduced a novel method where 
they form separate micropellets of smooth muscle cells and fibroblasts then combine 
them using a rapid prototyping bioprinter to generate a scaffold-free small diameter 
vascular graft [427]. They also suggest it may be possible to engineer even more 
complex grafts using micropellets as building blocks (Fig. 37) [428].   Similarly, I think 
the micropellets enable engineering tissue grafts in higher resolution provided by their 
micron-scale, controllable size. In the future, using zonal chondrocyte micropellets, it 
may be possible to engineer cartilage constructs with biomimetic zones (Chapter 3, Fig. 
18B). 
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Figure 37. Complex tissue engineering using micropellets. An illustration demonstrating how to use 
micropellets to engineer complex tissues. Image is courtesy of Elsevier, taken from [428], see App. G for 
permission. 
4. Closing remarks  
“Imagine that one day a patient will go to a human ‘body shop’ for a 
prescription for a lost leg, a failing liver, or a dysfunctional heart. In addition to the 
physiological, medical, and genetic information of the patient, the doctor will also 
collect three-dimensional images of the patient’s remaining leg (in the case of the lost-
leg patient) with detailed anatomical structures (bone, cartilage, tendons, ligaments, 
blood vessels, muscles, nerves, skin, and so forth) and the external shape. The doctor 
may collect the patient’s saliva or other body fluids to extract genetic material (DNA) 
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and also a tiny piece of tissue or bone marrow to obtain seeding cells for expansion. 
After the patient leaves the body shop, a computer is used by a tissue engineer to design 
the structure of the mirror leg (the lost leg) based on the symmetrical remaining leg, 
using various materials that simulate the extracellular matrices of the tissues of the leg 
(known as scaffolds or templates). Then, cells – from a universal cell source, specifically 
designed for the patient, or banked cells grown from the patient’s own cells – are seeded 
onto these scaffolds. These engineered cell-scaffold components are then grown 
separately and/or assembled in a special chamber (bioreactor) that provides the right 
nutrients, regulating molecules (such as proteins, growth factors, and differentiation 
factors), physical and mechanical stimuli, temperature, pressure, and mass transport 
conditions for cell proliferation, differentiation, and tissue/organ formation. While the 
tissue/organ is regenerating, the scaffolding materials degrade and disappear, leaving 
nothing foreign to the body. The regenerated leg or leg precursor will be surgically 
grafted onto the patient during the second visit to the human body shop. The engineered 
tissues will have the capacity to grow, model, and remodel in concert with the dynamic 
changes of the physiological environment of the body. The grafted leg will integrate into 
the body. The new leg will grow and age as the body’s natural leg. This scenario is an 
example of what the field of tissue engineering is hoping to do in the future.” (Quotation 
is re-used with permission from Elsevier, see App. A).  
Peter X. Ma explains the overall aim of tissue engineering studies in a very ideal 
and futuristic way in the previous paragraph [429]. Similarly, a closed bioreactor system 
was described by Martin et al., which takes a tissue biopsy as an input then designs, 
generates and presents the missing body part as an output ready to be implanted into the 
patient’s body (Fig. 38) [430]. Time will tell whether such systems are too ideal to be 
true or can be achieved via accumulation of research baby steps taken every day, in 
every laboratory all around the world, but I think the micropellets of varying size, cell 
type and composition will take their place as useful tools, as building blocks in the body 
shops or organ factories of the future. 
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Figure 38. A theoretical “organ factory”. The illustration describes where the field of tissue engineering 
is hoping to achieve in the future. Ideally the patients sees a doctor and a biopsy is taken, the cells are 
isolated, expanded, seeded on templates, cultured until the regenerated organ is mature enough to be 
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